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Supervisory Professor: Heinrich Taegtmeyer, M.D., DPhil 
   
The degradation of proteins by the ubiquitin proteasome system is essential for 
cellular homeostasis in the heart. An important regulator of metabolic homeostasis is AMP-
activated protein kinase (AMPK). During nutrient deprivation, AMPK is activated and 
intracellular proteolysis is enhanced through the ubiquitin proteasome system (UPS). 
Whether AMPK plays a role in protein degradation through the UPS in the heart is not 
known. Here I present data in support of the hypothesis that AMPK transcriptionally 
regulates key players in the UPS, which, under extreme conditions can be detrimental to 
the heart. The ubiquitin ligases MAFbx /Atrogin-1 and MuRF1, key regulators of protein 
degradation, and AMPK activity are increased during nutrient deprivation. Pharmacologic 
and genetic activation of AMPK is sufficient for the induction of MAFbx/Atrogin-1 and 
MuRF1 in cardiomyocytes and in the heart in vivo. Comprehensive experiments 
demonstrate that the molecular mechanism by which AMPK regulates MuRF1 expression is 
through the transcription factor myocyte enhancer factor 2 (MEF2), which is involved in 
stress response and cardiomyocyte remodeling. MuRF1 is required for AMPK-mediated 
protein degradation through the UPS in cardiomyocytes. Consequently, the absence of 
MuRF1 during chronic fasting preserves cardiac function, possibly by limiting degradation of 
critical metabolic enzymes. Furthermore, during cardiac hypertrophy, chronic activation of 
AMPK also leads to cardiac dysfunction, possibly through enhanced protein degradation 
and metabolic dysregulation. Collectively, my findings demonstrate that AMPK regulates 
expression of ubiquitin ligases which are required for UPS-mediated protein degradation in 
the heart. Based on these results, I propose that specific metabolic signals may serve as 
modulators of intracellular protein degradation in the heart.   
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LAY SUMMARY 
METABOLIC CONTROL OF PROTEIN DEGRADATION IN THE HEART  
Kedryn K. Baskin, BA 
 
A cure for heart failure has thus far eluded researchers, although symptoms can be 
managed and side effects can be treated. More than 5 million Americans have been 
diagnosed with heart failure, and each year an estimated 550,000 of them die as a result of 
this condition, often less than 5 years after initial diagnosis. AMPK, a protein known as the 
“fuel gauge of the cell”, is the target for metformin, commonly used in the treatment of type 
2 diabetes. This protein may potentially be a drug target to manage heart failure as well. 
 Heart failure is a complex disease caused by various factors including diabetes, 
obesity and high blood pressure. Heart failure patients often have hearts measuring up to 
three times the normal size, which is due to an the increased size of cells that make up the 
heart. The cells are bigger because they have more proteins than normal heart cells.  
Several studies have suggested that regulating cell size in the heart may be a way to 
combat the disease. Researchers also have known for some time that regulating the 
amount of healthy proteins within a cell regulates cell size. However, the details regarding 
how this process is regulated in the heart is not completely understood. 
 Enter AMPK, the “fuel gauge”. AMPK is the internal fuel gauge that tells the cell how 
to behave under different circumstances. When the cell has ample energy, AMPK does not 
allow the cell to take in more energy-producing material. When the cell is running low on 
energy, AMPK allows the cell to take in energy-producing material and possibly generate 
energy from other sources within the cell. Excess proteins in heart cells are disposed of in a 
highly organized manner through a process termed protein degradation. In this study I have 
shown that AMPK regulates protein degradation, which is another way to provide energy in 
the cell.  
The current study links the cell’s energy needs to the regulation of protein 
degradation. When the cell’s fuel gauge, AMPK, is stimulated it causes certain genes 
involved in protein degradation to become active. These genes then regulate degradation 
of excess proteins. This process can be protective or detrimental to the heart depending on 
the condition of the heart prior to enhanced protein degradation.  
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Chapter 1 
 
 
INTRODUCTION 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
“all we know is still infinitely less than all that remains unknown [1].” 
 
~William Harvey, M.D. (1628)  
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1. Introduction  
1.1. Setting the Stage: Cardiac Hypertrophy and Heart Failure  
 My thesis addresses certain molecular aspects of heart failure, a disease which 
claims the lives of more than 500,000 Americans every year. Heart failure is the leading 
cause of death in the United States [2]. To date there is no cure for heart failure because 
the cellular and molecular mechanisms are still not completely understood [3]. This is what 
is known: Heart failure is often preceded by pathological cardiac hypertrophy, which is 
driven by both endogenous (genetic) [4, 5] and exogenous (environmental) factors [6, 7]. In 
order for the heart to adapt to various types of stress, individual heart muscle cells 
(cardiomyocytes) change or “remodel” metabolically [8-11] and structurally [12]. Excessive 
remodeling results in enlarged cardiomyocytes, which translates into overall increased 
heart size (Figure 1.1.) [13, 14]. Over time, the enlarged cardiomyocytes fail to contract 
normally, and heart function declines leading to failure [15, 16]. Consequently it is critical to 
understand the mechanisms that can reverse cardiac hypertrophy in order to prevent or 
decrease the incidence of heart failure. 
 The regression of cardiac hypertrophy is associated with improved cardiovascular 
outcomes [17-19]. While these clinical results are promising, the regression of hypertrophy 
is correlated with the duration of treatment [20], and there is no guarantee that long term 
treatment of hypertrophy will also not result in contractile dysfunction [21]. Cardiac 
hypertrophy is regulated by a vast array of intracellular signaling pathways that are 
simultaneously activated and interlinked (Figure 1.2.) [21, 22]. The majority of pathways 
regulating cardiac hypertrophy lead to enhanced protein synthesis, structural remodeling, 
and enlarged cardiomyocyte size [23-25]. What is less well studied in the heart is the role of 
protein degradation and whether enhanced protein degradation can balance the enhanced 
protein synthesis that occurs in hypertrophy.  
It has recently been suggested that protein degradation is critical for normal 
cardiovascular function [26]. The regulation of intracellular processes, such as protein 
degradation, is critical in the adult heart because it is mainly comprised of terminally 
differentiated cardiomyocytes [27]. Consequently, cell size, and the resulting heart size, is 
determined by the overall balance of protein synthesis and protein degradation within 
cardiomyocytes [28]. While it is known from pulse-chase experiments that protein 
degradation occurs in the heart, it is not completely known how protein degradation in the 
heart is controlled. Therefore I set out to elucidate one of the mechanisms by which protein  
3 
 
 
 
 
 
Figure 1.1. The Concept of Cardiac Plasticity as proposed by Hill and Olson [12]. 
The heart adapts to various types of stress by remodeling metabolically and structurally 
(shown here: atrophy on the left, hypertrophy on the right). The heart hypertrophies, either 
in a physiological or pathological manner. Exercise and pregnancy cause the heart to adapt 
through physiological hypertrophy. Stresses such as hypertension cause the heart to 
hypertrophy in a pathological manner which can eventually develop into heart failure. The 
heart can also atrophy under certain circumstances (Reviewed in [29]) Reprinted with 
permission from Massachusetts Medical Society (MMS) [12]. 
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degradation is controlled in the heart and to determine whether these mechanisms can 
decrease hypertrophy.  
1.2. Pathways of Protein Degradation in the Heart 
 Much of what is known about protein degradation in the heart is based on studies in 
skeletal muscle [30]. Although the importance of protein degradation in the heart has been 
appreciated for some time [31], only recently have the specific proteolytic systems been 
investigated in detail. Protein degradation is regulated by three main proteolytic systems: 
the calpain system, the lysosomal-dependent autophagy system, and the Ubiquitin 
Proteasome System (UPS) (Figure 1.3.) [32]. The caspase system, specifically Caspase-3 
is also thought to be involved in myofibrillar protein degradation [33-35], although it will not 
be discussed here.  
The calpain system is composed of calcium-dependent cysteine proteases and 
calpastatin, a calpain-specific inhibitor [36]. At least 14 genes encoding calpains have been 
discovered, however, the most studied calpains are µ- and m-calpain (also referred to as 
Calpain 1 and 2) [37]. Calpains and calpastatin are expressed in all cell types investigated 
to date, however the levels of proteins in each cell differs [36]. In muscle, calpains cleave 
sarcomeric proteins [36] such as titin [38, 39], tropomyosin and troponins T and I [40], and 
myosin (Figure 1.4.) [41]. Calpain 3, which is mainly expressed in muscle, also cleaves 
titin, and loss-of-function mutations within this gene are associated with muscular dystrophy 
[42]. The calpain system has also been identified in the heart [43-45]. Recent studies have 
demonstrated that inhibition of calpain activity leads to the development of dilated 
cardiomyopathy with an accumulation of misfolded proteins, reviewed in [46]. Activation of 
calpains during reperfusion after ischemia contributes to apoptosis by cleavage of Bid and 
release of mitochondrial cytochrome C [47]. Calpains are also activated during hypertrophy 
and over-activation of calpains leads to atrial fibrillation and cardiac dysfunction, reviewed 
in [46] and [48]. The main calpain substrates are sarcomeric proteins, which are cleaved in 
a non-specific manner. Further degradation of specific sarcomeric proteins requires 
ubiquitin-mediated proteasomal degradation, which is discussed below.   
Autophagy, a term first used by the Belgian Nobel laureate Christian de Duve [49] 
who also coined the terms “endocytosis” and exocytosis” [50], refers to a process that 
degrades intracellular material within a vacuole [51]. Autophagic processes can be further 
classified as follows. Macroautophagy, usually referred to as simply autophagy, involves the 
formation of cytosolic vesicles with a characteristic double membrane (autophagosomes) 
that are of non-lysosomal origin [52]. Autophagosomes fuse with lysosomes to form  
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Figure 1.3. Proteolytic Systems according to Jackman and Kandarian [32]. 
Protein degradation is regulated by three main proteolytic systems. (A) The calpain system 
is thought to initiate sarcomere breakdown by cleaving large sarcomeric proteins in a non-
specific, calcium-dependent manner (described in greater detail in Figure 1.4.). (B) The 
lysosomal-dependent autophagy system is described in more detail in Figure 1.5. (C) The 
ubiquitin proteasome system (UPS) is expanded upon in Figure 1.6. Reprinted with 
permission from The American Physiological Society [32]. 
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Figure 1.4. Sarcomeric Cleavage by Calpains. 
(A) One sarcomere is represented with labeled regions. The Z lines outline each sarcomere 
and are where the actin filaments attach. The isotropic band (I band) of the sarcomere 
contains only actin filaments while the A band contains both actin and myosin. The middle 
region of the A band contains the H zone which is comprised of only myosin filaments. The 
H zone contains the M-line which is made up of many proteins. Titin (not shown here) links 
myosin filaments to the Z line. (B) The proposed process of calpain-induced sarcomere 
breakdown is described on the left and represented pictorially on the right. Tropomysin 
(TM). Reprinted with permission from The American Physiological Society [36] 
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autolysosomes, and acid hydrolases degrade the content within the autolysosome (Figure 
1.5.) [53]. Microautophagy refers to the selective or nonselective uptake of cytosol 
(including organelles) by the lysosome through protrusion, invagination, or septation of the 
lysosomal membrane [52]. Although considered a constitutively active form of autophagy 
involved in the turnover of long-lived proteins, the mechanism regulating microautophagy is 
not known presently [54]. The selective degradation of organelles, including lipophagy 
(degradation of lipid droplets), pexophagy (degradation of peroxisomes), reticulophagy 
(degradation of the endoplasmic reticulum), and ribophagy (degradation of reobosomes), is 
regulated by ubiquintation (discussed below) of adapter proteins or by receptors [52].  
The most commonly investigated example of organelle-targeted degradation is 
mitophagy, the selective degradation of mitochondria [55]. The mechanisms regulating this 
process have recently been reviewed [56]. Another type of autophagy is chaperone-
mediated autophagy (CMA) which degrades proteins containing the amino acid motif 
KFERQ by transporting them across the lysosomal membrane [52]. CMA requires the heat 
shock conjugate 70 (hsc70) and the integral membrane protein LAMP-2A [57]. Interestingly, 
mutations in LAMP-2 are associated with Danon’s disease [58], a lysosomal glycogen 
storage disease characterized by cardiomyopathy [59].  
 Autophagy removes misfolded and dysfunctional proteins and organelles. The 
process can be triggered by nutrient deprivation and growth factor withdrawal [60]. The high 
energy demand of the heart, and the postmitotic nature of cardiomyocytes, deems basal 
autophagy an important housekeeping process for the removal of proteins that are either 
damaged or no longer needed [60]. Consequently, the disruption of autophagy can be 
detrimental to the heart. For example, the inhibition of autophagy can lead to hypertrophy 
and heart failure [61, 62]. Conversely, enhanced autophagy in the heart can lead to 
apoptosis during ischemia reperfusion [63] and pressure overload-induced heart failure 
[64]. The degree of autophagy and the context in which it occurs is linked to the differential 
effects of autophagy on the heart [65]. While it is still not clear whether it is beneficial or 
detrimental, the necessity of autophagy in the heart cannot be contested [66].  
 The ubiquitin proteasome system (UPS) is an ATP-dependent multi-enzymatic 
pathway that degrades the majority of intracellular proteins in a specific manner [67], and is 
the main focus of my dissertation (Figure 1.6.). The groundwork for the discovery of the 
UPS was laid by Alfred Goldberg in the 1970s when he established that ATP was required 
for protein breakdown [68, 69]. Shortly thereafter, the proteolytic component of the system 
(now known as the proteasome) was discovered simultaneously by Alfred Goldberg [70]  
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Figure 1.5. Pathway of Macroautophagy according to Yang and Klionsky [53].  
Autophagy is initiated by phagophore formation followed by the elongation and expansion 
of the phagophore. The closure of the phagophore by completion of a double-membrane 
surrounding part of the cytoplasm creates an autophagosome. Autophagosomes mature by 
docking and fusing with an endosome or a lysosome, creating an amphisome or an 
autolysosome. After fusion, the contents of the autolysosome are degraded by 
acidhydrolases contained within the vesicle, and the products are recycled. The key 
regulators are show in the legended. Adapted from and reprinted with permission from 
Macmillan Publisher Ltd: [Nature Cell Biology] [53], copyright (2010). 
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Figure 1.6. The Ubiquitin Proteasome System (UPS). 
The Ubiquitin Proteasome System (UPS) consists of three enzymatic steps which degrade 
proteins in a targeted manner. Ubiquitin activating enzymes (E1) are first activated by ATP, 
followed by ubiquitin “charging”. Ubiquitin is then passed from the E1 to an ubiquitin 
conjugating enzyme (E2). E2s act with specific ubiquitin ligases (E3) to ubiquitinate 
proteins. E3s confer the specificity of the UPS by binding, ubiquitinating, and thus causing 
the degradation of targeted protein substrates. Proteins can also be deubiquitinated by 
deubiquitinating enzymes (DUB). Once protein substrates are ubiquitinated by a chain of at 
least 4 ubiquitin molecules, it is shuttled to the proteasome for degradation. The products of 
degradation (peptides, amino acids, and ubiquitin proteins) are recycled to make new 
proteins or are substrates for ATP production. Adapted from multiple sources.  
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and the Nobel laureates Avram Hershko, Aaron Ciechanover, and Irwin Rose [71]. The role 
of ubiquitin and the enzymatic steps required for the ubiquitination process were 
determined through several series of definitive experiments [72-76]. The culmination of 
these elegant studies defines what is widely recognized as the UPS.  
 What follows is a brief description of the UPS as we understand it today. Proteins 
degraded in the proteasome must first be ubiquitinated (Figure 1.7.) [77]. This process 
requires the activation of ubiquitin, a 76 amino acid protein, by an ubiquitin-activating 
enzyme (E1). The glycine residue on the C-terminus of ubiquitin forms a thiolester linkage 
with a cysteine residue on the E1, in an ATP-dependent reaction [78]. Once activated, 
ubiquitin is then transferred to a cysteine residue on an ubiquitin conjugating enzyme (E2), 
also called ubiquitin carrier proteins [79]. Enzymes belonging to the family of ubiquitin 
ligases (E3) confer the specificity of the system by binding to the protein substrate and 
transferring the ubiquitin from the E2 to the target protein [80]. Ubiquitin is linked to an ε-
amino group of a lysine residue on the target protein. Multiple ubiquitin proteins are added 
to the protein substrate until the isopeptide chain contains at least 4 ubiquitin molecules 
(linked mainly through Lys48 on ubiquitin) [81]. The protein is then targeted to the 26S 
proteasome where it is degraded into peptides and amino acids. Ubiquitin molecules are 
removed by the 19S proteasome (the cap of the 26S) and reused [82]. 
 The initial step in the UPS is the charging of ubiquitin. It was originally assumed that 
ubiquitin was only charged by the ubiquitin-activating enzyme UBE1, however several 
groups simultaneously discovered another enzyme also capable of activating ubiquitin, 
UBA6 [83-85]. The functions of UBE1 and UBA6 are not redundant because deletion of 
UBE1 in both yeast [86] and C. elegans [87] is lethal, and UBA6 knockout mice are 
embryonically lethal [85]. Both E1s activate ubiquitin but charge overlapping subsets of 
ubiquitin conjugating enzymes [84, 85].  
 To date there have been at least 38 human genes identified that encode ubiquitin 
conjugating enzymes (E2s) [79]. There are four classes of E2s but most E2s contain an 
active-site cysteine located within the conserved ubiquitin-conjugating (UBC) domain [88]. 
Conformational changes of E1s in response to ubiquitin charging allow for high affinity 
binding of the E1 to an E2 for ubiquitin transfer, and slight distinctions in these 
conformational changes allow for E2s to distinguish between the E1s [79]. Charging of E2s 
occurs quickly, and once charged with ubiquitin, E2s interact with E3s to catalyze ubiquitin 
transfer [84, 89] Although an E2 can interact with several E3s, there is evidence suggesting 
that certain amino acid residues on E2 are distinct for each E3 [90]. While E2-E3 
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Figure 1.7. Ubiquitination of Proteins according to Goldberg [77]. 
The three steps required to ubiquitinate target proteins are shown here. 
The chemistry involved in ubiquitination is outlined, including the binding 
and transfer of ubiquitin. Details are found in the text. Reprinted from 
Neuron, 45/3, Goldberg, A.L., Nobel committee tags ubiquitin for 
distinction, 339-44, (2005), with permission from Elsevier.  
13 
 
interactions are weak, E3 binding induces conformational changes in the E2 allowing for 
ubiquitin transfer [91]. The E1 and E3s bind to overlapping regions on the E2 thus requiring 
several rounds of “ubiquitin charging” in order to polyubiquitinate a target protein [92]. 
E2s were originally dismissed as simple ubiquitin carrier proteins, but recent work 
has revealed that E2s regulate the length and topology of ubiquitin chains that are added to 
the target protein [79, 90]. Several E2s have been identified as strictly involved in ubiquitin 
chain initiation while others only function in ubiquitin chain elongation. Some E2s, however, 
are involved in both ubiquitin chain initiation and elongation. Additionally, a select few E2s 
are capable of pre-assembling ubiquitin chains to speed up the ubiquitination process thus 
increasing rates of degradation for certain proteins. Specific examples of each type of E2 
are reviewed by Ye and Rape [79].  
Yet another property of the E2 is the ability to regulate the type of ubiquitin linkage 
added to the target protein [79]. It is thought that the ubiquitin linkage can be regulated by 
several factors, including the ubiquitin binding domain. For example, the ubiquitin-binding 
domain NZF is specific for ubiquitin linkage through Lys63 [93]. At present there are at least 
20 known ubiquitin binding domains and the structure of each domain is critical in 
determining the type of ubiquitin linkage E2s add to target proteins [94]. Although much 
more work is still needed to fully understand E2s, their functional output, the ubiquitination 
of target proteins, requires the presence of ubiquitin ligases (E3s) [91].  
As already mentioned, ubiquitin ligases (E3s) confer the specificity of the UPS by 
determining which proteins are ubiquitinated and potentially degraded [95]. Thus far over 
600 human genes have been identified that encode ubiquitin ligases. There are three types 
of E3s: HECT (homologous to the E6-AP carboxyl terminus)-type, RING (Really Interesting 
new Gene)-type, and U-box-type. While HECT-type ubiquitin ligases transfer ubiquitin to 
the active-site cysteine on the E3 before ligating the ubiquitin onto target proteins, RING-
type and U-box-type ubiquitin ligases act more like scaffolds for the conjugation reaction 
[96]. Ubiquitin ligases regulate cellular processes including cell cycle and growth, 
transcription, cell signaling, and DNA repair [95]. Furthermore, discussed in detail in the 
next section, tissue or cell-specific ubiquitin ligases, such as TRIM9 expressed in the brain 
[97] and Atrogin-1 and MuRF1 expressed in striated muscle cells [98, 99], are critical 
regulators of organ function.  
Much focus has been placed on ubiquitin ligases as they ubiquitinate target 
proteins; however recent work has highlighted the importance of the type of ubiquitin 
linkages conjugated to the target protein [93]. As previously mentioned, E2s also regulate 
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ubiquitin linkages. Ubiquitin is attached to ε-amino groups of lysine residues within ubiquitin 
binding domains of the target protein and of ubiquitin itself. Ubiquitin has 7 lysine residues 
giving rise to 7 possible types of homologous ubiquitin chains and many heterologous 
ubiquitin chains [94]. The most common ubiquitin chains are linked through Lys48 and 
Lys11, which target the protein for degradation, and Lys63 chains which play a role in DNA 
repair [94, 100]. An additional level of complexity in ubiquitination of proteins is that different 
lysines on the same protein can be ubiquitinated. The combination of the lysines that are 
ubiquitinated and which linkages are on each lysine can ultimately determine the fate of the 
protein. 
Although ubiquitination is an important determinant of the cellular localization, 
function, and degradation of proteins, this process is also reversible. Deubiquitinating 
enzymes (DUB) are proteases with several functions, one of which is cleaving ubiquitin 
from ubiquitinated proteins [101]. DUBs appear to have high specificity and thus may be 
promising drug targets to regulate the UPS [102]. Proteasome-associated DUBs, which 
cleave polyubiquitin chains from proteins being degraded [103], are of particular interest 
due to the positive clinical outcomes of cancer patients treated with Bortezomib 
(proteasome inhibitor) [104]. It has been suggested that targeting proteasome-associated 
DUBs for cancer therapeutics may decrease the toxicity of anticancer drugs [105]. While 
many questions still need to be answered, it is apparent that DUBs add another layer of 
complexity to the regulation of the UPS [106].   
The objective of the UPS is to degrade proteins in the proteasome [107]. The 26S 
proteasome is a multi-catalytic complex made up of the 20S core particle (CP) which 
carries out proteolysis, capped on either or both ends with homologous or heterologous 
regulatory particles (RP) [108]. There are three regulatory particles: the 19S particle (also 
known as PA700) which unfolds ubiquitin-tagged proteins [108], the 11S particle which 
degrades peptides in and ATP-independent manner [109], and the PA200 particle which 
regulates protein degradation during DNA repair [110]. The 20S has a barrel-like structure 
containing 4 heptameric rings organized in the following manner: α1-7β1-7β1−7 α1-7 [111]. The 
β subunits are proteolytically active and have caspase-, trypsin-, and chymotrypsin-like 
activities [112]. The most common regulatory particle, 19S, is comprised of a base, 
containing 6 different ATPases (regulatory triple A proteins (Rpt) 1-6s) and 3 non-ATPase 
proteins (Rpn), and a lid containing 9 Rpn subunits (Figure 1.8.) [113]. While ATP binding 
to the 19S is required for proteasome function, ATP hydrolysis is not [114].  
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The proteasome itself is not the focus of my thesis, and thus not extensively 
reviewed here, however, it is an important aspect of the cardiac UPS to consider. The 
activity of the proteasome is a heavily investigated area with therapeutic implications in 
cancer [115], aging [116], neurodegenerative diseases [117], and cardiovascular diseases 
[118]. Akin to autophagy, the degree by which proteasome activity is activated or inhibited 
can be protective or detrimental to the heart. A lapse in protein quality control for example, 
by chaperone deficiency or uncontrolled protein synthesis, can lead to the accumulation 
and aggregation of misfolded proteins and thus decreased proteasome activity [119]. While 
uncontrolled protein synthesis, protein misfolding, and decreased proteasome activity are 
characteristics of desmin-related cardiomyopathy (DRM), DRM is also caused by mutations 
in sarcomeric proteins which consequently lead to protein aggregation and proteasome 
insufficiency [119].  
Various stresses on the heart can lead to proteasome dysfunction. Proteasome 
activity is decreased in the heart during ischemia/reperfusion (I/R) [120], and the degree of 
proteasome dysfunction during reperfusion depends on the length of time the heart is 
subjected to ischemia [121]. Inhibition of the proteasome reduces infarct size and preserves 
cardiac function after I/R [122]. Ischemic preconditioning also improves proteasome 
dysfunction by decreasing the oxidative damage to the proteasome. These studies suggest 
that proteasome dysfunction during I/R is due to modification of the proteasome [123]. 
Furthermore, enhanced proteasome function during I/R (by overexpressing proteasome 
subunits) protects the heart from I/R-induced dysfunction [124]. Taken together these 
studies demonstrate that proteasome function is decreased after I/R and this may 
contribute to cardiac dysfunction. 
Proteasome activity is also altered during cardiac hypertrophy. Chronic hypertrophy 
induced by aortic banding increases trypsin- and chymotrypsin-like 26S proteasome 
activities and expression of proteasome subunits [125]. Additionally, isoproterenol-induced 
hypertrophy increases 26S proteasome activity and modifies the subpopulations of 
proteasomes in the heart [126]. The proteasome inhibitor epoxomicin prevents the 
development of hypertrophy after aortic banding suggesting that enhanced proteasome 
activity is required for the development of cardiac hypertrophy [125]. Furthermore, inhibition 
of the proteasome after the onset of cardiac hypertrophy reduces cardiomyocyte size and 
apoptosis, stabilizes ejection fraction, and decreases the incidence of heart failure [127]. 
Collectively these findings show that enhanced proteasome activity leads to cardiac 
hypertrophy. Although proteasome function is critical for proper protein degradation, 
ubiquitination of proteins by ubiquitin ligases is required.    
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Figure 1.8. Structure of the Proteasome. 
(A) A detailed illustration of the 26S proteasome containing 2 lids, 2 bases, and the 20S 
core. Descriptions of the subunits are found in the text. (B) A cross section of the 26S 
demonstrating unfolding and deubiquitination of the target protein by the 19S, the cleavage 
of the unfolded protein within the core, and peptide release from the lid. Reprinted with 
permission from John Wiley & Sons Ltd. [128]. 
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1.3 Muscle Specific Ubiquitin Ligases (E3s) 
 The ubiquitin ligases discussed in detail below, Atrogin-1 and MuRF1, are both 
RING-type ubiquitin ligases, although of different classes. It interacts with Skp1 (S-phase-
kinase-associated protein-1), Cul1 (Cullen1), and Roc1 to form an SCF complex (Figure 
1.9.) [98, 99, 129]. Cullen1 provides the RING domain, which by binding E2s, mediates 
ubiquitination of the target protein. Atrogin-1 contains an F-box domain through which it 
binds Skp1, the scaffolding protein required for complex formation [130]. Atrogin-1 also 
contains a substrate recognition domain [131] and recognizes the motif “LQALL” on target 
proteins [132].  
MuRF1 is also a RING-type ubiquitin ligase, but it ubiquitinates proteins solely with 
an E2 and does not require scaffolding proteins. MuRF1has two coiled-coil domains which 
are important for protein-protein interactions; it has been found as hetero- and homodimers 
(Figure 1.10.) [133]. The B-box domain is required for E2 binding [134] and the RING 
domain contains the ligase “activity” which is important for ubiquitin transfer to the target 
protein [130]. MuRF1 also contains a MFC domain (MuRF family conserved region) which 
binds target proteins, but the specific function of this domain is unclear.    
 Muscle Atrophy F-box (MAFbx) [99] also known as Atrogin-1 [98] was 
simultaneously discovered in two independent studies investigating the molecular 
mechanisms of skeletal muscle atrophy and muscle wasting. In all models of skeletal 
muscle atrophy investigated, including hindlimb suspension, immobilization, denervation, 
cancer, diabetes, fasting, and renal failure, Atrogin-1 was universally upregulated at the 
transcript level [98, 99]. Additionally, glucocorticoid treatment, a model used to investigate 
sepsis and cancer-induced cachexia, also increases Atrogin-1 expression [98].  
Muscle RING Finger 1 (MuRF1), a muscle-specific member of the RING family 
ubiquitin ligases, was originally identified in a yeast two-hybrid screen for binding partners 
that interact with titin, a sarcomeric kinase [135]. MuRF1 binds the N-terminus of titin, a 
region of the kinase localized on the M-line of sarcomeres [136, 137]. Three MuRF family 
proteins were identified and have high sequence homology but diverge at their C-terminus 
(Figure 1.10.) [135].  MuRF1 heterodimerizes with MuRF2 and MuRF3 but only MuRF1  
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Figure 1.9. The Ubiquitin Ligase Atrogin-1. 
(A) Linear structure of Atrogin-1 containing protein domains. NLS, nuclear localization 
sequence; LZ , leucine zipper; LCD, leucine charged domsin; Cyt C, cytochrome c heme 
family binding site; PDZ, postsynaptic density-95 (PSD-95)/Discs large/zona occludens-1 
domain. This research was originally published in the Journal of Biological Chemistry. 
Lionel A. Tintignac, Julie Lagirand, Sabrina Batonnet, Valentina Sirrill, Marie Peirre 
Leibovitch, and Serge A. Leibovitch. Degradation of MyoD Mediated by the SCF (MAFbx) 
Ubiquitin Ligase. J Biol Chem. 2005; 280:2847-56. [138]. (B) The SCF complex containing 
Atoring-1. See text for details. Adapted with permission from Wolters Kluwer Health [131]. 
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Figure 1.10. The Ubiquitin Ligase MuRF1. 
(A) The linear structure of MuRF1 containing protein domains. The titin and troponin binding 
sites are noted. Adapted with permission [133]. (B) Linear alignment of the MURF family. 
Splice variants are shown as MURF-2’ and MURF-3’. A region of titin is shown above the 
alignment and the regions where MuRF1 binds titin is outlined. Reprinted with permission 
from Springer [139]. RING, Really Interesting new Gene domain; MFC, MuRF family 
conserved region; CC, coiled-coil domain; AR, acidic region. 
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associates with titin. MuRF3, the first in the family to be identified, is involved in 
microtubular stabilization, which is important in myofibrillar assembly and contractile 
function [140]. While MuRF1 and 3 localize to the Z-lines of sarcomeres, MuRF3 is not 
found at the M-line [135]. MuRF1 and 3 are muscle specific; however, MuRF1 is expressed 
in all developmental stages, while MuRF3 seems to be important during development. 
MuRF2, on the other hand, is found in the liver in addition to striated muscle and is highly 
expressed in the fetal heart [135]. MuRF1, like Atrogin-1, was also found to be upregulated 
in several models of skeletal muscle atrophy [99].     
The first in vivo investigations on the functional implications of Atrogin-1 and MuRF1 
were performed using mice deficient for Atrogin-1 or MuRF1 [99]. Both strains of mice are 
resistant to skeletal muscle atrophy (induced by denervation), and the overexpression of 
Atrogin-1 in C2C12 muscle cells in vitro causes atrophy [99]. Since their original discovery, 
numerous reports have validated the importance of both ubiquitin ligases and have clarified 
their mechanistic regulation. Although most of what we know comes from studies performed 
in skeletal muscle and myotubes, the importance of these specific ubiquitin ligases in the 
heart has been validated and is a current field of investigation.          
1.3.1. Regulation of Atrogin-1 and MuRF1 
The earliest signaling pathways investigated in the regulation of Atrogin-1 and 
MuRF1 were growth signaling pathways. In addition to multiple skeletal muscle atrophy 
models, Atrogin-1 and MuRF1 expression are induced by food deprivation [141], suggesting 
that the inhibition of growth stimulating pathways positively regulates their expression. In 
skeletal muscle cells, insulin-like growth factor 1 (IGF-1) suppresses mRNA expression of 
Atrogin-1 and MuRF1 and inhibition of IGF-1 (through the PI3K-Akt pathway) increases 
Atrogin-1 expression and proteolysis [142]. Starvation-induced atrophy in C2C12 muscle 
cells decreases the Phosphatidylinositol 3-kinase - Protein Kinase B (PKB, also known as 
AKT) pathway, or PI3K-AKT pathway for short. Consequently, Forkhead box O (FOXO) 
transcription factors are activated thus increasing Atrogin-1 expression. Overexpression of 
IGF-1 or AKT inhibits FOXO3A and Atrogin-1 expression, and constitutively active FOXO3A 
regulates Atrogin-1 expression directly in skeletal muscle [143]. In the heart, FOXO3A 
overexpression also increases Atrogin-1 expression and prevents IGF-1-induced cardiac 
hypertrophy [144]. Furthermore, inhibition of FOXO1 by AKT also prevents the expression 
of Atrogin-1 and MuRF1 in muscle cells [145]. Glycogen synthase kinase 3 beta (GSK3β), 
also negatively regulated by AKT, mediates FOXO1-induced expression of Atrogin-1 to 
decrease cardiac hypertrophy [146], and in skeletal muscle, basal and atrophy-induced 
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Atrogin-1 mRNA expression requires GSK3β [147]. These and other pathways are outlined 
in Figure 1.11. 
The regulation of Atrogin-1 and MuRF1 expression through the PI3K-Akt pathway 
has been demonstrated by many groups in various experimental settings. Diabetes has 
been shown to induce skeletal muscle wasting, and indeed, streptozotocin (STZ)-induced 
diabetes increases both ubiquitin ligases [148]. Insulin deficiency in muscle suppresses 
PI3K, increases the inhibitory phosphorylation of IRS-1 (Insulin receptor substrate 1), and 
increases muscle proteolysis [149]. Furthermore, mice heterozygous for Phosphatase and 
tensin homolog (PTEN), a negative regulator of the PI3K-AKT signaling pathway, exhibit 
decreased protein degradation and reduced expression of Atrogin-1 and MuRF1 in muscle 
[150].  
 Additional studies on muscle atrophy and the PI3K-AKT pathway suggest that 
transcription of Atrogin-1 and MuRF1also occurs downstream of mammalian target of 
rapamycin (mTOR), but independent of FOXO [151]. Furthermore, the regulation of 
FOXO3A, independent of the PI3K-AKT pathway also regulates Atrogin-1 expression. The 
histone acetyltransferase (HAT) p300/cyclic AMP-response element-binding protein 
(CREB), known as p300/CREB, represses FOXO3A activity and thus decreases Atrogin-1 
expression, suggesting that acetylation by p300/CREB may differentially regulate the FOXO 
isoforms and more specifically direct atrophic signaling [152].  
 In the heart, chronic left ventricular dysfunction caused by myocardial infarction (MI) 
leads to cardiac and skeletal muscle atrophy. In response to MI there is enhanced protein 
ubiquitination, increased proteasome activity, activation of FOXO-mediated transcription, 
and increased Atrogin-1 expression. Local IGF-1 injection, however, prevents MI-induced 
muscle atrophy [153]. Congestive heart failure associated with hypertension (the activation 
of renin-angiotensin system (RAS)) also leads to skeletal muscle wasting.  Angiotensin-II 
infusion in rats increases muscle proteolysis and Atrogin-1 and MuRF1 expression, which is 
reversed by inducing IGF-1 expression [154]. While Atrogin-1 expression in the heart is 
regulated by FOXO1/3A, Atrogin-1 also inhibits AKT-induced physiological cardiac 
hypertrophy by binding to, ubiquitinating (through Lys63 linkages), and thus transcriptionally 
co-activating FOXO1/3A. Consequently, IGF-1-induced physiological cardiac hypertrophy is 
decreased in Atrogin-1 transgenic mice due to increased activity of FOXO1/3A. Moreover, 
Atrogin-1-/- hearts hypertrophy to a greater extent after exercise [155]. This study unveils a 
feed forward mechanism for FOXO1/3A-Atrogin-1 in the heart, although the ramifications of 
this pathway under normal conditions have yet to be reported [156].   
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Figure 1.11. Pathways regulating Atrogin-1 and MuRF1. 
Detailed pathways regulating Atrogin-1 and MuRF1 expression. Yellow arrows symbolize 
activation; red lines symbolize inhibition; white lines are the topic of Chapter 3. See text for 
details. Designed using resources from SA Biosciences. 
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Another signaling pathway that regulates Atrogin-1 and MuRF1 is the transforming 
growth factor beta (TGF-β) signaling pathway (Figure 1.11.). Myostatin, a member of the 
TGF-β super family, induces skeletal muscle wasting (cachexia) in part by increasing the 
expression of Atrogin-1 and MuRF1. Myostatin reverses the PI3K-AKT signaling pathway 
by inhibiting AKT phosphorylation [157, 158]. Myostatin-/- mice have increased muscle size 
and overexpression of myostatin in C2C12 myotubes attenuates IGF-1-induced-
hypertrophy [159]. Myostatin is also required for Dexamethasone (glucocorticoid)-induced 
skeletal muscle atrophy [160]. TGFβ family members, including myostatin, signal through 
the transcription factor Smad3 (mothers against decapentaplegic homolog 3) in muscle. 
Smad3 is sufficient and necessary for myostatin-induced Atrogin-1 expression through 
FOXO1, but is not required for MuRF1 expression [161].  
 Tumor necrosis factor (TNFα), a cytokine involved in inflammation, also induces 
muscle wasting under conditions such as cachexia and sepsis. TNFα causes atrophy in 
C2C12 cells in part by increasing Atrogin-1 expression [162], and this is partially reversible 
with IGF-1 treatment [163] (Figure 1.11.). Injection of TNFα into skeletal muscles of mice 
also induces Atrogin-1 mRNA expression, and inhibition of p38 mitogen activated protein 
kinase (MAPK) blunts the increase of Atrogin-1. These studies demonstrate that the 
TNFα/p38 pathway regulates Atrogin-1 expression in skeletal muscle [162]. TNFα also 
regulates Atrogin-1 through FOXO4, independent of AKT, in muscle cells [164]. Muscle 
wasting in cancer-induced cachexia increases Atrogin-1 by activating p38 [165]. Activated 
p38 regulates Atrogin-1 transcription by phosphorylating and thus activating the 
transcription factor CCAAT/enhancer-binding protein beta (C/EBPβ), which then induces 
Atrogin-1 expression independent of FOXO1/3 [165].  
In chronic heart failure, TNFα levels are increased, which induces expression of 
Atrogin-1 and MuRF1. Like in muscle cells, TNFα enhances Atrogin-1 expression in a p38-
dependent manner, while MuRF1 requires p42/44 in cardiomyocytes. TNFα also increases 
troponin I (TnI) degradation and decreases contractility of cardiomyocytes [166]. 
Furthermore, occlusion of the left anterior descending coronary artery (in the heart) (LAD) 
also increases TNFα levels and Atrogin-1 and MuRF1 expression [167]. Doxorubicin (DOX) 
treatment, an anti-neoplastic agent that intercalates DNA, causes cardiomyopathy. DOX 
increases Atrogin-1 expression, however, inhibiting p38 abrogates DOX-mediated 
increases in Atrogin-1 [168]. While Atrogin-1 ubiquitinates target proteins for degradation, 
Atrogin-1 itself is ubiquitinated, which is enhanced in the presence of Skp1-Cul1-Roc1 and 
the E2 UbcH3. Atrogin-1 ubiquitination and degradation is increased when p38 is inhibited 
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[169]. These data suggest that p38 is a switch regulating the expression of Atrogin-1 
(summarized in Figure 1.11.).  
 Inflammatory signaling pathways, such as TNFα discussed above, can also activate 
c-Jun N-terminal kinase (JNK), potentially through p21-activated kinase 1 and 2 (PAK1 and 
PAK2) [170]. FOXO3A is not only inhibited by AKT, but also by stress-activated protein 
kinase (SAPK). This process involves JNK signaling, but is independent of AKT. Activation 
of SAPK decreases Atrogin-1 expression in C2C12 cells [171] (Figure 1.11.). In the heart, 
ischemia/reperfusion (I/R) induces apoptosis and JNK signaling to enhance Atrogin-1 
expression. Furthermore, Atrogin-1 sustaines JNK in its activated form by ubiquitinating and 
degrading the MAPK phosphatase-1 (MKP-1) [172]. Unlike Atrogin-1, MuRF1 is protective 
in ischemia/reperfusion by decreasing cell death through inhibition of JNK signaling by 
ubiquitinated degradation of phospho c-Jun [173]. 
 Another signaling pathway activated during stress and in the presence of cytokines 
is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Muscle 
atrophy caused by hindlimb immobilization increases NF-κB activation in part by 
downregulating its inhibitor IκB. However, overexpressing IκB by in vivo electroporation 
inhibits unloading-induced atrophy and expression of Atrogin-1 [174]. Additionally, the 
overexpression of active IκB kinase beta, which activates NF-κB, causes muscle wasting 
that correlates with increased MuRF1 expression in muscle [175]. Interleukin-1 (IL-1) 
treatment decreases IkappaB, increases NF-κB, and thus increases the expression of 
Atrogin-1 and MuRF1 in C2C12 muscle cells [176] (Figure 1.11.). Collectively, these 
studies provide evidence that Atrogin-1 and MuRF1 regulate muscle proteolysis in 
response to cytokines. 
Lipopolysaccharide (LPS) is used in vitro and in vivo to elicit an immune response 
and therefore activate several signaling pathways mentioned above. LPS treatment 
increases Atrogin-1 and MuRF1 expression [177] and increases the alpha subunits of the 
proteasome in muscle [178]. LPS-induced muscle atrophy is reduced by curcumin, a non-
toxic anti-inflammatory reagent [179]. LPS activates the inflammatory receptor toll-like 
receptor 4 (TLR-4), which consequently increases expression of Atrogin-1 and MuRF1 in a 
p38-dependent manner [180]. Sepsis occurs in response to LPS, consequently inducing 
muscle atrophy [181]. Sepsis-induced muscle wasting increases the transcriptional activity 
of FOXO1/3A but not FOXO4 [182]. Furthermore, muscle wasting is partially inhibited with 
the calpain inhibitors calpeptin or BN82270, but the expression of Atrogin-1 and MuRF1 is 
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unaffected by calpain inhibition. This study demonstrates that in muscle the UPS is 
regulated independently of calpains during sepsis [183].  
Denervation causes skeletal muscle atrophy and upregulates myogenin, a member 
of the myogenic regulatory factor (MRF) family of transcription factors involved in muscle 
development, repair, and differentiation [184]. Denervation, which regulates Atrogin-1 and 
MuRF1 expression, does so through myogenin, while denervated myogenin-/- mice do not 
have increased Atrogin-1 and MuRF1 expression [185]. Atrogin-1 is a bona fide target for 
myogenin as its promoter contains binding sites for myogenin and MyoD, another member 
of the MRF transcription factor family [186]. MyoD is an important trophic mediator during 
skeletal muscle hypertrophy and atrophy. Interestingly, Atrogin-1 targets MyoD for 
degradation by ubiquitinating MyoD on Lys133 [138] in several models of muscle atrophy 
[187]. Moreover, the MAP kinase MEK1 phosphorylates MyoD and inhibits its ubiquitination 
and degradation by Atrogin-1, allowing for muscle differentiation [188]. These studies 
provide further evidence for importance of Atrogin-1-mediated protein degradation in 
skeletal muscle atrophy (Figure 1.11.).  
Glucocorticoids regulate MuRF1 transcription, presumably though the glucocorticoid 
response elements (GRE) found within the MuRF1 promoter, but MuRF1 is synergistically 
regulated by FOXO1 and the glucocorticoid receptor in skeletal muscle [189]. The 
glucocorticoid dexamethasone induces cachexia by increasing MuRF1 expression. 
Consequently, protein levels of myosin heavy chain (MHC) are decreased but MHC levels 
are spared in dexamethasone treated MuRF1-/- mice [190]. Glucocorticoids are sufficient to 
induce skeletal muscle wasting; however daily injections of the glucocorticoid receptor (GR) 
antagonist RU-486 neither prevent atrophy after hindlimb casting, nor prevented Atrogin-1 
and MuRF1 expression [191]. These results do not rule out the possibility of the direct effect 
of glucocorticoids on Atrogin-1 and MuRF1 mRNA transcription or stability independent of 
the GR. Tillis et.al. have recently reported that dexamethasone stabilizes surfactant protein-
B mRNA in a posttranscriptional manner, which may be the case with Atrogin-1 and MuRF1 
[192]. Colectively these studies suggest that glucocorticoids regulate Atrogin-1 and MuRF1 
but may not be the predominant pathway controlling muscle atrophy (Figure 1.11.). 
Another mediator of muscle atrophy is the class of statin drugs used to treat 
hypercholesterolemia. Statins inhibit HMG-CoA reductase which is involved in cholesterol 
synthesis. Lovestatin increases Atrogin-1 and removal of Atrogin-1 prevents muscle 
damage mediated by lovestatin [193]. Lovestatin causes damage, presumably by altering 
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post translational modifications, specifically inhibiting geranylgeranylation; however the 
mechanism by which this occurs is unknown [194].  
Because Atrogin-1 and MuRF1 are induced under a variety of stimuli leading to 
muscle proteolysis and atrophy, there will most likely be more pathways uncovered in the 
future that regulate Atrogin-1 and MuRF1. As I began work on my thesis project, several 
papers were published demonstrating, in line with our hypothesis, that AMPK was involved 
in the regulation of the ubiquitin ligases Atrogin-1 and MuRF1; however, the studies were 
correlative and not mechanistic in nature. These reports are discussed in more detail in 
chapter 3.  
Atrogin-1 and MuRF1 are expressed at differing levels at baseline in skeletal muscle 
and in the heart. While many transcriptional regulators of these ligases have been 
described, only one inhibitor of their expression has recently been identified. MicroRNA 
(miRNA) are short RNA (roughly 22 nucleotides) that act as post-transcriptional modifiers of 
gene expression. They bind to complementary sequences on target mRNA to repress or 
degrade the mRNA [195]. miR23 promotes cardiac hypertrophy and its expression is 
regulated through NFATc3, a pro-hypertrophy transcription factor [196]. miR23 suppresses 
translation of Atrogin-1 and MuRF1 and the ectopic expression of miR23a protects against 
skeletal muscle atrophy [197] (Figure 1.11.). These initial descriptions of the repression of 
Atrogin-1 and MuRF1 are presumed to be the first, with many more to come.   
1.3.2. Targets of Atrogin-1 and MuRF1 
As discussed above, studies identifying pathways that regulate Atrogin-1 and 
MuRF1 were initially performed in skeletal muscle. On the other hand, the identification of 
the targets of the ligases has been mainly performed in cardiomyocytes and in the heart. In 
yeast two-hybrid screens using Atrogin-1 as bait, Li and colleagues found that Atrogin-1 
interacts with Calcineurin A (CnA) and α-actinin-2. Both of these proteins are localized to 
the Z-disc in cardiomyocytes and CnA is an important mediator in pathological hypertrophy. 
Atrogin-1 overexpression enhances the ubiquitination of CnA and in Atrogin-1 transgenic 
mice (Tg), the hypertrophic response is blunted, presumably due to decreased CnA levels. 
This group also discovered that Atrogin-1 displays ubiquitin ligase activity in complex with 
Skp1-Cul1-Roc1, and the E2 with which Atrogin-1 ubiquitinates some proteins is 
UbcH3/CDC34 [129] (Figure 1.9.).  
Recently, the endogenous role of Atrogin-1 in cardiac hypertrophy was reported 
[198]. Transverse aortic constriction (TAC), an in vivo model that induces cardiac 
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hypertrophy (see chapter 2 for a detailed description), leads to increased Atrogin-1 
expression in the heart, verifying previously published results from our lab [199]. Atrogin-1-/- 
mice did not hypertrophy to the same extent as wild type animals after TAC and have less 
cardiac fibrosis. Surprisingly, CnA levels were inhibited in the Atrogin-1-/- hearts. Microarray 
analysis revealed that NF-κB-regulated genes were down-regulated in Atrogin-1-/- hearts 
after TAC, indicating a potential pathway protecting the heart from the development of 
pathological hypertrophy. Furthermore, Atrogin-1 regulates ubiquitination and degradation 
of IκB-alpha in cardiomyocytes, which leads to the activation of NF-κB [198]. Although 
these in vivo TAC studies provide mechanistic insight into the role of Atrogin-1, their 
conflicting results make it difficult to conclusively determine whether Atrogin-1 is protective 
or detrimental to the heart during cardiac hypertrophy.  
  Another target of Atrogin-1 has been the focus of several reports. In muscle, 
Atrogin-1 targets eukaryotic initiation factor 3 subunit 5 (eIF3-f) for degradation, and siRNA 
against Atrogin-1 prevents the degradation of eIF3-f during atrophy. The overexpression of 
eIF3-f causes hypertrophy and increases expression of muscle structural proteins, while 
knockdown of eIF3-f induces atrophy [200]. Atrogin-1 ubiquitinates the C-terminus of eIF3-f 
but mutating 6 Lysine residues within this region causes hypertrophy and protects against 
starvation-induced muscle atrophy [201]. The overexpression of Atrogin-1 induces skeletal 
muscle atrophy and leads to degradation of eIF3-f; however, an eIF3-f mutant insensitive to 
Atrogin-1 abrogates these changes [202]. While this has not yet been investigated, it will be 
interesting to determine whether eIF3-f is targeted by Atrogin-1 in the heart.  
 In the heart, MuRF1binds to and co-localizes with RACK1 (receptor for activated 
protein kinase C), which associates with protein kinase C (PKCε) during hypertrophy. The 
overexpression of MuRF1 prevents PKCε localization to focal adhesions and thus focal 
adhesion formation, a critical step in the development of cardiomyocyte hypertrophy. 
Furthermore, overexpression of MuRF1 abolishes the hypertrophic response to 
phenylephrine in cardiomyocytes [203]. Thus enhanced MuRF1 expression might be one 
way to decrease cardiac hypertrophy.  
Another anti-hypertrophic protein has been identified as a target for MuRF1-
mediated degradation in cardiomyocytes. Cardiac troponin I (cTnI) is part of the troponin 
complex and plays an inhibitory role in contraction by binding actin and preventing it from 
binding myosin in the relaxed phase. cTnI localizes to the M-line, coimmunoprecipitates 
with MuRF1, and is directly ubiquitinated by MuRF1 [133]. Interestingly, MuRF1 
differentially ubiquitinates troponin I depending on which E2 is utilized. MuRF1, when 
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working with the E2 UbcH1, ubiquitinates TnI using Lys48 linakges, which leads to the 
degradation of TnI. However, when MuRF1 works with the E2 UbcH13/Uev1a, TnI is 
ubiquitinated with Lys63 linkages and is not degraded. Furthermore, MuRF1 interacts with 
the E2 Ubc9 [204] and ubiquitinates proteins with Lys48, Lys63, Lys11, and forked ubiquitin 
linkages using the E2 UbcH5, although the consequence of differential ubiquitination is at 
present unknown [205].  
 Additional binding partners of MuRF1 were found using yeast two-hybrid 
screenings. MuRF1 interacts with the myofibrillar proteins telethonin (Tcap), myotilin, 
nebulin, nebulin-related protein, troponin T1 and T3, and myosin light chain 2 (MLC-2). 
MuRF1 also interacts with proteins involved in energy metabolism including muscle creatine 
kinase, NADH dehydrogenase, adenylate kinase, aldolase A, pyruvate kinase, and 
pyruvate dehydrogenase kinase, to name a few.  Although this study has identified 
additional targets for MuRF1, functional studies are still needed to conclusively verify 
ubiquitination of these proteins [206]. The potential metabolic consequences of MuRF1-
mediated degradation of these proteins is discussed in Chapter 5.  
Several follow-up studies have focused on MuRF1 regulation of target proteins 
mentioned above, one being muscle creatine kinase (CK). CK is involved in energy 
reservation during the resting state of muscle contraction. When CK is damaged, or 
otherwise unnecessary, it becomes oxidized and thus inactive. MuRF1degrades the 
oxidized form of CK [207]. Mice starved of amino acids (AA) (aproteinogenic diet) in vivo, 
used here as a model of skeletal muscle atrophy, have decreased levels of muscle CK, 
while MuRF1-/- on the same diet have increased levels of CK. Additionally, AA-starved 
MuRF1-/- mice also have decreased plasma AA and branched chain AA (BCAA), and 
enhanced levels of muscle protein synthesis. Moreover, glucocorticoid modulatory element 
binding protein-1 (GMEB1), a transcription factor that regulates gene expression in 
response to glucocorticoid levels, and 3-hydroxyisobutyrate dehydrogenase (HIBADH), an 
essential enzyme in valine catabolism, were increased in muscles of AA-starved MuRF1-/- 
mice [208].  
Transgenic mice overexpressing MuRF1 16-fold in skeletal muscle have decreased 
protein levels of pyruvate dehydrogenase (PDH) and its regulator pyruvate dehydrogenase 
kinase 2 (PDK2), two enzymes initially discovered in yeast-two hybrid screens, discussed 
above. MuRF1 Tg mice have higher blood insulin levels, lower glycogen levels in the liver, 
and during glucose tolerance tests, insulin levels are further increased in Tg mice. MuRF1 
seems to preserve energy by inhibiting rate-limiting catabolic pathways [209]. These in vivo 
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studies support findings of yeast-two hybrid screens by providing indirect evidence that 
MuRF1 is involved in degrading metabolic enzymes in muscle.  
 MuRF1 interacts with sarcomeric proteins, also initially described in yeast-two hybrid 
studies. In myofibrils, MuRF1 ubiquitinates myosin light chains 1 and 2 (MyLC1, MyLC2) 
and the degradation of these proteins leads to thick filament disassembly and myosin heavy 
chain (MyHC) ubiquitination by MuRF1[210]. While calpains are assumed to be required for 
initial breakdown of sarcomeres, MuRF1 regulated myofibril degradation may be 
independent of the calpain system as MuRF1also ubiquitinates skeletal muscle actin [211], 
although, this has not yet been tested directly. However, in support of this hypothesis, 
MuRF1 and MuRF2 were found to be required for type-II muscle fiber maintenance through 
the regulation of myozenin-1/calsarcin-2, an inhibitor of calcineurin, and a determinant of 
muscle fiber-type [212]. MuRF1 also functions redundantly with MuRF3 (through the E2s 
UbcH5a, -b, -c) to degrade β Myosin Heavy Chain (MHC) and MHCIIα in muscle and in the 
heart. Deletion of both MuRF1 and MuRF3 in mice causes abnormal accumulation of 
proteins (MHCs) within the sarcomere leading to muscle dysfunction and myopathy [213]. 
 MuRF1-/- mice have an exacerbated hypertrophic response to pressure overload 
compared to wild type mice or MuRF2-/- mice, suggesting that MuRF1 negatively regulates 
cardiac hypertrophy [214]. Furthermore, pathological hypertrophy induced by TAC is not 
reversible with the removal of TAC in the absence of MuRF1, even though gene expression 
patterns in WT and MuRF1-/- mice returned to baseline [215]. Interestingly, older mice 
(greater than 6 months of age) lacking MuRF1have enlarged hearts, however cardiac 
function is normal. However, AKT signaling is increased and proteasome activity is 
decreased in the absence of MuRF1 in the hearts of older mice [216]. MuRF1 Tg mice 
overexpressing 45-fold in the heart have a mild cardiac phenotype at baseline (thinner left 
ventricular (LV) wall thickness, increased LV dimension, and decreased fractional 
shortening (FS)) but this does not progress with age, and cardiac dysfunction does not 
develop. With TAC, MuRF1 Tg mice develop rapid heart failure with significant decline in 
LV wall thickness, increase in LV dilation, and decrease in FS, all characteristics of 
eccentric cardiac hypertrophy. MuRF1 Tg mice also have decreased CK activity and display 
a cardiac metabolic phenotype. PGC1 is increased in MuRF1 Tg mice after TAC indicating 
a possible cardiometabolic defect [217].  
The majority of studies reported to date have focused on the degradation of proteins 
by either Atrogin-1 or MuRF1; however, one study has reported redundancy of the ubiquitin 
ligases in regulating cardiac myosin-binding protein C (cMyBP-C). Familial hypertrophic 
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cardiomyopathy can result from mutations in cMyBP-C resulting in C-terminal truncated 
mutant protein which is not detected in the tissue of patients. Using the premise that the 
absence of detection may denote rapid degradation of cMyBP-C in cardiomyocytes, 
experiments provide evidence that Atrogin-1 targets a mutated form of cMyBP-C (M7t-
cMyBP-C) for degradation. Additionally, MuRF1 indirectly reduces cMyBP-C by regulating 
transcription of myosin heavy chain [218]. 
Atrogin-1 and MuRF1 are the main ubiquitin ligase studied in muscle and heart, and 
their target proteins are summarized in Table 1.1. The abundance of predicted ubiquitin 
ligases (over 600) suggests that others may be required or necessary for atrophy. Indeed, a 
recent study described Cbl-b, an E3 ligase that is upregulated during skeletal muscle 
unloading. Cbl-l interacts with, ubiquitinates, and degrades IRS-1. Consequently decreased 
PI3K-AKT signaling activates FOXO3-dependent induction of Atrogin-1. Mice deficient for 
Cbl-b are resistant to unloading [219]. Although not completely independent of Atrogin-1 
and MuRF1, this study suggests that we are just beginning to understand ubiquitin ligases 
and their role and regulation in protein degradation.  
1.4. Metabolic Regulation of Cardiac Function 
 Like all living cells, heart muscle cells liberate the energy contained in organic 
molecules to support their function. This process is both highly regulated and oxygen 
dependent. It produces ATP from fatty acids, glucose, lactate, ketone bodies, and (under 
extreme circumstances) amino acids [220]. For a given environment the source of ATP 
production can be changed from one fuel to another, and the heart has therefore been 
termed a “metabolic omnivore” [221]. In the fasted state and under resting conditions the 
heart prefers fatty acids [222] while carbohydrates become a major fuel for the stressed 
heart [8]. 
 A key enzyme involved in the metabolic response to stress in the heart is AMP-
activated protein kinase (AMPK). AMPK, also known as the “fuel gauge” of the cell [223], is 
activated under a variety of conditions that decrease the ratio of [ATP]/[AMP]. AMPK 
regulates processes involved in ATP production, such as glucose uptake, glycolysis, fatty 
acid oxidation, and mitochondrial biogenesis. At the same time, AMPK inhibits processes 
involved in high ATP consumption, such as protein synthesis, glycogen synthesis, 
gluconeogenesis, and fatty acid synthesis [224]. Details on the regulation of AMPK and the 
consequences of AMPK activation on cardiac metabolism are discussed in more detail in 
the following section.   
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Table 1.1. Protein targets of Atrogin-1 and MuRF1.  
A summary of the protein targeted by Atrogin-1 and MuRF1, including which ligase targets 
the protein, and what the consequence of the interaction is. There are other potential 
targets of Atrogin-1 and MuRF1 that have been describe using yeast-two hybrid sreens, 
however, they have not been validated in vitro. 
 
  
Protein targets of Atrogin-1 and MuRF1 
Target Protein Targeted by Consequence of interaction Reference 
Titin MuRF1 Binds, ubiquitinates [136, 137] 
RACK1/PKCε MuRF1 Binds, localization [203] 
cTnI MuRF1 Ubiquitinates, degrades [133] 
CK MuRF1 Ubiquitinates, degrades [207] 
GMEB1 MuRF1 Unknown, increased in MuRF1-/- [208] 
HIBADH MuRF1 Unknown, increased in MuRF1-/- [208] 
PDH MuRF1 Unknown, decreased in MuRF1 Tg [209] 
PDK2 MuRF1 Unknown, decreased in MuRF1 Tg [209] 
MyLC1 MuRF1 Ubiquitinates, degrades [210] 
MyLC2 MuRF1 Ubiquitinates, degrades [210] 
MyHC MuRF1 Ubiquitinates [210] 
βMHC MuRF1 Ubiquitinates, degrades [213] 
MHCα MuRF1 Ubiquitinates, degrades [213] 
PGC1 MuRF1 Unknown, increased in MuRF1 Tg [217] 
cMBP-C MuRF1, Atrogin-1 Ubiquitinates, degrades [218] 
CnA Atrogin-1 Ubiquitinates, degrades [129] 
α-actinin Atrogin-1 Binds, colocalizes [129] 
IκBα Atrogin-1 Ubiquitinates, degrades [198] 
eIF3-f Atrogin-1 Ubiquitinates, degrades [200-202] 
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1.4.1. Structural and Functional Aspects of AMPK 
AMP-activated protein kinase (AMPK) is a serine threonine kinase comprised of a 
catalytic subunit, α, and two regulatory subunits: β and γ, each subunit existing as several 
isoforms (α1, α2, β1, β2, γ1, γ2, γ3) [225]. The catalytic α1 subunit is expressed in all 
tissues, while α2 is mainly expressed in the heart and skeletal muscle [226, 227]. Akin to 
the catalytic subunit, β1 is ubiquitously expressed and β2 is expressed at very high levels in 
heart and skeletal muscle [228, 229]. The γ1 regulatory subunit is also ubiquitously 
expressed and most of the complexes found within the heart contain this isoform (at least 
during ischemic conditions) [230]. The γ2 subunit has 2 splice variants: one is expressed in 
most tissues excluding the heart, and the other vice versa [231]. The γ3 subunit is only 
expressed in skeletal muscle [231]. The details of the isoform specificity are not completely 
known, but proposed functions include subcellular localization and differential signaling of 
AMPK isoform combinations [232]. 
The protein domains of the AMPK subunits are well documented and several crystal 
structures have been reported [233-235]. The catalytically active subunit of AMPK (α) 
contains an N-terminal kinase domain with an activation loop. Thr172 within the activation 
loop is phosphorylated by upstream kinases, thereby activating AMPK [236]. The C-
terminus of αAMPK contains an autoinhibitory domain and a β-subunit interacting domain. 
The β regulatory subunit acts as a scaffold between the α and γ subunits, and may 
potentially be involved in intracellular localization [237]. This subunit contains a glycogen 
binding domain (GBD), or carbohydrate binding domain (CBD), and a C-terminal subunit 
binding sequence that binds both α and γ [238]. The other regulatory subunit, γ, contains 
four bateman domains or CBS motifs, which are adenyl binding sites. CBS1 and CBS3 can 
be occupied by AMP or ATP, CBS4 is only occupied by AMP, while CBS2 is occupied by 
ADP (Figure 1.12.) [234].   
 The “adenylate energy charge” hypothesis describes the allosteric regulation of 
enzyme activity by the ratio of [ATP]/[ADP][AMP] [239]. This concept was originally thought 
to be the regulatory mechanism of acetyl-CoA carboxylase (ACC), which we now know is 
regulated by AMPK [240]. More correctly, AMPK is an example of the “adenylate energy 
charge” hypothesis, and consequently, ACC is directly affected.  As a result, the 
phosphorylation status of ACC is measured as the indicator of the activation status of 
AMPK. 
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Although only first described in 1988 [241], much is known about the regulation and 
function of AMPK. In addition to its allosteric regulation by the ratio [ATP]/[AMP], AMPK can 
also be regulated by other metabolic signals. As mentioned above, the β-subunit contains a 
GBD and indeed, AMPK binds glycogen, which then inhibits AMPK activity [242]. Therefore, 
AMPK is also known as a glycogen sensor. βAMPK can also be myristoylated, which 
results in decreased AMPK activity and localization to cellular membranes. Although not 
well defined, myristoylation of AMPK may be another regulatory mechanism of intracellular 
localization and localized activity [243].    
The catalytic subunit of AMPK has been investigated in detail and it is well 
established that AMPK requires phosphorylation in order to be active [244]. What is less 
understood is the autoinhibitory/autoregulatory domain (AID) of the catalytic subunit. The 
AID, a sequence of 23 amino acids (313-335) (Figure 1.12.) [245], is thought to modulate 
the kinase domain and block activity; however, proof of this mechanism is lacking [238]. C-
terminal to the AID is a less characterized region, now termed the α-hook (Figure 1.12.). In 
an elegant study published earlier this year, structural analysis of AMPK provided new 
evidence that there is a direct interaction between the α and γ subunits, which potentially 
regulates kinase activity. The α-hook interacts with CBS3 on the γ subunit when it is bound 
to AMP, protecting the exchange of AMP with ATP at this site. Moreover, this interaction 
protects AMPK Thr172 from dephosphorylation through an overarching structural stabilizing 
conformation [235].  Thus, not only does adenylate binding regulate AMPK activity, the 
conformational changes that occur as a result of adenylate binding are also critical for 
AMPK activation.  
AMPK is allosterically activated by AMP under conditions of nutrient stress, which 
changes the ratio of [ATP]/[AMP]. Allosteric activation of AMPK initially increases its kinase 
activity fivefold [231]. AMP binding not only deems AMPK a better substrate for 
phosphorylation by its upstream kinases [244], but also prevents dephosphorylation by 
phosphatases [246]. AMPK is phosphorylated on Thr172 by LKB1 (liver kinase B1), a 
serine threonine kinase which acts in a complex with the scaffolding protein MO25 and 
pseudokinase STRAD (also known as protein kinase LYK5) [247]. The recent generation of 
LKB1-/- mice [248, 249], specifically in the heart [250], has further demonstrated the 
importance of LKB1 regulation of AMPK. AMPK can also be phosphorylated by 
Ca2+/Calmodulin-dependent protein kinase kinases (CaMKK α and β) [251, 252], although 
its implications in the heart have not been investigated. Another kinase that phosphorylates 
AMPK on Thr172 is TGF-β-activated kinase-1 (TAK1), although this kinase is not well  
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Figure 1.12. The structure of mammalian AMPK. 
(A) The linear structure of AMPK containing protein domains of the α1, β2, and γ1 subunits. 
The kinase domain of α1 (and α2, not shown) contains Thr172 within the activation loop. 
The β-subunit binding domain (L) is also labeled.  Domains within the β2 subunit include the 
glycogen binding domain (GBD), and shown in green, the α- and γ- subunit binding 
sequence. Shown in red on the γ1-subunit are the bateman domains (CBS1-4) which are 
responsible for adenylate binding. (B) Ribbon diagram of the structure of AMPK showing 
the interaction between all three subunits. The inset is a zoomed-in view of the activation 
loop. Key amino acid residues are labeled. (C) A space filling model of the 3 dimensional 
structure of AMPK. Colors identifying domains within the subunits are consistent throughout 
the figure. Reprinted with permission from Macmillan Publishers Ltd. [Nature] [235]. 
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characterized [253, 254]. Other phosphorylation sites on αAMPK have been identified such 
as Thr258 and Ser485/491: however, the kinases involved have not been determined [255].   
AMPK activity is not only prevented by its autoinhibitory domain within its catalytic 
subunit as previously discussed, it is also attenuated by several protein phosphatases (PP). 
AMPK can be dephosphorylated by PP1 [256], PP2A [257] and PP2C [246, 258].The tissue 
specificity and other details regarding AMPK dephosphorylation is an area that requires 
more investigation.  
While the regulatory mechanisms of AMPK activity have been investigated mostly in 
vitro, the in vivo consequences of AMPK activation on metabolism, organ function, and 
disease continue to be a hot topic of investigation. Because of the vast amount of 
knowledge on AMPK, only a minor fraction will be discussed here, with an emphasis on 
AMPK in the heart, the focus of the next section. 
1.4.2. An Overview of the Central Role of AMPK in the Heart 
 AMPK is activated under conditions of metabolic stress, as discussed above. In the 
heart specifically, such conditions include ischemia and exercise. While it is clear that 
AMPK is an important factor in heart disease, conflicting reports complicate our 
understanding of the role of AMPK in conditions of pressure overload, volume overload, 
and various models of heart failure. Whether AMPK activation is a cause or consequence in 
these settings is yet to be determined [259, 260]. 
 During ischemia, decreased delivery of substrates to cardiomyocytes results in 
decreased ATP production, increased levels of AMP, and consequently activation of AMPK 
in the heart [261]. Once activated, AMPK increases glycolysis, glucose uptake, and fatty 
acid oxidation [261-263]. Initially during ischemia, when oxygen levels are low and the 
energy demand of the heart is high, glycogen stores are mobilized to glucose, which is 
metabolized further to produce ATP [264]. AMPK also promotes glucose uptake through the 
translocation of the glucose transporter GLUT4, although the exact mechanisms through 
which this occurs are still uncertain [265]. Activation of AMPK enhances fatty acid oxidation 
by inhibiting acetyl-CoA carboxylase (ACC), which carboxylates acetyl-CoA to malonyl-
CoA. Because malonyl-CoA inhibits fatty acid entry into the mitochondria for β oxidation, 
decreased malonyl-CoA levels lead to enhanced fatty acid oxidation, which occurs in the 
heart during ischemia [261]. Thus, activation of AMPK during ischemia seems to protect the 
heart by providing the necessary fuel for cardiac function through increased glucose uptake 
and enhanced fatty acid oxidation.  
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 Prolonged ischemia and reperfusion after ischemia can be detrimental to the heart, 
partially due to activated AMPK. As mentioned above, activation of AMPK during the initial 
phase of ischemia leads to glycogen breakdown, specifically by glycogen phosphorylase 
through AMPK-mediated activation of phosphorylase kinase. However, with continual low 
oxygen availability during instances of severe prolonged ischemia, the heart relies almost 
exclusively on ATP derived from glycolysis [266]. Accumulation of the byproducts from 
glycolysis is detrimental to the heart and can lead to apoptosis and cardiac dysfunction 
[267]. AMPK is also activated during reperfusion after ischemia, which can be injurious to 
the heart [261]. AMPK increases fatty acid oxidation during acute ischemia. Upon 
reperfusion, the high levels of fatty acid oxidation contribute to decreased cardiac function 
[266].     
 While the role of AMPK during cardiac hypertrophy is still unclear and is somewhat 
controversial, a brief discussion is necessary. The first report of AMPK in the hypertrophic 
heart showed increased AMPK phosphorylation after 17 weeks of ascending aortic banding 
[268]. It is not clear from this study whether AMPK activation was cause or consequence of 
hypertrophy, but after 17 weeks hearts from banded rats displayed a severe cardiac 
metabolic phenotype. The ratio of [ATP]/[AMP] was significantly decreased, AMPK activity 
was increased, and glucose uptake was enhanced [268]. An independent study found that 
in late stage hypertrophy, glycolysis was also increased [269]. In vitro evidence suggests 
that AMPK activation is a consequence of hypertrophy as phenylephrine-treated 
cardiomyocytes hypertrophy but show no signs of AMPK phosphorylation [270]. 
Furthermore, rats treated with the AMPK activator AICAR showed signs of decreased 
hypertrophy after 7 weeks of banding [271]. Although many more studies are still required, 
it is tempting to speculate that the activation of AMPK occurs after the onset of hypertrophy 
as the heart metabolically adapts to the stress. Continual hemodynamic stress, however, 
leads to chronic AMPK activation, causing metabolic derangements which lead to 
maladaptation [272], and ultimately heart failure.   
 AMPK is a critical metabolic enzyme; however, it is also involved in other cellular 
processes not generally thought to be “metabolic” in nature. When investigating the role of 
AMPK in hypertrophy, Chan et.al. discovered that in cardiomyocytes activation of AMPK 
reverses phenylephrine-induced hypertrophy [270]. AMPK attenuates hypertrophy by 
inhibiting protein synthesis through inactivation of the mTOR signaling pathway [273, 274]. 
Protein synthesis is an energetically demanding process. Therefore when the cell 
experiences energetic stress it is reasonable that protein synthesis would be decreased to 
preserve energy and that this process would be regulated by AMPK. In keeping with this 
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reasoning, it is logical that AMPK would concomitantly enhance protein degradation, a 
reservoir of substrates for ATP production via amino acid catabolism.   
 The ATP requirement for protein degradation has been recognized for some time 
[31, 68], but the direct role that AMPK plays in regulating this process has only recently 
been investigated. The first evidence that AMPK is directly involved in protein degradation, 
specifically through autophagy, was reported 10 years ago in a mutant yeast strain that had 
deficient glycogen stores. The gene responsible for this defect, snf1, is the yeast 
homologue of mammalian AMPK. Furthermore, two regulators of autophagy, Apg1 and 
Apg13, that are required for maintenance of glycogen storage, were found to be regulated 
by AMPK [275, 276]. Recent studies have demonstrated that AMPK is also required for 
autophagy in mammalian cells [277, 278]. Moreover, the importance of AMPK-regulated 
autophagy in the heart, particularly during glucose deprivation and ischemia/reperfusion 
has been reported [279]. Recent developments in AMPK-regulation of autophagy are 
reviewed in [280]. 
 At the onset of my thesis project nothing had been reported on AMPK-mediated 
protein degradation through the ubiquitin proteasome system. However, after the 
generation of my early results suggesting the positive effect of AMPK on proteasome-
mediated protein degradation, several reports with conflicting results were published (see 
chapter 5 for further discussion). One report suggested that AMPK activation by AICAR 
reduced proteasome activity and that this could be rescued by ectopic expression of 
dominant negative AMPK [281]. The same group reported that AMPK interacts with a 
subunit of the proteasome, PSMD11, using a yeast two-hybrid screen [282]. Although 
initially identified by its interaction with β2MPK, coimmunoprecipitation experiments found 
that PSMD11 also interacts with and is phosphorylated by α2AMPK [282]. The AMPK 
phosphorylation sight on PSMD11 has not been determined and it is unclear whether 
AMPK-mediated phosphorylation of PSMD11 decreases proteasome activity [282]. The 
yeast two-hybrid screening in this study was performed using human skeletal muscle cDNA 
library. Interestingly, some of the same proteins found to interact with Atrogin-1 and MuRF1 
were also identified as potential binding partners with AMPK. This study identified 
tropomodulin 1 and myozenin 1 as α2AMPK binding partners, and the receptor for 
activated protein kinase C (RACK1) as a binding partner for β2AMPK [282]. Although 
follow-up studies have not been reported, these results provide insight into AMPK 
localization within muscle cells, and AMPK-regulated processes yet to be defined. These 
intriguing discoveries and their ramifications are discussed in more detail chapter 5.  
38 
 
 Another cellular process regulated by AMPK which has been the focus of recent 
studies is transcriptional regulation [283]. Early reports focused on the transcriptional 
regulation of metabolically-regulated genes by AMPK in the liver [284]. AMPK inhibits 
gluconeogenesis and does so in part by phosphorylating and inactivating carbohydrate 
response element binding protein (ChREBP), thereby decreasing transcription of pyruvate 
kinase [285]. Additionally, AMPK phosphorylates the CREB regulated transcription 
coactivator -1 (CRTC2), which consequently inhibits transcription of phosphoenolpyruvate 
carboxylase and glucose-6-phosphate [286]. AMPK-mediated inhibition of fatty acid 
synthesis and storage also occurs in a transcriptional manner. AMPK phosphorylates and 
inactivates sterol response element binding protein-1c (SREBP-1c) in liver, subsequently 
decreasing expression of the lipogenic genes fatty acid synthase and acetyl-CoA 
carboxylase in liver [287]. AMPK inhibits fatty acid storage partly by phosphorylating the 
transcriptional coactivator p300 and thus decreasing its interaction with peroxisome 
proliferator-activated receptor-γ (PPAR-γ) [288].  
 AMPK also positively regulates transcription. Activation of AMPK enhances 
glycolysis by increasing hexokinase II (HKII) though phosphorylation of the transcription 
factor CREB [289]. This same mechanism also increases expression of uncoupling protein 
3 (UCP3) thereby enhancing ATP production [290]. Additionally, AMPK enhances 
mitochondrial biogenesis at the transcriptional level by two known mechanisms. First, 
AMPK increases the expression of PPAR-γ coactivator-1α (PGC1-α) [291] and second, 
AMPK activates silent information regulator two number 1 (SIRT1) [292]. The most 
commonly investigated metabolic consequence of AMPK activation is enhanced glucose 
uptake, which is also regulated at the transcriptional level. AMPK activates MEF2-regulated 
expression of GLUT4 [293] in an HDAC 5-dependent manner in skeletal muscle [294]. 
Perhaps the most intriguing finding to date is that AMPK appears to regulate transcription of 
entire “gene programs”. In mammalian cells, AMPK phosphorylates histone 2B, thus 
allowing for a more global transcriptional response during metabolic stress [295, 296]. 
 In an effort to delineate the role of AMPK in the heart, numerous mouse models 
have been generated and are summarized in Table 1.2 and reviewed in [297]. A major 
obstacle in this effort is the multidimensional nature of AMPK (three isoforms with some 
containing splice variants) as discussed previously. The first mouse models generated were 
transgenic mice overexpressing a mutant form of AMPKα2 resulting in the expression of a 
dominant negative kinase. AMPKα2 D157A expressed in the heart (Tg) resulted in normal  
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Table 1.2. AMPK transgenic and knockout mice.   
A list of transgenic and knockout mouse pertinent to the heart. See text for detailed 
description of the disease and phenotype of each mouse. Reprinted with permission from M 
Arad, CE Seidman, and JG Seidman, AMP-activated protein kinase in the heart: role during 
health and disease, Circulation Research, 100, 4, 474-488 [305].  
Genetically Engineered AMPK Mice 
Name Gene Mutation Promoter Disease/ Pheontype Reference 
α1-/- 
PRKAA1 
(α1) 
KO Endogenous None [299] 
α2
-/- 
PRKAA2 
(α2) 
KO Endogenous 
Glucose intolerance, 
increased 
catechoalamines 
[300] 
Tg α2DN 
PRKAA2 
(α2) 
D157A αMHC 
Decreased glucose 
uptake 
[298] 
Tg α2DN 
PRKAA2 
(α2) 
K45R Creatine kinase 
Decreased glucose 
uptake and ischemic 
tolerance 
[301] 
TgR302Q 
PRKAG2 
(γ2) 
R302Q αMHC 
PRKAG2 
cardiomyopathy, 
glycogen storage 
[302] 
TgN488I 
PRKAG2 
(γ2) 
N488I αMHC 
PRKAG2 
cardiomyopathy, 
glycogen storage 
[303] 
TgR531G 
PRKAG2 
(γ2) 
R531G αMHC 
PRKAG2 
cardiomyopathy 
[304] 
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cardiac phenotype at baseline [298]. During ischemia, hearts from Tg mice fail to increase 
glucose uptake and develop left ventricular dysfunction. Hearts from whole body AMPKα2-/- 
mice are phenotypically normal, based on echocardiographic measurements. In response 
to ischemia, ACC was not phosphorylated in the heart. The hearts from these mice, like the 
AMPKα2 D157A Tg mice, failed to adapt metabolically to ischemia but were still able to 
functionally recover during reperfusion [306]. Moreover, AMPKα2-/- mice subjected to 7 
days of isoproterenol injections developed greater hypertrophy than WT mice [307]. These 
studies support initial claims that AMPKα2 is the prominent catalytic subunit in the heart 
and is required for adaptation to stress.  
 Another AMPKα2 transgenic mouse was generated using a creatine kinase 
promoter, resulting in transgenic expression in both skeletal muscle and heart. AMPKα2 
K45R, like D157A, results in a dominant negative kinase. These mice were exclusively 
used to study the consequences of inactive AMPK in muscle [301].  Akin to the D157A 
mutation, K45R results in decreased glucose uptake in muscle, although the ramifications 
of this mutation on the heart are not known at present. Mice deficient for AMPKα1, like the 
AMPKα2-/- mice, are phenotypically normal, although the cardiovascular phenotype in these 
mice has not been investigated [299].   
The γ−subunit has been well studied in the mouse heart. Patients with hypertrophic 
cardiomyopathy characterized by enhanced glycogen storage and electrical abnormalities 
seen in Wolff-Parkinson-White syndrome, have genetic mutations within prkag2, the gene 
encoding for AMPKα2 [305]. As a result, three different strains of mice have been 
generated to investigate the different human genetic mutations on prkag2. All three 
mutations in the heart result in cardiomyopathy, whereas only the R302Q and N488I 
mutation lead to glycogen storage [302, 303, 308]. All mouse models discussed above have 
been instrumental to our understanding of AMPK; however, much more work is required to 
completely understand the complex regulation of AMPK and the consequences of its 
activation in the heart.               
1.5. AMPK: A Proposed Link Between Cardiac Metabolism and Protein Turnover 
 It is well established that AMPK inhibits protein synthesis and increases autophagy, 
but whether AMPK regulates the ubiquitin proteasome system in the heart is not known.  
Stress, particularly nutrient stress has been shown to increase protein degradation in the 
heart [309]. Nutrient stress also alters the ratio of [ATP]/[AMP] and thus activates AMPK is 
activated in the heart. Furthermore, the ubiquitin ligases Atrogin-1 and MurF1 are 
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significantly increased in response to nutrient deprivation in muscle [141]. Based on these 
studies I set out to test the hypothesis that AMPK regulates the ubiquitin proteasome 
system in the heart, potentially though regulation of ubiquitin ligases.  
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Chapter 2 
 
 
MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The techniques have galloped ahead of the concepts. We have moved away from studying 
the complexity of the organism; from processes and organisation to composition [310].”   
~~Sir James W. Black, (1988) Nobel Prize for the invention of propranolol [311] 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Animals 
 All animals were cared for according to the National Institutes of Health guidelines. 
The protocols were approved by the Animal Welfare Committee of The University of Texas 
Health Science Center at Houston.  
 For some of the experiments I used rats. Neonatal Sprague-Dawley rats (1-2 days 
old, Texas Animal Specialties, Humble, TX) were used for the isolation of neonatal rat 
cardiomyocytes (NRVM), see section “2.2.4. Isolation of neonatal rat ventricular 
cardiomyocytes”. 
 For some of the experiments I used genetic mouse models. Mice heterozygous for 
MAFbx/Atrogin-1 or MuRF1 were kindly provided by Regeneron Pharmaceuticals 
(Tarrytown, NY) [99]. The research group was headed by Dr. David Glass (now with 
Novartis, Cambridge, MA), and they discovered the muscle specific ubiquitin ligases MAFbx 
and MuRF1 in screens for so-called “atrogenes”, genes involved in the regulation of skeletal 
muscle atrophy [99]. Simultaneously, Dr. Alfred Goldberg’s group, Harvard Medical School, 
Boston, MA,  identified Atrogin-1 (MAFbx) as a key ubiquitin ligase in muscle induced by 
fasting, diabetes, cancer, and renal failure [98]. Both MAFbx/Atrogin-1+/- or MuRF1+/- strains 
were previously backcrossed into C57BL/6 mice. Heterozygous mice were bred to generate 
MAFbx/Atrogin-1-/-, MuRF1-/-, MAFbx/Atrogin-1-/- MuRF1-/- (double knockout), and 
MAFbx/Atrogin-1+/+ MuRF1+/+ (wild type, WT) mice. 
 Transgenic mice expressing desMEF2-LacZ were kindly provided by Drs. Eric Olson 
and Rhonda Bassell-Duby, The University of Texas Southwestern Medical Center, Dallas, 
TX  [312]. These mice harbor a lacZ reporter gene downstream of three tandem repeats of 
the MEF2 binding site flanked by desmin enhancer sequences. LacZ is expressed in the 
heart and muscle during development, particularly during embryonic days 7.5-14.5. The 
expression of lacZ declines after birth, and is not basally expressed in the adult heart and 
muscle. Although MEF transcription factors are not solely expressed in the heart and 
muscle, lacZ expression in this mouse line is driven by the desmin promoter, which is. 
Therefore, this transgenic line is a valuable tool to study MEF2-regulated processes in the 
heart and muscle [312].   
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2.1.2. Cell Lines 
H9c2(2-1) cardiac myoblasts (Figure 2.1.) were purchased and cultured according 
to American Type Culture Collection (ATCC, Manassas, VA) guidelines. These cells are a 
subclone of the original H9c2 cells derived from BDIX rat heart tissue (embryonic day 13) 
using a modified selective serial passage technique [313]. The ventricular portion of the 
embryonic rat heart was cultured and passaged for two months. The resulting cells were 
spindle-shaped and grew in a parallel fashion. The cells from the H9c2(2-1) subclone 
resemble skeletal muscle because they can fuse to form multinucleated tube-like structures 
when confluent. The cell line displays many properties characteristic of both skeletal muscle 
and cardiomyocytes such as the existence of T-tubules and the ability to generate action 
potentials [313]. H9c2 cells have been further characterized as having cardiac L-type 
calcium currents (slow depolarization, compared to skeletal muscle) [314, 315]. 
Because primary cardiomyocytes are difficult to genetically manipulate without the 
use of viral transduction, H9c2 myoblasts were used for lacZ reporter assays and some 
preliminary experiments. Upon arrival on dry ice, H9c2 cells (approximately 1mL) were 
thawed at 37ºC, resuspended in preincubated media1(0mL), and cultured in a sterile 
incubator at 37ºC in 95% air, 5% CO2. Cells were passaged every 3-4 days to prevent over-
confluency, which changes the phenotype of the cells. Cells to be passaged were rinsed 
once with warm sterile PBS and incubated for several minutes with Trypsin (0.25% w/v) - 
EDTA (0.53 mM) until they lifted off the plate. Cells were split at a 1:4 ratio and subcultures 
were preserved in freezing medium (FBS [20%], Complete medium [60%], DMSO [20%]) at 
-20ºC for 24 hours and then stored at -80ºC. Experiments were performed in low passage 
H9c2 cells to prevent loss of cardiac phenotype. 
 HEK293 cells were kindly provided by Dr. Carmen Dessauer; The University of 
Texas Health Science Center at Houston, Department of Integrative Biology and 
Pharmacology. These cells were used for the propagation and titration of adenoviruses as 
they are currently the only cell line available to generate high titer adenoviruses [316]. The 
cells were passaged every 3-4 days and grown to 90% confluency according to ATCC 
guidelines.  
2.1.3. Equipment 
The following equipment was used for my experiments. ABI Prism® 7000 Sequence 
Detection System (Applied Biosystems, Carlsbad, CA); Axioskop 40 fluorescent microscope 
(Carl Zeiss MicroImaging, LLC, Thornwood, Thornwood, NY); Baker Company SterilGARD  
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A 
B 
C 
D 
Figure 2.1. Cells used for mechanistic studies. 
(A) H9c2 cardiac myoblasts expressing nuclear β-galactosidase in bright field. 
(B) Neonatal rat ventricular cardiomyocytes (NRVM) in bright field. (C) NRVM 
expressing green fluorescent protein (GFP) in bright field. (D) 
Immunocytochemistry of WT adult mouse cardiomyocites (AMCM); alpha-actinin
in green and nucleus in blue (DAPI stain). 
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VBM-400 Biological Safety Hood (Artisan Scientific Corporation, Champaign, IL); Beckman 
Coulter Allegra 25R centrifuge (Beckman Coulter, Brea, CA); Biospec USR70/30 magnetic 
resonance imager (MRI)  (Bruker Biospin MRI, Billerica, MA); Doppler Signal Processing 
Workstation (Indus Instruments, Webster, TX); ELx800 Absorbance Microplate Reader 
(BioTek, Winooski, VT); Eppendorf 5804R refrigerated centrifuge (Eppendorf, Hauppauge, 
NY); Gemini Cautery System (SouthPointe Surgical Supply, Inc., Coral Springs, Florida); 
Hermle Z300 Centrifuge (HERMLE Labortechnik GmbH,  Wehingen, Germany); IN835 
Inverted Compound Microscope (Nova, Portland, OR); Isotemp* Economy Analog-Control 
Water Bath (ThermoFisher Scientific, Waltham, MA); Isotemp* PPO Heating Circulator 
(Fisher Scientific, Waltham, MA); Mouse Cardiovascular Research System (MVRS) Doppler 
and electrode board (Indus Instruments, Webster, TX); MyCycler Thermal Cycler (Bio-Rad, 
Hercules, CA); NanoDrop® ND-1000 spectrophotometer (Nanodrop Technologies, 
Wilmington, DE); Ohaus AS120 scale (Ohaus, Florham Park, NJ); Packard 2200 liquid 
scintillation counter (Packard Instruments, Warrenville, IL); POLARstar OPTIMA 
fluorometer (BMG LABTECH, Cary, NC); Power Gen 35 Micro Homogenizer (Omni 
International, Kennesaw, GA); Professional Cell Culture CO2 Incubator (Sanyo Electric 
Biomedical Co., Ltd., Moriguchi City Osaka, Japan); PTC-100 Thermoblock (MJ Research, 
Waltham MA); Revco® -80ºC freezer (Thermo Scientific, Asheville, NC); Small animal 
monitoring system Model 1025 (Small Animals Instruments, Inc., Stony Brook, NY); SRX-
101A Medical Film Processor (Konica Minolta Medical Imaging USA, Inc., Wayne, NJ); TD-
1000R Bi-O-Vision Dual-Light Transilluminator (Spectroline, Westbury, NY); Precision 2870 
Reciprocal Shaking Bath (Thermo Fisher Scientific, Waltham, MA); Variable-Flow Peristaltic 
Pump (ThermoFisher Scientific, Waltham, MA); Vevo 770 ultrasound system (Visual Sonics 
Inc., Tornoto, Ontario, Canada);  Sanyo® -20ºC freezer (Sanyo Scientific, Bensenville, IL).  
2.1.4. Reagents 
The following chemicals of analytical or appropriate grade were used. From Sigma 
(St. Louis, MO): 0.25% (w/v) Trypsin-0.53 mM, Ethylenediaminetetraacetic acid (EDTA), 
2,3-butanedione monoxime (BDM), 3-Methyladenine (3-MA), Agarose, Ammonium 
persulfate (APS), β-glycerophosphate, β-mercaptoethanol, Boric acid, Bovine Serum 
Albumin, Bromophenol blue, Calcium Chloride (CaCl2), Dimethyl sulfoxide (DMSO), 
Disodium hydrogen orthophosphate (Na2HPO4), Dithiothreitol (DTT), 
Ethylenediaminetetraacetic acid (EDTA), Ethylene glycol tetraacetic acid (EGTA), Ethanol 
(100%), Ethidium bromide, Formaldehyde, Glucose, Gluteraldehyde, Glycine, Hydrochloric 
acid (HCl), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), Isopropanol 
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(100%), Isoproterenol, Lithium chloride (LiCl), Magnesium sulfate (MgSO4), Magnesium 
sulfate heptahydrate (MgSO4-7H2O), Methanol, Monopotassium phosphate  (KH2PO4), 
Monosodium phosphate (NaH2PO4), Octyl phenoxypolyethoxylethanol (Nonidet P-40), 
Pancreatin, Pencillin G Potassium Salt, Paraformaldehyde, Phenol red, Phenylephrine 
(PE), Potassium chloride (KCl), Potassium ferricyanide (K3Fe(CN)6), Potassium 
ferrocyanide (K4Fe(CN)6), Proteinase K (10mg/mL), Sodium ATP (Na-ATP), Sodium azide, 
Sodium bicarbonate (NaHCO3), Sodium chloride (NaCl), Sodium-deoxycholate, Sodium 
Fluoride (NaF), Sodium-HEPES, Sodium molybdate (Na2MoO4 ); Sodium pentobarbital, 
Sodium pyrophosphate (Na4P2O7), Taurine, Tergitol-type nonyl phenoxypolyethoxylethanol 
(NP-40), Tetramethylethylenediamine  (TEMED), Trichloracetic acid (TCA), Tris base, Tris-
buffered phenol, Tris-HCl, Trisodium phosphate (Na3PO4), Triton X-100, and Tween 20.   
 The following chemicals and reagents were obtained from EMD Biosciences (San 
Diego, CA): Compound C, Cyclosporin A, DAB substrate buffer, and Rapamycin. Additional 
chemicals used were from different venders and are listed as follows: Bortezomib (Selleck 
Chemicals, Houston, TX), Bovine Serum Albumin protein standard (1mg/mL) and 
Chloroform (Invitrogen, Carlsbad, CA), 30 % Acrylamide/Bis and Precision Plus Protein All 
Blue Standards and Sodium dodecyl sulfate (SDS) (BioRAD, Hercules, CA), Collagenase II 
(Worthington Biochemical Corporation, Lakewood, NJ), Heparin (MP Biomedicals, Irvine, 
CA), N-(β-D-Ribofuranosyl)-5-aminoimidazole-4-carboxamide (AICAR) (Toronto Research 
Company, Ontario, Canada), Percoll (Pfizer, New York, NY), Protease inhibitor complete 
tablet (Roche, San Francisco, CA), and Radiolabeled phenylalanine (Perkin Elmer, Boston, 
MA). 
The following reagents were from Sigma (St. Louis, MO): Bradford Reagent, Insulin/ 
Transferrin, Selenium (ITS, medium supplement), Ponceau Stain, and Synthesized 
oligonucleotide primers/ probes/ cDNA. 
The following reagents were from Thermo Fisher Scientific (Waltham, MA ): Bovine 
Calf Serum, Calf serum (Hyclone, Logan, UT), Newborn Calf Serum, and Ultima Gold® 
liquid Scintillation Cocktail.  
The following reagents were from VWR (Radnor, PA): CellGro DMEM 4.5g/L 
Glucose & L-Glut, w/o Sodium Pyruvate, Diethylpyrocarbonate (DEPC)-treated water, 
FK506, and Laminin coating solution.  
 The following reagents were from Invitrogen (Carlsbad, CA): β-Galalactosidase 
Assay Kit, MEM (Eagle’s with HBSS), Penicillin/Streptomycin (100U/mL), Phosphatase 
inhibitor cocktails I-III, Phosphate Buffered Saline (PBS; without calcium and magnesium), 
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Prolong Gold mounting media with DAPI, Proteinase K, Reverse transcriptase and PCR 
reaction buffers, and Superscript II. 
 Additional reagents used were from Eton Biosciences (San Diego, CA): aAMPK 
adenovirus, dnAMPK adenovirus, and a null adenovirus; and from Promega Corporation 
(Madison, WI):  β-galactosidase (1 unit/µL), β-galactosidase Enzyme Assay System, 
Luciferase Assay System, and QuantiLum® Recombinant Luciferase. The β-galatosidase 
expression vector [317] was kindly provided by Dr. Joseph Alcorn (University of Texas 
Medical School, Houston). Additional reagents used were from different venders and are 
listed as follows: PolyJet™ (SignaGen® Laboratories, Rockville, MD); Taq polymerase 
(recombinant origin, isolated in the lab from Escherichia coli), TRI® Reagent (Molecular 
Research Center, Cincinnati, OH), Western Blotting Luminol Reagent (Santa Cruz, Santa 
Cruz, CA), and X-Gal (5-bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside (Fermentas, 
Ontario, Canada ). 
The following kits were used according to the manufacturer’s instructions: AdEasy 
viral titer kit (Stratagene, La Jolla, CA), DNeasy Blood & Tissue Kit (Qiagen, Germantown, 
MD), Nuclear Extract Kit and TransAM™ MEF2 Transcription Factor Assay Kit (Active Motif, 
Carlsbad, CA).  
The following antibodies were used (Table 2.1.). All antibody dilutions were made in 
non-fat powdered milk (5%, in Tris-Buffered Saline containing Tween 20 [0.4%], [TBST]). 
Primary antibodies were preserved with sodium azide [0.2% in ddH2O]. AMPKα  (1:1000), 
phospho-AMPKα (Thr172, 1:1000), Acetyl CoA Carboxylase (ACC)  (1:1000), phospho- 
ACC (Ser79, 1:1000), β-Tubulin (9F3,1:1000), Forkhead transcription factor 3 (FOXO3A) 
(1:500), phospho-FOXO3A (Ser253,1:500), AKT (1:1000), phosphor-AKT (Thr308, 1:500), 
mammalian target of Rapamycin (mTOR) (1:1000), phosphor-mTOR (Ser2488, 1:500), and 
CD31 (Platelet Endothelial Cell Adhesion Molecule-1: PECAM-1) (1:200) antibodies were 
from Cell Signaling Technology (Danvers, MA). Histone deacetylase 5 (1:500), phospho-
histone deacetylase 5 (Ser498,1:500), MuRF1 (1:500), and anti-adenovirus hexon protein 
(1:1000) antibodies were from Abcam (Cambridge, MA), the Atrogin-1 antibody (1:1000) 
was from ECM biosciences LLC (Versailles, KY),  the Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, 1:60,000) antibody was from Fitzgerald Industries International 
(Acton, MA),  and the MEF2 (C-21) antibody was from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). 
The following items from Thermo Fisher Scientific (Waltham, MA) were also used: 
Cell strainer, Hemacytometer, Primaria cell culture plates.  
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Table 2.1. Antibodies and dilutions. 
Detailed list of antibodies used. See text for details. 
  
Antibodies and Dilutions 
Name Dilution Molecular Weight (kDa) Vender/Product 
AMPKα 1:1000 62 Cell Signaling/ 2532 
pAMPKα (Thr172) 1:1000 62 Cell Signaling/ 2531 
ACC 1:1000 280 Cell Signaling/ 3662 
pACC (Ser79) 1:1000 280 Cell Signaling/ 3661 
β-Tubulin 1:1000 55 Cell Signaling/ 2128 
FOXO3A  1:500 82-97 Cell Signaling/ 9467 
pFOXO3A (Ser253) 1:500 82-97 Cell Signaling/ 9466 
AKT 1:1000 60 Cell Signaling/ 4685 
pAKT (Thr308) 1:500 60 Cell Signaling/ 4056 
mTOR 1:1000 289 Cell Signaling/ 2972 
pmTOR (Ser2488) 1:500 289 Cell Signaling/ 2971 
CD31 1:200 Used for staining Cell Signaling/ 2538 
HDAC5 
1:500,  
2µg for ChIP 
122 Abcam/ ab1439 
pHDAC5 (Ser498) 1:500 122 Abcam/ ab47283 
MuRF1 1:500 40 Abcam/ ab77577 
anti-adenovirus 
hexon protein 
1:1000 Used for staining Abcam/ ab21116 
Atrogin-1 1:1000 41 
ECM biosciences LLC/ 
AP2041 
GAPDH 1:60,000 37 
Fitzgerald Industries 
International/ 10R-
G109A 
MEF2  2µg for ChIP Used for IP Santa Cruz/ C-21 
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2.2. Methods 
2.2.1. Maintenance of Mouse Lines 
The following mouse lines were maintained: MAFbx/Atrogin-1-/-, MuRF1-/-, MAFbx/Atrogin-
1+/+ MuRF1+/+ (wild type, WT) all from Regeneron (Tarrytown, NY) through Dr. David Glass 
(now at Novartis, Cambridge, MA). Single knockout mice were crossed to generate 
MAFbx/Atrogin-1-/- MuRF1-/- (double knockout) mice, and desMEF2-LacZ transgenic mice 
from Dr. Eric Olson (The University of Texas Southwestern, Dallas, TX) were also 
maintained. Breeding pairs successfully produced 6-8 litters and were retired thereafter. 
Mice were routinely genotyped by PCR using genomic DNA extracted from the tail. Tails 
were clipped (<0.5mm) at age 3 weeks and cauterized to prevent bleeding. Tails were 
digested and DNA was isolated using the DNeasy Blood & Tissue Kit (Qiagen) according to 
the manufacturer’s instructions. The primer sequences and PCR protocols for 
MAFbx/Atrogin-1, MuRF1, and desMEF2-LacZ genotyping are shown in Table 2.2. and 2.3. 
For double knockout and WT mice, MAFbx/Atrogin-1 and MuRF1 genotyping PCR 
reactions were performed independently. PCR products (20µL) were mixed with DNA 
loading buffer (5µl of glycerol [3mL of 100%], bromophenol blue [25mg], ddH2O [7mL]) and 
run on a 1% agarose gel in TBE buffer (Tris base [1.08g], Boric acid [5.5g], EDTA [20mL of 
0.5M] in 1L DEPC-treated water) at 150mV (Figure 2.2). Genotyping results, mouse 
identification and location, breeding pairs, and experimental setup were all recorded in a 
database using Microsoft® Access.  
2.2.2. Transverse Aortic Constriction in Mice 
 Transverse aortic constriction (TAC), originally described by Rockman et.al., is a 
surgical procedure used to induce cardiac hypertrophy in vivo [318]. Although hypertrophy 
develops more rapidly than what occurs physiologically, this method allows for the 
reproducible development of extreme hypertrophy and is used to investigate mechanisms 
of development, inhibition, and reversal of cardiac hypertrophy. These experiments were 
performed in collaboration with Drs. Aarif Khakoo and Vishnu Chintalgattu at The University 
of Texas MD Anderson Cancer Center (presently at Amgen, San Francisco, CA). Animal 
protocols were approved by the Animal Welfare Committee of The University of Texas MD 
Anderson Cancer Center. 
Male mice (C57/BL6, 8 weeks old) were kept under continuous anesthesia with 
isofluorane (2%) and taped to a heated procedure board (37ºC) containing ECG electrodes 
in the supine position. Mice were intubated, ventilated, and a cervical incision was made  
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Table 2.2. Mouse genotyping primers. 
PCR was performed on mouse tail DNA using the primers above. Atrogin-1-/- mice were 
genotyped using two reactions: one to detect the WT gene (using MA61KO, F1 and 
MA61KO, R1) and one to detect the knockout gene (using MA61KO, F1 and MA61KO, 
LacZ). MuRF1-/- mice were genotyped using one reaction with MA16KO5’F2, LacZ-R, and 
MA16KO5’R2. MEF2-LacZ transgenic mice were genotyped using one reaction with LacZ 
3’ and LacZ 5’. 
  
Primer Name Primer Sequence 
MAFbx/Atrogin-1 forward primer 
(MA61 KO, F1) 
5’ – AACAAAGAGACGGGGCAGCG – 3’ 
MAFbx/Atrogin-1 KO forward primer 
(MA61 KO, LacZ) 
5’ – TGAGGGGACGACGACAGTATCG – 3’ 
MAFbx/Atrogin-1 reverse primer 
(MA61 KO, R1) 
5’ –TCGGCGAATGTCCTCACCTG– 3’ 
MuRF1 forward primer 
(MA16 KO5’F2) 
5’ – CTCCTGGGGCTCATGTGACAGAGG – 3’ 
MuRF1 KO forward primer 
(LacZ-R) 
5’ – TAGATGGGCGCATCGTAACCGTGC – 3’ 
MuRF1 reverse primer 
(MA16 5’R2) 
5’ – GATGTCGTTGGCACACTTCCGGCA – 3’ 
LacZ 3’ 5’ – CAGTACAGCGCGGCTGAAATC – 3’ 
LacZ 5’ 5’ – CAAACTGGCAGATGCACGGTTAC – 3’ 
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PCR Reaction Mix  PCR Procotol Amplicon Length 
MAFbx/Atrogin-1 WT  
95ºC x 5 minutes 
 
94ºC x 30 seconds 
65ºC x 45 seconds     x 29 
cycles 
72ºC x 50 seconds 
 
72ºC x 2 minutes 
 
4 ºC x ∞ 
422 base pairs 
10X PCR Buffer      
MgCl2 (50mM) 
dNTP’s (2.5mM) 
MA61 KO, F1 Primer 
MA61 KO, R1 Primer 
Taq (Invitrogen) 
DEPC-treated H2O 
DNA 
2.0µL 
1.0µL 
2.0µL 
0.2µL 
0.2µL 
0.2µL 
12.2µL 
2.0µL 
MAFbx/Atrogin-1 KO    
95ºC x 5 minutes 
 
94ºC x 30 seconds 
65ºC x 45 seconds     x 29 
cycles 
72ºC x 50 seconds 
 
72ºC x 2 minutes 
 
4 ºC x ∞ 
553 base pairs 
10X PCR Buffer      
MgCl2 (50mM) 
dNTP’s (2.5mM) 
MA61 KO, F1 Primer 
MA61 KO, LacZ Primer 
Taq (Invitrogen) 
DEPC-treated H2O 
DNA 
2.0µL 
1.0µL 
2.0µL 
0.2µL 
0.2µL 
0.2µL 
12.2µL 
2.0µL 
MuRF1  
94ºC x 5 minutes 
 
94ºC x 30 seconds 
63ºC x 30 seconds     x 30 
cycles 
72ºC x 50 seconds 
 
72ºC x 2 minutes 
 
4 ºC x ∞ 
WT: 324 base pairs 
KO: 470 base pairs 
10X PCR Buffer      
MgCl2 (50mM) 
dNTP’s (2.5mM) 
MA16 KO5’F2 Primer 
LacZ-R Primer 
MA16 5’R2 Primer 
Taq (In-house) 
DEPC-treated H2O 
DNA 
2.00µL 
1.00µL 
2.00µL 
0.05µL 
0.05µL 
0.20µL 
12.65µL 
2.00µL 
desMEF2-LacZ Tg  
95ºC x 5 minutes 
 
95ºC x 30 seconds 
60ºC x 30 seconds     x 30 
cycles 
72ºC x 30 seconds 
 
72ºC x 10 minutes 
 
4 ºC x ∞ 
Tg: 400 base pairs 
10X PCR Buffer      
MgCl2 (25mM) 
dNTP’s (10mM) 
LacZ 3’ Primer 
LacZ 5’ Primer 
Taq (Invitrogen) 
DEPC-treated H2O 
DNA 
2.5µL 
1.5µL 
0.5µL 
0.5µL 
0.5µL 
0.5µL 
1.0µL 
1.0µL 
 
Table 2.3. Genotyping PCR protocols and amplicon lengths.  
PCR was performed on DNA from mouse tails as described in the text and according to the 
protocols above.  
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Figure 2.2. Genotyping Results. 
Genotyping PCR reaction products. (A) Atrogin-1 PCR performed using two reactions: one 
with primers detecting the WT allele, one with primers detecting the KO allele (labeled 
below the gel. The genotyping results are labeled above the gel; DNA from control animals 
are also labeled. (B) MEF2-lacZ PCR performed in one reaction. The genotyping results 
(including controls) are labeled above the gel. (C) MuRF1 PCR performed in one reaction. 
The genotyping results (including controls) are labeled above the gel. See text for more 
details.    
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exposing the trachea and carotid arteries. The aortic arch was isolated and a 27-gauge 
needle was tied to the transverse aorta using 7.0 silk suture (Figure 2.3.A.). The needle 
was removed creating an aortic stenosis of 0.4mm diameter (originally 1.0mm diameter). 
The chest was surgically closed, the animal was allowed to recover, and the animal was 
monitored daily. Sham operations were also performed using the same procedure except 
for the tying of the suture.Non-invasive Doppler imaging was performed the day after TAC 
surgery to verify successful placement of the suture and pressure differences across the 
carotid arteries [319]. Mice were anesthetized and placed on a procedure board as 
described above. Cardiac parameters and blood velocity signals from the right and left 
carotid arteries were obtained using a 2-mm-diameter 20-MHz Doppler probe connected to 
a Doppler Signal Processing Workstation (Indus Instruments, Webster, TX). After TAC 
surgery 90% of mice displayed an increase in peak blood velocity in the right carotid artery 
and a decrease in peak blood velocity in the left carotid artery (Figure 2.3.B.) [320, 321]. 
Heart function was analyzed (see section 2.2.5.2. Magnetic Resonance Imaging) 7, 14, 21, 
and 28 days after surgery, and tissues were collected 29 days after surgery and processed 
as described below (2.2.6. Cell and Tissue Collection and Preservation).  
2.2.3. Assessment of Cardiac Function 
2.2.3.1. Echocardiography 
Echocardiography uses high frequency sound waves (ultrasound) to transmit live 2- 
dimensional images of the heart. We used the Vevo 770 ultrasound system (above) to 
calculate cardiac dimensions (interventricular septal thickness in diastole [IVSd] and systole 
[IVSs], left ventricular posterior wall thickness [LVPW], left ventricular inner diameter in 
diastole [LVIDd] and systole [LVIDs], and left ventricular mass), cardiac volumes (left 
ventricular volume in diastole and systole), and functional parameters (heart rate [HR], 
stroke volume [SV], cardiac output [CO], fractional shortening [FS], and ejection fraction 
[EF]) [322, 323].  
Cardiac parameters and function was assessed in mice using echocardiography 
[324]. Mice were anesthetized (2% isoflurane) and the body fur was shaved from the 
anterior thorax and upper abdominal area. Acoustic coupling gel was applied to the 
abdomen. Mice were placed in the supine position with all four limbs taped to electric plates 
on a temperature-controlled board with leads used for electrocardiographic monitoring. 
Mice were maintained under 1% isoflurane during analysis of cardiac function (Vevo 770 
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Figure 2.3. Transverse aortic constriction and Doppler measurements. 
(A) Suture placement for transverse aortic constriction (TAC) surgery. (B) Doppler 
measurements 24 hours after surgery. Velocity of blood flow through the left carotid artery 
is blunted due to placement of the aortic band (top frame) whereas velocity of blood flow 
through the right carotid artery is normal (middle frame). Electrocardiogram (ECG) tracings 
of the banded heart (bottom frame). Reprinted from Ultrasound Med Biol, 34/6, Hartley CJ, 
Reddy AK, Madala S, Michael LH, Entman ML, Taffet, GE, Doppler estimation of reduced 
coronary flow reserve with pressure overload cardiac hypertrophy, Pages 892901, (2008), 
with permission from Elsevier[321] 
 
B 
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ultrasound system, Visual Sonics). After echocardiography was performed, mice were 
monitored as they recovered from anesthesia. 
M-mode parasternal short-axis scans were used to quantify ventricular diameters in 
diastole and systole. Left ventricular diameters in diastole and systole were determined by 
making 5 measurements for each parameter (IVSd, LVPW, LVIDd, LVIDs) on four different 
images of each mouse heart (Figure 2.4.). Based on these measurements, the Vevo 770 
software estimates the end-diastolic volume (EDV) and end-systolic volume (ESV). The 
parameters were then used to assess cardiac function using the following equations.  
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2.2.3.2. Magnetic Resonance Imaging  
Magnetic Resonance Imaging (MRI) was used to obtain high resolution images of 
the heart. A magnetic field within the MRI machine aligns protons within the specimen and 
radio frequency pulses alter the alignment of the protons. Consequently, protons produce a 
rotating magnetic field that is detected and recorded. Fourier transformation converts the 
collected signals into images. Gradient magnets are rapidly turned on and off to alter the 
magnetic field in a local region of the specimen, producing slices (200-300µm) of images 
[325]. MRI is optimized for cardiac imaging by using electrocardiography (ECG) gating and 
rapid imaging sequences. ECG gating allows for cardiac images to be acquired by 
synchronizing frequency pulses with the beating heart, enabling the visualization of cardiac 
motion and the accurate evaluation of cardiac output [326-328].  
Mice were anesthetized with isofluorane (2%), and parameters were monitored 
using a small animal monitoring system (Model 1025, Small Animals Instruments, Stony 
Brook, NY). Body temperature was maintained at 37ºC using a circulating water-filled 
imaging platform, heart rate (HR) was kept between 350-500 beats per minute (bpm) and 
respiration rate (RR) was kept between 25-40 (breaths per minute). Mice were placed on 
the imaging platform and positioned using sagittal and coronal images; short axis images  
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Figure 2.4. Echocardiographic tracings in the mouse. 
(A) Parasternal-long-axis B-mode image and (B) Short-axis B-mode image of an adult 
mouse heart. (C) M-mode image depicting left ventricular structure and function in an adult 
mouse. Functional calculations are based on measurements taken for LVIDs, LVIDd, IVSs, 
and IVSd. LV, left ventricle; RV, right ventricle; Ao, aorta; AW, anterior wall; LVIDd, left 
ventricular inner diameter in diastole; IVSs, interventricular septum in systole; IVSd, 
interventricular septum in diastole. Images courtesy of Meredith Rees, Taegtmeyer 
laboratory.  
C 
LV LV 
RV 
AW 
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were used for analysis or cardiac structure and function. Slices of the heart (1mm) were 
imaged every 6 milliseconds with 3 milliseconds between pulses. Using the Paravision® 
MRI Software, six slices (images) of the heart taken during different phases of contraction 
and relaxation were used for analysis, including end-diastolic and end-systolic images 
(Figure 2.5.). For each slice, the interventricular septal and posterior wall thickness (mm) 
was measured, the contours of the left ventricle were traced, and the ventricular area was 
calculated. The area and slice thickness were used to calculate left ventricular end-systolic 
(LVESV) and diastolic (LVEDV) volumes using Simpson’s rule algorithm for volume 
determination: 
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Other cardiac parameters (EF, SV, and CO) were calculated as described in section 
2.2.5.1. Echocardiography. Serial MRIs were taken at days 7, 14, 21, and 28 after TAC. 
After imaging, mice were monitored as they recovered from anesthesia. These experiments 
were performed in collaboration with Drs. Aarif Khakoo and Vishnu Chintalgattu at The 
University of Texas MD Anderson Cancer Center (presently at Amgen, San Francisco, CA). 
Animal protocols were approved by the Animal Welfare Committee of The University of 
Texas MD Anderson Cancer Center.  
2.2.4. Isolation of Neonatal Rat Ventricular Cardiomyocytes (NRVM) 
The isolation of neonatal rat ventricular cardiomyocytes (NRVM) was performed 
under sterile conditions in a biological safety hood and all solutions were made in the hood 
and/or sterile filtered. This protocol is adapted from a method used in Dr. Diane Bick’s lab at 
The University of Texas Health Science Center at Houston, Department of Pathology [329]. 
Neonatal Sprague-Dawley rats (1-2 day old) were quickly washed in 70% ethanol, and 
decapitated. Their heads were placed in liquid nitrogen. The chest cavity was opened and 
the heart was removed and placed in 1X ADS buffer (NaCl [6.8g], KCl [0.4g], glucose 
[1.0g], NaH2PO4 [1.5g], MgSO4 [0.1g], HEPES [4.76g], and pH adjusted to 7.38 with 
HCl/NaOH in 1L total volume of double distilled water [ddH2O]) at room temperature until all 
hearts were collected. Hearts were then rinsed once with 1X ADS buffer using a transfer 
pipet, cut in half, and transferred to a 25mm2 culture flask containing enzyme buffer (9-
15mL of 1X ADS containing Pancreatin [0.6mg/mL] and Collagenase Type II [73U/mL]) with  
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Figure 2.5. Magnetic Resonance Images of the mouse heart. 
(A) Short axis MRI image of an adult mouse in diastole and (B) 
systole. Cardiac parameters were calculated based on 
measurements made using the Paravision® MRI Software. See 
text for details. RV; right ventricle, LV; left ventricle. 
A 
B 
LV 
RV 
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15 cut hearts per flask. Flasks were incubated for 20 minutes at 37ºC with shaking (110-
120rpm) and the supernatant fraction was discarded and replaced with fresh enzyme 
buffer. The same digestion step was performed four additional times, 25 minutes of 
incubation for each step. The supernatant fraction from each digestion was collected, 
centrifuged for 5 minutes at 300g and the pellet was resuspended in 2-3mL newborn calf 
serum and kept in the incubator.   
 Cell pellets from all four digestion steps were pooled together, centrifuged for 5 
minutes at 300g and the pellet was resuspended in 4mL of Percoll gradient (1.082 g/mL). 
Percoll gradient tubes were prepared by adding 4mL of each gradient: 1.05g/mL, 
1.062g/mL, and 1.082g/mL containing cells. Gradients were added in increasing density by 
slowly pipetting the gradient into the bottom of the tube through a 15 gauge filling needle so 
as not to disturb the layers. Percoll gradients were then centrifuged for 25 minutes at 1000g 
in a swing bucket rotor at room temperature. The cardiomyocytes remain in the percoll 
gradient layer (1.082 g/mL), and were collected in 1X ADS (for a final volume of 30mL 
containing phenol red), and  centrifuged for 5 minutes at 300g. The supernatant fraction 
was discarded; the pellet was again resuspended in 1X ADS (30mL), and centrifuged for 5 
minutes at 300g. The supernatant fraction was discarded and the myocytes were 
resuspended in complete media (1 mL per heart, comprised of DMEM [500 mL], BCS [50 
mL], and Penicillin/Streptomycin [10 mL of 100U/mL]). Cardiomyocytes were then counted 
and plated at a density of 2 million cells per 60mm dish or 0.75 million cells per well in a 6-
well plate, and media was replaced the next morning. NRVM spontaneously contract after 
brief culture and continue to do so for up to 7 days, at which time they lose viability. 
Although structurally distinct from adult cardiomyocytes (Figure 2.1.), NRVM express 
cardiomyocyte structural properties such as T-tubules and sarcomeres [330]. Always 
difficult to manipulate genetically, the ease and abundance of NRVMs per single isolation 
(compared to adult cardiomyocytes) makes them the model of choice for investigating 
mechanisms in vitro in the cardiomyocyte [331].       
2.2.5. Isolation of Adult Mouse Cardiomyocytes (AMCM) 
 The isolation of adult mouse cardiomyocytes (AMCM) was performed under semi-
sterile conditions. All solutions were made in the hood and/or sterile filtered and surgical 
equipment was sterilized by autoclaving, but the cell isolation was not performed under the 
hood until the culture of the AMCM. This protocol is adapted from O’Connell et.al. [332]. 
Preparation for this procedure is crucial to a successful isolation. Key steps include: priming 
the perfusion apparatus, preparing the buffers (perfusion, digestion, and stopping buffer), 
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preparing and pre-incubating plating and culturing medium, laminating the plates for 
culturing cardiomyocytes, and sterilizing the surgical tools.    
Mice (6-10 weeks old) were anesthetized using pentobarbital (0.5mL of 5mg/mL). 
Once anesthetized, Heparin (0.2mL of 1000U/mL) was injected intraperitoneally. When fully 
anesthetized and unresponsive to the toe-pinch reflex test, a thoracotomy was performed. 
The beating heart was removed with the lungs and immediately placed in ice-cold PBS. The 
lungs were dissected away, the thymus pealed back and removed to reveal the aorta. The 
thoracic aorta was traced up to the aortic arch, the aortic branches were identified, and the 
aorta was trimmed at the ascending aorta. The aorta was cannulated using a 22 gauge 
catheter cover on a 1mL sterile syringe containing perfusion buffer (NaCl [120.4mM], KCl 
[14.7mM], KH2PO4 [0.6mM], Na2HPO4 [0.6mM], MgSO4-7H2O [1.2mM], Na-HEPES [10mM], 
NaHCO3 [4.6mM], Taurine [30mM], BDM [10mM], and glucose [5.5mM] in cell culture grade 
water and adjusted to pH 7.0 with HCl). The heart was fastened to the cannula using a 
micro clip and the syringe was depressed to verify the absence of leaks in the aorta. The 
cannula and heart were then connected to the primed water-jacket of the Langendorff-style 
apparatu containing perfusion buffer at 37ºC. The heart was perfused in a retrograde 
manner at 4mL/minute with perfusion buffer for 3 minutes, followed by perfusion with 15mL 
digestion buffer (perfusion buffer with Collagenase Type II) and finally re-circulated 
digestion buffer with calcium (40µM).  
After the extracellular matrix of the heart was digested by perfusing for a total of 16-
20 minutes, the heart was removed from the perfusion apparatus and placed in a 60mm2 
dish (non-tissue-culture treated) containing 5mL stopping buffer (18mL perfusion buffer, 
2mL Calf serum, and CaCl2 at a final concentration of 100mM). The heart was minced in 
stopping buffer and further mechanically digested using a transfer pipet. The digested 
suspension was filtered through a cell strainer (100µM), transferred to a 15mL conical tube, 
and centrifuged at room temperature at 20g for 3 minutes. The supernatant fraction was 
removed and the cell pellet was resuspended in  stopping buffer (5-10mL containing CaCl2 
[100µM]),  incubated at room temperature for 2 minutes, and centrifuged at 20g for 3 
minutes. This step was repeated with stopping buffer containing CaCl2 [400µM] and then 
CaCl2 [900µM] to slowly restore calcium to near physiological concentration in the 
cardiomyocyte. After centrifugation in stopping buffer containing CaCl2 [900µM], 
supernatant fraction was removed and cardiomyocytes were resuspended in plating 
medium (MEM [Eagle’s with HBSS] containing Calf serum [10%], BDM [10mM], Penicillin 
[100U/mL], and ATP [2mM]) and plated with appropriate cell densities. Cells were 
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incubated for one hour at 37ºC in 2% CO2 and the medium was changed to culture medium 
(MEM [Eagle’s with HBSS] containing BSA [1mg/mL] and  Penicillin [100U/mL]). For long 
term culture, medium was supplemented with ITS (insulin [5µg/mL], transferrin [5µg/mL], 
and selenium [5ng/mL]) and BDM [10mM] to inhibit contraction. 
Cardiomyocyte density is determined by counting the number of rod-shaped 
cardiomyocytes (Figure 2.1.). The quality of the isolation is determined by the total number 
of cardiomyocytes obtained and the ratio of rod-to-round-shaped cells. The higher the 
percentage of rod-shaped cells that is obtained (>60%), the higher the quality of the 
isolation. Adenoviral transductions and pulse-chase experiments in AMCM were started two 
hours after initial plating of the cells. 
2.2.6. Cell and Tissue Collection and Preservation 
2.2.6.1. Total RNA Isolation and Quantification 
 Total RNA was isolated using TRI Reagent® per the manufacturer’s protocol with 
slight modifications [333]. Cells were scraped off plates using of TRI Reagent® (0.5-1.0 
mL). Lysate was either snap frozen in liquid nitrogen or passed several times through a 
pipette tip. Frozen tissue was pulverized under liquid nitrogen using a mortar and pestle 
and 50mg was added to TRI Reagent® (1.0 mL) in a 2.0 mL eppendorf tube. The 
suspension was kept on ice and homogenized using a micro homogenizer. To separate the 
RNA (aqueous phase) from DNA and protein (organic phase), chloroform (0.2 mL) was 
added to the TRI Reagent® (per 1.0 mL), the samples were shaken vigorously, incubated 
at room temperature for 5-10 minutes, and centrifuged at 11,500g for 15 minutes at 4ºC. 
The RNA in the aqueous phase was then precipitated with roughly the same volume of  
isopropanol (100%) for 5-10 minutes at room temperature. The precipitated RNA was 
pelleted by centrifugation at 11,500g for 10 minutes at 4ºC. The supernatant fraction was 
removed and the RNA pellet was washed with ethanol (70% in DEPC-treated water [0.75 
mL]), followed by centrifugation at 11,500g for 5 minutes at 4ºC. The supernatant fraction 
was removed and the pellet was briefly air-dried and resuspended in DEPC-treated water 
(25-50µL). Following complete solubilization, total RNA was quantified using the NanoDrop 
100 spectrophotometer.  
The purity of isolated RNA is determined by the 260nm:280nm and 260nm:230nm 
ratios. The Beer Lambert Law (A=ECL; where A=absorbance, E=molar extinction 
coefficient, C=concentration, L=length light travels through the sample) is used to calculate 
the concentration of RNA, given that the average extinction coefficient for single-stranded 
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RNA at 260nm is 0.027 ug/mL/cm. The accepted 260:280 ratio for “pure” RNA is 1.8-2.0. 
Organic contaminants absorb light at 230nm, thus samples with a 260:230 ratio below 1.8 
have significant contamination [334].    
2.2.6.2. Protein Isolation and Quantification 
Protein was isolated using cell lysis buffer (Stock cell lysis buffer [7.4mL] containing 
HEPES [5mM,  pH 7.4], EDTA [0.1mM, pH 8.0], MgCl2 [0.1mM], DTT [0.1mM], Triton [1%], 
NaCl [150mM], and protease and phosphatase inhibitor cocktails) for cells or tissue lysis 
buffer (HEPES [30mM], EGTA [2.5mM], EDTA [2.5mM], KCl [20mM], β-glycerophosphate 
[40mM], NaF [40mM], Na4P2O7 [4mM],  protease and phosphatase inhibitor cocktails) for 
tissue. Cells were washed twice with ice-cold PBS and collected in cell lysis buffer (0.2-
0.5mL) on ice. Lysate was passed through a 1mL 27.5 gauge syringe five times (on ice), 
the lysate was centrifuged at 13,500g for 5 minutes at 4ºC, and the supernatant fraction 
was collected in a new tube on ice. Frozen tissue was pulverized under liquid nitrogen 
using a mortar and pestle and 50mg was added to tissue lysis buffer (0.2 mL) in a 2.0 mL 
eppendorf tube. The suspension was kept on ice and homogenized using a 
microhomogenizer, the lysate was centrifuged at 13,500 g for 5 minutes at 4ºC, and the 
supernatant fraction was collected in a new tube on ice. 
Protein concentration was quantified using the Bradford method [335]. Proteins in 
solution form a complex with Brilliant Blue G dye causing a shift in the absorption of the dye 
from 465nm to 595nm. The absorption is proportional to the amount of protein present in 
the sample. A series of known protein concentrations were diluted to generate a standard 
curve (50-1000 µg/µL). Protein samples were diluted (1:5-1:20), diluted sample (5µL) was 
added to Bradford Reagent (200µL) in a 96-well plate, and the absorbance was read at 
595nm using an absorbance microplate reader. Protein concentration was calculated based 
on the standard curve values.    
2.2.6.3. Nuclear Fractionation of Cells 
Nuclear extracts were isolated from NRVM or H9c2 myoblasts plated on 100mm2 
dishes using a modified protocol and reagents from the Nuclear Extract Kit (Active Motif). 
Cells were washed on ice with ice cold PBS (containing phosphatase inhibitors), gently 
scraped in 3mL of the same into pre-chilled 15mL conical tubes, and centrifuged at 500rpm 
for five minutes at 4ºC. The supernatant fraction was removed, cells were resuspended in 
Hypotonic Buffer (500µL containing Hepes [20mM at pH 7.5], NaF [5mM], Na2MoO4 
[10µM], and EDTA [0.1mM]),and  cells were incubated on ice for 15 minutes. Detergent 
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(25µL, Active Motif) was added and lysate was vortexed for 10 seconds and centrifuged at 
14,000g for 30 seconds at 4ºC. The supernatant (cytoplasmic) fraction was snap frozen in 
liquid nitrogen and stored at -80ºC for other experiments. The pellet (nuclear fraction) was 
resuspended in Complete Lysis Buffer (DTT [2.5µL of 10mM], Protease Inhibitor Cocktail 
[0.25µL], and Lysis Buffer AM1 [22.25µL]), vortexed for 10 seconds, and incubated for 30 
minutes with gentle rocking on ice and at 4ºC. The nuclear lysate was then vortexed for 30 
seconds, centrifuged at 14,000g for 10 minutes at 4ºC, and the supernatant (nuclear) 
fraction was transferred to a new tube. A Bradford assay was performed to determine the 
protein concentration of the nuclear protein.  
2.2.6.4. Histology and Immunohistochemistry 
A thoracotomy was performed on terminally anesthetized mice, hearts were 
removed, rinsed in ice cold PBS and a transverse slice of the apex was fixed in 
paraformaldehyde (4% in PBS) at 4 ºC overnight. The remainder of the heart was snap-
frozen in liquid nitrogen and used for biochemical analysis. Tissue was processes and 
stained by Tommy Reese (Department of Pathology, St. Luke’s Episcopal Hospital, 
Houston, TX). Briefly, after fixation, heart tissue was dehydrated by incubating the tissue 
with increasing concentrations of ethanol (50%, 70%, 95%, and 100%). Tissue was cleared 
in xylene, imbedded in paraffin, sectioned using a microtome, and mounted on microscope 
slides. Slides were prepared for staining by removing the paraffin, rehydrating the sample 
with alcohol (100%), and rinsing (distilled water). Several slides from each animal were 
stained with hematoxylin and eosin (H&E). Hematoxylin stains nuclei blue and the 
counterstain eosin stains proteins pink. H&E staining was used to determine the outline of 
cardiomyocytes in order to quantify cell size and number. Several slides from each animal 
were also stained with CD31 (Platelet Endothelial Cell Adhesion Molecule-1: PECAM-1) 
and the number of capillaries were counted. 
2.2.7. Biochemical Assays (Luciferase, β-galactosidase, CHiP)  
 2.2.7.1. Luciferase Reporter Constructs and Activity Assays 
 The following luciferase reporter constructs were designed and submitted to 
GenScript Corporation (Piscataway, NJ) for synthesis. The promoter region and upstream 
sequence (1kB) of the rat MuRF1 gene containing a putative MEF2 binding site was 
subcloned into a luciferase reporter plasmid pGL4.10 (Promega, Madison, WI). The same 
construct containing three adenine-to-cytosine mutations in the putative MEF2 binding site 
was also subcloned into the luciferase reporter plasmid pGL4.10 (Promega). Previous studies 
65 
 
have used A→C mutations within MEF2 binding domains to study MEF2-dependent 
transcription [336]. Luciferase reporter constructs pGL4.10 (1µg) were cotransfected with a 
vector encoding β-galactosidase (1µg) into H9c2 cells using the polymer-based DNA 
transfection reagent, PolyJet™ (SignaGen® Laboratories, Rockville, MD). 
 H9c2 myoblasts were grown to 85% confluency in 6-well plates and the medium 
(1mL) was changed one hour before transfection. Transfection mixtures (100µL) containing 
PolyJet™ (3µL), DNA (1µg of the MuRF1 promoter or the mutated MuRF1 promoter and β-
galactosidase), and serum-free culture medium were added to each well; 12 hours later 
medium was replaced with fresh medium and treatments were started (AICAR and 
Compound C). For luciferase expression in response to aAMPK or dnAMPK, H9c2 myoblasts 
were transformed with either aAMPK, dnAMPK, or a null adenovirus (MOI 10) and 24 hours 
later were transfected with luciferase and β-galactosidase constructs using the same 
protocol. Twenty-four hours after transfection, cells were washed with ice-cold PBS and 
collected in 1X Reporter Lysis Buffer (100µL, Promega). Lysate was vortexed for 15 seconds, 
frozen in liquid nitrogen and thawed at 37ºC, vortexed again for 15 seconds to completely 
lyse the cells, and centrifuged for 1 minute at 12,000g at 4ºC. Samples were kept on ice for 
immediate analysis or snap frozen for future analysis. 
 Luciferase is an enzyme that catalyzes the oxidation of luciferin to oxyluciferin in the 
presence of ATP and magnesium. The reaction generates a luminescent signal with a half-life 
of 10 minutes that is detected by a fluorescent plate reader. A luciferase standard curve 
(consisting of tenfold dilutions from 5x10-12 to 5x10-21 moles/µL) was generated using 
QuantilLum® Recombinant Luciferase (Promega) diluted in 1X Reporter Lysis Buffer 
(Promega) containing BSA (2mg). Luciferase activity was quantified in duplicate in wells 
containing luciferase standards, blank wells, and cell lysate (20µL). The POLARstar OPTIMA 
fluorescent plate reader (BMG Labtech) was set to take 10-one-second luminescent end 
point readings after automated injections of Luciferase Assay Reagent (100µL, Promega), 
with a Gain Adjustment (background) automatically detected at 4095. Values were averaged 
and normalized to β-galactosidase activity (see below).    
 2.2.7.2. β-galactosidase Activity Assays and Staining 
A β-galactosidase expression plasmid was kindly provided by Dr. Joseph Alcorn, 
The University of Texas Health Science Center at Houston, Department Pediatrics. This 
plasmid comprises gene fusions between the simian virus 40 early promoter and E.coli lacZ 
[317]. β-galactosidase is an enzyme that cleaves β-galactosidic linkages, hydrolyzing 
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ONPG (o-nitrophenyl-β-D-galactopyranoside, colorless) to o-nitrophenol (yellow). The 
reaction is terminated with sodium carbonate and the reaction is analyzed 
spectrophotometrically by taking an absorbance reading at 420nm [334].   
H9c2 myoblasts were transfected using PolyJet™ (SignaGen® Laboratories), 
collected in 1X Reporter Lysis Buffer (100µL, Promega), and lysed as described above. A 
standard curve was generated (0 - 6.0 milliunits) using β-galactosidase (1 unit/µL, 
Promega).  Assay 2X Buffer (sodium phosphate buffer [200nM at pH 7.3], MgCl2 [2mM], β-
mercaptoethanol [100mM], and ONPG [1.33mg/mL], Promega) was added to cell lysate 
(50µL) in a 96-well plate. Samples were mixed well, covered, and incubated at 37ºC for 3 
hours. During this time a faint yellow color developed. The reaction was terminated with 
sodium carbonate (150µl of 1M) and the absorbance was read at 420nm using an ELx800 
Absorbance Microplate Reader (BioTek).  β-galactosidase activity was used to normalize 
luciferase activity in gene reporter assays. 
    β-galactosidase staining was performed on whole hearts from WT or desMEF2-
LacZ transgenic mice using a modified protocol [337, 338]. Mice were anesthetized with 
pentobarbital and hearts extracted as described above. Hearts were rinsed with ice-cold 
PBS and incubated on ice in  β-galactosidase fixative (paraformaldehyde [2%], 
gluteraldehyde [0.2%], EGTA [5mM at pH 8.0], MgCl2 [2mM], and Na3PO4 [100mM at pH 
8.0] in ddH2O) for 90 minutes. Hearts were washed three times with washing buffer (MgCl2 
[2mM]sodium deoxycholate [0.01%], Nonidet P-40 [0.02%], and phosphate buffer [100mM 
at pH 8.0] in ddH2O) for 20 minutes each wash. Hearts were incubated in  β-galactosidase 
staining solution (K4Fe(CN)6 [5mM], K3Fe(CN)6 [5mM], X-gal [1mg/mL] in washing buffer) at 
room temperature overnight and photographed the next morning.    
2.2.7.3. MEF2 Activity Assay 
 The activity of transcription factors, or the ability of transcription factors to bind to their 
respective DNA binding motifs, can be measured using an Enzyme-linked immunosorbent 
assay (ELISA)-based  TransAM™ method (Active Motif). The consensus binding sequence 
for MEF2 is immobilized on a 96-well plate and the ability of “active” MEF2 in cell lysate to 
bind to the sequence is detected as follows. The immobilized MEF2 from cell lysate is 
detected with a primary antibody against MEF2, the MEF2 antibody is detected with a 
secondary antibody conjugated to HRP, and HRP intensity is quantified 
spectrophotometrically.  
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 Nuclear fractions from NRVM and H9c2 myoblasts were isolated as described above 
and nuclear lysate (22µg in Complete Binding Buffer, 40µL total volume) was added to each 
well. Positive controls were provided by Active Motif and added to the plate as well. The plate 
was sealed and incubated for one hour at room temperature with gentle shaking. Wells were 
washed 3 times with 1X Wash Buffer (200µL, Active Motif), and incubated with a MEF2 
antibody (100µL of 1:1000 in 1X Antibody Binding Buffer, Active Motif) for one hour at room 
temperature, covered. Washes were repeated and wells were incubated with an HRP-
conjugated secondary antibody (100µL of 1:1000 in 1X Antibody Binding Buffer, Active Motif) 
for one hour at room temperature, covered. Washes were repeated and Developing Solution 
(100µL, Active Motif) was added to the wells. The plate was incubated for 2-10 minutes in the 
dark until a blue color was visible in the wells. The reaction was terminated using Stop 
Solution (100µL, Active Motif), and a yellow color was produced. The absorbance was read at 
450nm and raw values were used to compare MEF2 “activity” between samples.   
 2.2.7.4. Proteasome Activity Assay 
The proteasome “core” is made up of multiple subunits collectively referred to as the 
20S proteasome [70, 71, 339]. The proteasome degrades proteins via trypsin and 
chymotrypsin proteases within its core. To measure proteasome activity, a fluorogenic 
substrate (Suc-Leu-Leu-Val-Tyr-AMC) is incubated with cell lysate [340]. Chymotrypsin 
proteases within the 20S proteasome (in the lysate) cleave the substrate which emits a 
signal at 460nm after excitation at 380nm.   
20S proteasome activity was measured using a modified protocol and reagents from 
EMD Biosciences. Cells were collected or tissue was homogenized on ice as described 
above except in 1X Reaction Buffer (HEPES [25mM] and EDTA [0.5mM at pH 7.6]). Protein 
concentration was determined using the Bradford Assay. To each well in a black 96-well 
plate the following was added in order for a reaction volume of 190µL: protein lysate (20µg), 
1X Reaction Buffer, and SDS (2µl of 3% [w/v]). The reaction was initiated by the addition of 
Substrate solution (10µL of 200µM fluorogenic substrate) and the fluorescence was 
recorded. Results are expressed as fold change of 20S proteasome activity.  
2.2.7.5. Chromatin Immunoprecipitation Assay (ChIP) 
Chromatin Immunoprecipitation (ChIP) is a method used to investigate interactions 
between proteins (such as transcription factors) and DNA [341, 342]. H9c2 myoblasts were 
grown in 100cm2 dishes (a large amount of cells is required for this assay). Formaldehyde 
(final concentration of 1%) was added to the media to crosslink proteins and DNA. Cells 
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were incubated for 20 minutes with gentle shaking at room temperature. The cross-linking 
reaction was terminated by adding glycine (0.125M final concentration) to the media and 
gently rocking for 5 minutes. Media was poured off and cells were washed twice with ice-
cold PBS. Cells (2 plates per condition were pooled together) were scraped in 5mL PBS per 
plate and were centrifuged for 5 minutes at 4000rpm at 4ºC.  The supernatant fraction was 
discarded and the pellet was resuspended in nuclei lysis buffer (250µL containing HEPES 
[50mM at pH 7.5], EDTA [1mM], NaCl [140mM], Triton X-100 [1%], Na-deoxycholate 
[0.1%], SDS [0.1%], and protease inhibitors) and incubated on ice for 10 minutes. Cells 
were sonicated on ice in the cold room (20 times for 5 seconds with at least 30 second 
intervals between each sonication). Samples were centrifuged for 10 minutes at 14,000rpm 
at 4ºC. The supernatant fraction was transferred to a new tube and the lysate was 
precleared with Protein A agarose beads (50uL, Santa Cruz) for one hour at 4ºC with 
rotation. The lysate was centrifuged for 5 minutes at 4,000rpm at 4ºC and the supernatant 
fraction was transferred to a new tube. Ten percent of this “input” fraction was snap frozen 
in liquid nitrogen and stored at -80ºC. MEF2 antibody (10µL, Santa Cruz) was added and 
the samples were incubated overnight at 4ºC with rotation.  
After incubation with the antibody, Protein A agarose beads (50uL, Santa Cruz) 
were added and the samples were incubated for 2 hours at 4ºC with rotation. Samples were 
centrifuged for 2 minutes at 4,000rpm at 4ºC. The supernatant fraction was discarded and 
the pellets were washed a total of 8 times with the following buffers: twice with ice-cold 
nuclei lysis buffer (1mL containing HEPES [50mM at pH 7.5], EDTA [1mM], NaCl [140mM], 
Triton X-100 [1%], Na-deoxycholate [0.1%], SDS [0.1%], and protease inhibitors), twice with 
ice-cold nuclei lysis buffer (1 mL containing HEPES [50mM at pH 7.5], EDTA [1mM], NaCl 
[500mM], Triton X-100 [1%], Na-deoxycholate [0.1%], SDS [0.1%], and protease inhibitors), 
twice with ice-cold buffer (1mL containing Tris base [20mM of pH 8.0], EDTA [1mM], LiCl 
[250mM], NP-40 [0.5%], Na-deoxycholate [0.5%]), and twice with ice-cold TE (1mL 
containingTris-HCl [1M] and EDTA [0.5M]). For each wash the samples were incubated for 
10 minutes at 4ºC with rotation and then centrifuged for 1 minute at 4,000rpm at 4ºC. After 
each wash, the resuspended pellet was transferred to a new tube to reduce the 
background.  
After the last wash the antibody-protein-DNA complexes were eluted with IP elution 
buffer 1 (1mL containing SDS [1%], EDTA [1mM], and Tris-HCl [10mM at pH 8.1]), 
incubated at 65ºC for 15 minutes, and centrifuged for 3 minutes at 14,000rpm at 4ºC. The 
supernatant fraction was transferred to a new tube, and elution buffer 2 (1mL containing 
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SDS [0.67%], EDTA [1mM], and Tris-HCl [10mM at pH 8.1]) was added to the pellet, mixed 
well, and centrifuged for 3 minutes at 14,000rpm at 4ºC. The supernatant was combined 
with the eluent from IP elution buffer 1 and SDS (20µL of 10%), and the volume was 
brought up to 250µL with TE. Samples were incubated overnight at 65ºC to reverse the 
formaldehyde crosslinks.    
    Samples were centrifuged for 1 minute at 14,000rpm at 4ºC, TE (250µL) and 
proteinase K (10µL of 10mg/mL) were added to each sample, and the samples were 
incubated for 1-2 hours at 37ºC. LiCl (55µL of 4M) was added to each sample and the DNA 
was extracted once with Tris-buffered phenol (500µL) and once with chloroform (500µL), 
vortexing both times. Glycogen (2µL of 20mg/mL) was added to each sample, mixed well, 
ethanol was added (900µL of 100%), and DNA was precipitated on ice for 10 minutes. 
Samples were centrifuged for 30 minutes at 14,000 rpm at 4ºC, the supernantant fraction 
was discarded, and pellets were air dried and resuspended in TE (20µL). 
Immunoprecipitant products were amplified by PCR; the location within the MuRF1 
promoter and the sequences of the primers are shown in Figure 2.6. and the PCR protocol 
is described in Table 2.4. PCR products were visualized by adding DNA loading buffer 
(5µL) and running the samples on 3% agarose gel with ethidium bromide at 50mV for 
several hours.  
2.2.8. Amplification and Quantification of Adenoviruses 
 Adenoviruses expressing active AMPKα2 (aAMPK), dominant-negative AMPKα2 
(dnAMPK), or a null control were purchased from Eton Biosciences Inc. (San Diego, CA). 
The adenovirus encoding aAMPK expresses a truncated form (amino acids 1-312) of the 
alpha (active) subunit of AMPK. Amino acids 1-312 lack the βγ binding domains and auto- 
inhibitory domain but retain the activating phosphorylation site (Thr192), thus encoding an 
active kinase [343]. The adenovirus encoding dnAMPK contains a K45R mutation within the 
kinase domain and thus lacks kinase activity, acting as a dominant negative form of the 
kinase [344]. 
Adenoviruses expressing active AMPKα2 (aAMPK), dominant-negative AMPKα2 
(dnAMPK), or a null control were amplified in HEK293 cells using a modified protocol [345]. 
HEK293 cells were grown to 80% confluency, medium (Eagle’s MEM with 10% FBS) was 
replaced, and four-100mm2 plates of confluent cells were infected with 15µL of stock 
aAMPK, dnAMPK, or null adenovirus (2x109 PFU/mL). Cells were incubated for 5  
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CCTCCCAGATGACAAGCATGTCCAGGACACAGACAGCAGCAAGGCCCCTCCCCTTTA
CACACCGCTGATCCAAACCCACTCTCCACTGCCTGGGCTGCTCTTGTTGCCTTCCGCT
CGAGCTGTTCTTCAGGACAGGATTTCTCTTCGTAGTCCTTGGTTTTCATCTCTCCCTTC
CCCTCCCCCTCAGGTGATCTGAATGTATCAACCTGTTCCCAAACACACCTCCACAGAG
ACACAAGCTCGTTAGGGGCTGTGTCTCAGAGCCACCGCTGCTGGCTGTGTGACTTTTC
GGGGGTTGCTATGCCTCTCTGTGCCTAACCTGTCTGTCCACGAATGGGGGTGCAAGG
GTTCTCCCACTGTAGACTGTTCAGGTGGAGACTTGAACCTAAGCCCTAATCCCATATG
CTAGGCAAGTGCTCTATCATTAAGCCATATTGCTAGCTTTCTTTTTTTAAAAACCCTTTT
TAAATAAAATTTATTTTTCTTCTTCATGTGCGTGTTTTGCATGAATGCATTTCTGTACACC
ATGTTCAGCCAGAAAAGGTATCGGATCCCTTGGAACTAGAGTTTCAGACAATTGTGAA
CTAAAACGTGGGTGCTGGGATTTGAACCCAGGTCCTCTGAAAGAGCAGCTGGGATTCT
TAGCCGATGAGCTATCTCTCTAGCCCCTACTATTTTAAAATTTTAATTTTTTTTATTTTTA
TGTATATTATGTGCCTCACAAGCATGCAGTTCTCATGCCGGCCAGAAGAGGGAGCCAG
ACCTCCTGGAAGTGAATAACTTGCGAGCTGCCACCTGGATGCCAGGAACCAAACCCT
GGTCTTCTGCTCTGTCTTTTTACTTTTAAAAACGCATTTTTAAACAAGGAGATGGTGACA
CACACCTTCAATCCTAGTACTTGGGGGTGGGGGGGCAGATGTTTACAAAGCACGTTCC
ATGATAGCCAGGACCACACGAGCAACTCTGTCTCTTAAAACCTAAAAACCAAACCAAAA
CAAAAAACCCCATATTTTAATACCTGTTCTTTTGGGGTTTGTGGTGAGGGGTCGTGGTG
GTGACTGGGGGTGTGTAGTGACATTATTTTGTTATTTTGTGATAGGGTCTCATATAGTC
CAGGCTTGCTTTGAACTCCTGCCTCTGCCTTCTAAGTACTGGGGTTATTGGCATTTACC
CATCATGCCCTGCTTTACCTTTTATTCCAAGACATGATATCACTATGTAGCTCATGGCC
TTAAACTTTGGATCCTCCTGCCTCAGCCTCCTGAGGAGCTGGGAATATAGGCTGCAGA
TCACCCGCTCTTAGAACTCTGTTCACTCCTGTCTCCAGAGAACCCCATATTCCAATGCC
CCGGAAGTTCTTCCTGGGACCCAAGAATGAACACATATGTAAAGAGTCCAGTGGAGCC
TCCTGTATCCACAGGTGTCAGGGCAGGTTCTGAGGCAGCACAGGAAGTTCCTGTTTGT
CTCTGGGCTGTGAGCATGGCAGTTCAGGGAAAACACAGGAACCTGGGAAGGCAAGTT
GTCAGCCTTGGCGGCAAGCACCTTTACCCACTGAGCCATCGAGCTGGCCCTCATGAA
ACCCTTGTCAGCATGTAGTGTGATGATTGGCTGAGGGCTGTCAGGGTGGGCTGCCCA
ACATGGGAGTCTCAAAAGACTCTAGTGAAATGCTTGACTGGAGTCTGGGGCAGGAGA
AAGCCCTTTCACAGAAGGGCTATCCCAAGGCCTTAGAGCTGTTCAGAATCCAGAAGGG
GAACAGACTTAGGTTGGTACAGGGGCGCTGGCTGTTAATCTTGTGTATGCCAACCCCA
CCCCCCACCCAAGTTCCACTCCCTTACTCCCAATTCACTGGAGGGGCAGGAGGGTGG
AGACCAACTTCTTCATGAAACTAGGGTACCTGGCCCTCCCCTGAACCTGGCTCTGAAC
AATCTGTTCTTGTTTACGACCCCCATTGCAGGGCAACAGCGATTGCTCACCCCTGCAT
GTGATCTGAGAGGGCCAAATCTTTGAGGCCTGGAGGAAACTCAAGCCCTGCCAGCCG
CTTGGCTTCGGAATGCTCAGCTGGTCCCCTCCTGGGGCTCATGTGACTGAAGGGCAG
CTATCCCTATCAGAAGGGCCTCAGACCAAGACAGAAGCCGGGTGTTCGGGGAGGAAG
ACAAAGAGGATCCGAGTGGGATCCCTTCCACTCGGTGTGACGCAGGTGGAAGAGACA
GTCGCAGTTTCGAAGCAATATGGATTATAAATCTGGCTTGATTCCGGACGGAAATGCT
ATGGAGAACCTGGAGAAGCAG 
 
 
Figure 2.6. MuRF1 promoter sequence and ChIP primers. 
Rat MuRF1 promoter sequence was used to generate primers for amplification of MEF2 
ChIP products. Yellow highlighted sequence: potential MEF2 binding sequence; Red 
highlighted sequence: Start codon; Blue highlighted sequences: ChIP primers, MEF2 
binding region;Green highlighted sequences: ChIP primers, distal region. 
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Table 2.4. ChIP PCR primers and protocol. 
PCR was performed on DNA from chromatin immunoprecipitation. 
The primers are listed in Figure 2.6. See text for details.  
 
  
PCR Reaction Mix PCR Procotol 
10X PCR Buffer      
MgCl2 (50mM) 
dNTP’s (2.5mM) 
Forward Primer 
Reverse Primer 
Taq (Invitrogen) 
DEPC-treated H2O 
DNA 
5.0µL 
1.5µL 
4.0µL 
2.5µL 
2.5µL 
0.3µL 
7.2µL 
2.0µL 
95ºC x 3 minutes 
 
94ºC x 45 seconds 
60ºC x 45 seconds     x 32 cycles 
72ºC x 45 seconds 
 
72ºC x 10 minutes 
 
4 ºC x ∞ 
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days until cytopathic effects were evident in 80% of the cells. Cells were collected, pooled, 
and centrifuged at room temperature for 5 minutes at 1000rpm. The supernatant fraction 
was stored at -20ºC while the pellet was resuspended in 10mL of the supernatant fraction. 
The cell pellet was lysed by three consecutive freeze-thaw cycles in liquid nitrogen and in a 
37ºC water bath and vortexed after each thaw cycle. After the third cycle, debris was 
centrifuged at room temperature for 5 minutes at 1000rpm, and the pellet was discarded. 
 The viral titer in the crude lysate (combined with the supernatant fraction stored at -
20ºC)  was determined using a modified version of the protocol available in the AdEasy™ 
Viral Titer Kit (Stratagene) [346]. HEK293 cells were plated in a 24-well plate at a density of 
2.2x105 per well in 0.5mL media. Several hours after plating 10-fold serial dilutions of the 
viral stock from 10-1 to 10-5 were made and added (85µL of each dilution) to the cells in 
duplicate. After 18 hours of incubation at 37 ºC in 95% air, 5% CO2, media was removed 
and plates were dried for 5 minutes at room temperature. Cells were fixed by incubating 
with ice-cold methanol (0.5mL of 100%) at -20ºC for 10 minutes, washed twice with PBS 
(0.5mL containing BSA [1%]), and incubated with an anti-hexon primary antibody (1:500 
PBS with 1% BSA) at 37 ºC for an hour. This antibody recognizes the hexon protein, a 
major coat protein on adenoviruses. Cells were washed twice with PBS (0.5mL containing 
BSA [1%]), and incubated with an HRP-conjugated secondary antibody (1:1000 PBS with 
1% BSA) at 37 ºC for an hour. The secondary antibody was removed and the cells were 
washed twice with PBS (0.5mL containing BSA [1%]) and incubated with DAB (3,3' 
Diaminobenzidine) substrate for 15-20 minutes at room temperature. In the presence of 
horseradish peroxidase (HRP-conjugated secondary antibody), DAB produces a brown 
precipitate visible using a light microscope.   
 To determine the titer of the amplified viruses, the number of DAB-positive cells was 
quantified. The infectious units per milliliter of virus (IFU) were calculated using the 
following formula: 
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The IFU values were then used to calculate the volume of adenovirus needed for 
experiments using the following equations, where MOI is multiplication of infectivity.   
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Due to high amplification, experiments performed using these viruses required a low MOI. 
2.2.9. Quantitative Real Time RT-PCR (qRT-PCR) Transcript Analysis 
 Quantitative real time RT-PCR (qRT-PCR) is a method used to analyze expression 
of specific RNA sequences. RNA is reverse transcribed to DNA using a gene–specific 
reverse primer. The DNA is then amplified using gene-specific forward and reverse primers 
and a gene-specific probe. The probe is conjugated on either end to a fluorophore and a 
quencher, and when in close proximity, the fluorophore is quenched. As Taq polymerase 
amplifies the DNA, its exonucleotide activity breaks down the probe, disrupting the reporter-
quencher proximity and allowing for the detection of the fluorescent signal. The amount of 
fluorescence detected is proportional to the amplified sequence.  
 2.2.9.1. Design and Verification of qRT-PCR Assays 
 Assays for quantitative real time RT-PCR (qRT-PCR) were designed using Primer 
Express® Software. The coding DNA sequence of the gene of interest, including the splice 
sites, was obtained and exported into Primer Express.  Forward and reverse primers were 
designed with the following parameters: 18-26 nucleotides in length, melting temperature 
(Tm) between 59-61ºC, GC content between 40-60% with no GC clamp residues, no more 
than 3G/C nucleotides in a row, low primer dimer formation, and contain a secondary 
structure that is easily linearized. Probes were designed with the following parameters: 27-
30 nucleotides in length and no more than 3G/C nucleotides in a row with the fluorophore 6-
carboxyfluorescein (FAM) conjugated to the 5’-end of the probe and the quencher 
tetramethylrhodamine (TAMRA) conjugated to the 3’-end. Assays were designed to be 80-
120 nucleotides in length and the sequences of the amplicons were tested for specificity in 
silico using BLAST (Basic Local Alignment Search Tool) [347]. The assays were tested 
using the buffers and protocol below, and the product was run on a 2% agarose gel in TBE 
buffer (Tris base [1.08g], Boric acid [5.5g], EDTA [20mL of 0.5M] in 1L DEPC-treated water) 
to verify the specificity of the amplicon. 
2.2.9.2. Gene Expression Analysis using qRT-PCR Assays 
Gene expression analysis was performed on total RNA (60-120ng) as previously 
described [199, 348]. cDNA standards spanning the entire length of each amplicon, reverse 
and forward primers, and Taqman® probes were purchased (Table 2.5.) (Sigma). For each 
gene expression assay cDNA was serial diluted to generate a standard curve ranging from 
20pg-0.2fg. Additionally, non-template controls (NTC, without mRNA) and non-amplification 
controls (NAC, without reverse transcriptase) were used. qRT-PCR was performed in two 
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steps in the same 96 well plate. RNA was reverse transcribed with Superscript™ II 
(Invitrogen) using a modified version of the manufacturer’s protocol. Reverse transcription 
buffer (5X First-Strand Buffer [1µL] (containing Tris-HCl [250mM, pH 8.3 at room 
temperature], KCl [375mM], and MgCl2 [15mM]), dNTP mixture [1.2µL of 2.5mM], DTT 
[0.6µL of 0.1M], reverse primer [0.1µL of 20µM], DEPC-treated water [0.6µL], and 
Superscript™ II[0.03µL]) was added to the RNA sample (1.5µL), incubated at 50ºC for 30 
minutes, and the reaction was inactivated at 75ºC for 5 minutes. Samples were then placed 
on ice and mixed with PCR buffer (10X PCR buffer [2.5µL, comprised of Tris-HCl [200mM, 
pH 8.4] and KCl [500mM], dNTP mixture [2.5µL 2.5mM], MgCl2 [1.3µL of 50mM], reverse 
primer [0.6µL of 20µM], forward primer [0.6µL of 20µM], Taqman™ probe [0.25µL of 10µM], 
DEPC-treated water [11.75µL], and Taq polymerase [0.5µL]). The DNA was denatured at 
95ºC for 1 minute and amplified with 40 cycles of PCR (95ºC for 12 seconds, 60ºC for 1 
minute).  
 Gene expression was analyzed using ABI Prism® 7000 Sequence Detection 
System Software. The results are visualized on an amplification plot comparing the cycle 
number (independent value) and the ∆Rn (magnitude of the fluorescent signal, dependent 
value) (Figure 2.7.A.). When the ∆Rn is plotted on a linear scale the baseline can be 
determined (Figure 2.7.B.). The baseline is the initial PCR cycles that yield no or little 
fluorescence signal. Once the baseline is set, the threshold can be defined by plotting ∆Rn 
on a logarithmic scale. The threshold is set above baseline and intersects with the 
amplification plot to define the CT, the cycle number in which the fluorescence passes 
through the threshold. Once the baseline and threshold have been defined, the standard 
curve can be evaluated. The standard curve is plotted on a linear scale: CT versus the 
concentration of cDNA [Log(CO)]. The efficiency (E) of the PCR can be determined from 
the slope of the standard curve (Figure 2.7.C.) using the following formula: 
 = 10		 −1(	 − 1 
A good PCR reaction should have an efficiency between 90-110% or a slope between -3.58 
and -3.10 and the coefficient of correlation (R2) for the standard curve should be >0.99 
[349-352]. Once all settings were adjusted, the absolute copy number of each transcript, 
measured in triplicate, was used for comparison between samples. 
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Quantitative Real Time RT-PCR (qRT-PCR) primer and probe sequences 
Transcript Primer/Probe Sequence 
mAtrogin-1 590F (forward primer) TGTATCGGATGGAGACCATTC 
 677R (reverse primer) GTGATCGTGAGGCCTTTGAAG 
 620T (probe) AGCAGCAGCTGAATAGCATCCAGATCA 
mMuRF1 29F (forward primer) ATGGAAACGCTATGGAGAACCT 
 170R (reverse primer) GGATTCGCAGCCTGGAAGAT 
 115T (probe) TGCCAACACAACCTCTGCCGGAA 
rAtrogin-1 371F (forward primer) GGCTGTTGGAGCTGATAGCA 
 505R (reverse primer) CATGACTTTCAGGAACTTCTGGTCG 
 rAtrogin-1 (probe) CACATCCCTGAGTGGCATCGCC 
rMuRF1 487F (forward primer) TTCCAAGGACAGAAGACTGAACTG 
 582R (reverse primer) TTCCTTGGTCACTCGGCAG 
 519T (probe) CATCTCCATGCTGGTGGCAGGGAAC 
r/mUCP3 r/mUCP3 (forward primer) GTGACCTATGACATCATCAAGGA 
 r/mUCP3 (reverse primer) GCTCCAAAGGCAGAGACAAAG 
 r/mUCP3 (probe) CTGGACTCTCACCTGTTCACTGACAACTTCC 
r/mGLUT4 783F (forward primer) CCCCCGATACCTCTACAT 
 872R (reverse primer) CTGCCCGAAAGAGTCTAAAGCGCCT 
 r/mGLUT4 (probe) GCATCAGACACCATCAGCCCAG 
mMHCα 1907F (forward primer) GCAAAGGAGGCAAGAAGAAAGG 
 1990R (reverse primer) TGAGGGTGGGTGGTCTTCAG 
 1942T (probe) ACAGTGTCTGCTCTCCACCGGGAA 
mMHCβ 1650F (forward primer) AGGGCGACCTCAACGAGAT 
 1744R (reverse primer) CAGCAGACTCTGGAGGCTCTT 
 mMHCβ (probe) AGCTCAGCCATGCCAACCGTA 
rANF rANF (forward primer) AGTGCGGTGTCCAACACAG 
 rANF (reverse primer) CTTCATCGGTCTGCTCGCT 
 rANF (probe) TCTGATGGATTTCAAGAACCTGCTAGACCAC 
rGLUT1 697F (forward primer) CATCGTCGTTGGGATCCTTA 
 749R (reverse primer) GAGACAGTAGAGGCCACAAGTCT 
 rGLUT1 (probe) AGGTGTTCGGCTTAGACTCCATCATGG 
m/rAtg12 195F (forward primer) AGGCTGTAGGAGACACTCCCATAA 
 276R (reverse primer) GAAGTCGATGAGTGCTTGGACAGT 
 m/rAtg12 (probe) AAAACGAAGAAATGGGCTGTGGAGCGG 
h/m/rBeclin 466F (forward primer) CCTCAGCCGAAGACTGAAGGT 
 547R (reverse primer) CTCACAGAGTGGGTGATCCACAT 
 h/m/rBeclin (probe) TTTGACATCATGTCGGGCC 
m/rAtg5 m/rAtg5 (forward primer) GGTGATCAACGAAATGCAGAGAA 
 m/rAtg5 (reverse primer) GTCCAAAACTGGTCAAATCTGTCA 
 m/rAtg5 (probe) ACCACAAGCAGCTCTGGATGGGACTG 
LC3 LC3 (forward primer) GTGGAAGATGTCCGGCTCAT 
 LC3 (reverse primer) CTCCCCCTTGTATCGCTCTATAATCA 
 LC3 (probe) AGCAGCACCCCACCAAGATCCCA 
 
 
Table 2.5. Quantitative Real Time RT-PCR (qRT-PCR) primer and probe sequences. 
Forward primers, reverse primers, and probes used to analyze specific mRNA levels. See 
text for details. 
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Figure 2.7. Quantitative Real Time RT-PCR analysis. 
(A) An amplification plot comparing the cycle number (independent value) and the ∆Rn 
(magnitude of the fluorescent signal, dependent value). 10 fold dilutions of the cDNA are 
used as a standard curve. The concentration of cDNA used (20pg – 20fg) is labeled in 
black. Two representative samples are shown in triplicate and labeled in blue. The 
threshold is shown in green. (B) 82-97Rn is plotted on a linear scale to determine the 
baseline (shown here: cycle 12) and the start cycle (baseline cycle minus 3; in this case 9). 
(C) The standard curve is plotted on a linear scale to determine the efficiency of the 
reaction. See text for details.  
A 
B 
C 
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2.2.10. SDS-PAGE, Western Blot Analysis and Quantification 
Proteins are separated by charge and mass using polyacrylamide gel 
electrophoresis (PAGE). While nondenaturing PAGE separates proteins according to their 
mass-to-charge ratio, denaturing /reducing SDS-PAGE separates proteins solely by mass. 
SDS denatures proteins and makes them evenly negatively charged, thus they migrate 
from a negatively to a positively charged electrode. SDS-polyacrylamide gels ranging from 
8-12% were used to analyze protein content and posttranslational modifications of proteins. 
A lower percentage gel is used to separate larger proteins and higher percentage gel for 
smaller proteins.  
Gels were cast in a two-step fashion. The lower “resolving” gel contained the 
percentage desired for separation, and the upper “stacking” gel (comprised of lower percent 
acrylamide and lower pH) concentrated proteins before being resolved. To cast two gels, 
components were combined in the following order. For 10% resolving gels: 8mL 
resolving/lower buffer stock (Tris base [36.3g], SDS[0.8g], adjusted to pH 8.8 in ddH2O 
[200mL]), Acrylamide/Bis (10.5mL of 30%), water (13.4mL), APS (540µL), and TEMED 
(54µL). For stacking/upper gels: 2.5mL stacking/upper buffer stock (Tris HCl [6g], SDS 
[0.4g], adjusted to pH 6.8 in ddH2O [100mL]), Acrylamide/Bis (1.5mL of 30%), water 
(6.0mL), APS (90µL), and TEMED (9µL). Once the resolving gel was poured (80% of total 
casting height), a layer of isopropanol was slowly pipetted over the gel to ensure a smooth 
transition from stacking to resolving gels. Once the resolving gel had solidified, the 
isopropanol was poured out, the stacking gel was poured, and the combs were put in place. 
When the stacking gel was solidified, the gel running apparatus was assembled, the combs 
were removed, running buffer (Tris base [6g], Glycine [28.8g], SDS [1g] in water [1L]) was 
added, and the wells were rinsed with running buffer.   
Protein (10-20µg/µL in 5X loading buffer) (Tris base [312.5mM], glycerol [10%], and 
SDS [11.5%]) was boiled for 5 minutes at 100ºC and cooled to room temperature before 
running gels. One lane was loaded with a protein standard (10µL) and the other lanes with 
the appropriate amount of protein. Gels were run at 50mV until the protein traveled through 
the stacking gel and 100mV thereafter.  
Separated proteins were immobilized for analysis by transferring them to a PVDF 
(PolyVinyliDene Fluoride) membrane by western blotting using a wet transfer method. The 
principle behind the electrophoretic transfer of proteins to a membrane is based on Ohm’s 
law. 
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Proteins migrate to the membrane following a current generated by applying a voltage 
across electrodes. 
PVDF membranes were briefly soaked in methanol, rinsed several times with 
ddH2O, and stored in transfer buffer (Tris base [144g], Glycine [30g], SDS [0.5g] in water 
[1L]) until used. Sponges and filter paper were also soaked in transfer buffer until used.  A 
“sandwich” was created between the plastic supports of a transfer cassette such that the 
order from the bottom of the cassette (the side facing the cathode) to top (the side facing 
the anode) was sponge, filter paper, gel, PVDF membrane, filter paper, sponge. Air bubbles 
between the gel and membrane were gently rolled out of the sandwich using a conical tube 
and the cassette was closed and placed in the proper orientation within the cassette case. 
An ice pack was added to the cassette case which was then filled with transfer buffer. Gels 
were transferred at 4ºC for 75 minutes at 110mV with stirring.  
Once transferred, membranes were briefly rinsed with water and placed in Ponceau 
stain with gentle shaking for several minutes. Ponceau stain has a negative charge and 
binds to positively charged amino acids of proteins for visible detection on the membrane. 
This stain is used to verify the even transfer of proteins and to aid in cutting membranes at 
different molecular weights for simultaneous detection of several proteins. Ponceau stain is 
easily removed by rinsing with water, but complete removal of the stain is not necessary 
because there is no noticeable change in antibody detection of proteins. Once rinsed, 
membranes were incubated with primary antibodies overnight at 4ºC with gentle rocking. 
Membranes were washed 3 times for 5-10 minutes in TBST with gentle shaking and 
incubated with HRP (horseradish peroxidase)-conjugated secondary antibody (in 5% milk in 
TBST) for 1 hour at room temperature. Membranes were then washed 3 times for 5-10 
minutes in TBST with gentle shaking and developed using Western Blotting Luminol 
Reagent. HRP (conjugated to secondary antibodies) converts the substrate in the luminol 
reagent to a chemiluminescent precipitate which is then captured on film. After developing, 
antibodies were removed from the membrane by incubating them in stripping buffer (Tris 
HCl [6mL of 1M at pH 6.8], SDS [19.2mL of 10%], β-mercaptoethanol [0.675mL], ddH2O 
[70mL]) for 75 minutes at 60ºC with gentle shaking. Membranes were briefly rinsed with 
ddH2O and washed 3 times for 10 minutes in TBST with gentle shaking. Membranes were 
then reprobed for other proteins using the same protocol.  
To quantify protein levels, films were scanned and Adobe Photoshop was used to 
convert the films to a standard black and white setting for consistent analysis. Images were 
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saved as tiff files and densitometric analysis was performed with ImageJ software. The 
densities of proteins on the same film were compared using a normalizing protein such as 
β-tubulin or GAPDH.  
2.2.11. Protein Turnover Assays 
 Protein turnover was assessed using pulse-chase analysis. Radiolabeled amino acids 
in the cell culture medium are incorporated into newly synthesized proteins during the “pulse” 
period. Cells are collected over time and radioactivity measurements are used to calculate 
rates of protein synthesis. To determine protein degradation, the cells are pulsed with 
radiolabeled amino acids. After the “pulse” period, medium containing radiolabeled amino 
acids is washed away and replaced with non-radioactive medium. Aliquots of medium over 
time are taken during the “chase” period, and the radioactivity measurements are used to 
calculate protein degradation rates. The amino acid used for pulse-chase analysis is critical in 
order to accurately determine protein turnover rates. The intracellular concentration of the 
amino acid used must be stable. Additionally, the amino acid must be readily taken up by the 
cell and have a detectable rate of incorporation into proteins, but should not be synthesized, 
degraded, or converted to other amino acids within the cell. In the heart, phenylalanine (Phe) 
fits all criteria and thus has been used to measure protein turnover in the heart and in isolated 
cardiomyocytes [353, 354].    
 Radioactivity is assessed using liquid scintillation counting [355]. Radioactive samples 
are mixed with scintillation fluid containing an aromatic solvent and one or several 
luminophors (scintillants). Samples containing carbon-14, for example, emit β particles that 
transfer energy to the solvent and subsequently to the luminophors. The excited luminophors 
emit light that is detected by the scintillation counter. Radioactivity is measured as counts per 
minute (CPM), the detectable decay of atoms per minute. CPM is then converted to 
disintegrations per minute (DPM), the “corrected” number of atoms that have decayed per 
minute. DPM values were used for comparisons between samples. 
 To measure protein synthesis rates, NRVM or AMCM were incubated with pulse 
medium containing radiolabeled Phe (1 µCi/mL [14C]) and cells were collected at various time 
points. Cells were washed with ice-cold PBS and cells were incubated at 4°C overnight in 
TCA (700µL of 10% in ddH2O per well in a 6-well plate). Cells were scraped and collected in 
eppendorf tubes and centrifuged at 21,000g for 5 minutes at 4ºC. The supernatant fraction 
was discarded and the cell pellet was resuspended in buffer (100uL of Triton X-100 [1%] and 
NaOH [1M]). The lysate (85uL) was added to glass scintillation vials (containing scintillation 
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fluid [10mL]) and counted using the following counting protocol: 2 counting cycles with 1 
minute count time and no sigma coindidence [356]. 
 To measure protein degradation rates, NRVM or AMCM were incubated with “pulse” 
medium containing radiolabeled Phe (1 µCi/mL [14C]) for 24 hours prior to adenovirus 
infection or 48 hours prior to treatments. After 48 hours of incubation, media were switched to 
chase medium. Aliquots of chase medium (500µL) were collected over 24 hours, combined 
with TCA (500µLof 20% in ddH2O) and incubated at 4°C overnight to precipitate proteins. 
Precipitated proteins were centrifuged 9600g for 5 minutes at 4ºC. The supernatant fraction 
(950µL) was added to glass scintillation vials (containing scintillation fluid [10mL]) and 
counted using the protocol described above. Cells were also collected and the radiolabeled 
Phe remaining in the cells was measured as described above. The acid-soluble radioactivity 
from the chase medium was used to denote the amount of protein degraded over time while 
total protein was used for normalization. Results are expressed as percent protein 
degradation or fold change over control [356]. 
2.2.12. Statistical Analysis 
 Results are expressed as means ± SEM. Analysis was performed using two-tailed, 
unpaired Student’s t test or one-way ANOVA with Tukey post hoc test. A value of P<0.05 was 
considered significant. 
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Chapter 3 
 
 
THE ROLE OF 5’-AMP-ACTIVATED PROTEIN KINASE IN 
PROTEIN DEGRADATION IN THE HEART 
 
 
 
 
 
 
 
 
 
 
 
 
“Scientific principles and laws do not lie on the surface of nature. They are hidden, and 
must be wrested from nature by an active and elaborate technique of inquiry [357].” 
 
~John Dewey, PhD. (1920) 
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3.1. Nutrient Deprivation Upregulates Markers of Protein Degradation in 
Cardiomyocytes 
As outlined already in Chapter 1, protein degradation, specifically protein 
degradation through the ubiquitin proteasome system (UPS), has been extensively studied 
in skeletal muscle. Comparatively less is known about the cardiac UPS. In skeletal muscle 
and in the heart, nutrient deprivation in vivo leads to enhanced protein degradation. Nutrient 
deprivation increases expression of the ubiquitin ligases Atrogin-1 and MuRF1 in myotubes 
[141], but whether the absence of nutrients regulates expression of Atrogin-1 and MuRF1 in 
cardiomyocytes is not known.  
To test the hypothesis that Atrogin-1 and MuRF1 are regulated by nutrient 
deprivation in cardiomyocytes, I first isolated and cultured neonatal rat ventricular 
cardiomyocytes (NRVM) under a variety of nutrient deprivation conditions. Complete 
nutrient deprivation significantly increased Atrogin-1 and MuRF1 expression over time. 
Atrogin-1 mRNA levels increased quickly (3.5 fold increase with 2 hours of nutrient 
deprivation) and continued to increase to greater than 5 fold after 24 hours. MuRF1 mRNA 
also increased over time, nearly 4 fold after 24 hours (Figure 3.1.A.). 
To determine the consequence of enhanced expression of the ubiquitin ligases, I 
analyzed their protein levels. After 24 hours of nutrient deprivation, both Atrogin-1 and 
MuRF1 protein levels increased. Furthermore, AMPK activity, denoted by its 
phosphorylation status, was significantly enhanced (Figure 3.1.B.). It is an established fact 
that nutrient deprivation decreases the ratio of [ATP]/[AMP] and, consequently, activates 
AMPK [224]. My results now demonstrate that nutrient deprivation also activates AMPK in 
cardiomyocytes, and thus activation is associated with increased mRNA and protein levels 
of Atrogin-1 and MuRF1.  
The IGF-1/AKT pathway is downregulated with nutrient deprivation in skeletal 
muscle which permits FOXO to initiate transcription of target genes [145]. Indeed, FOXO3A 
regulates Atrogin-1 in the heart [144]. Because Atrogin-1 and MuRF1 are upregulated 
under a variety of conditions, and complete nutrient deprivation can affect multiple 
pathways simultaneously, I focused on an as yet unexplored pathway that could regulate 
their expression, namely AMPK. 
 To determine whether AMPK is involved in regulating Atrogin-1 and MuRF1, NRVM 
were incubated without glucose. Glucose deprivation activates AMPK. Even though glucose 
deprivation activates other pathways as well, potentially fewer pathways are activated than 
what occurs with complete nutrient deprivation. Glucose deprivation increased Atrogin-1  
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 Figure 3.1. Regulation of ubiquitin ligases and AMPK by nutrient deprivation in 
cardiomyocytes. 
(A) Atrogin-1 and MuRF1 expression in response to nutrient deprivation. NRVM were 
isolated as described in “2.2.4. Isolation of Neonatal Rat Ventricular Cardiomyocytes” and 
incubated overnight in culture medium. NRVM were washed twice with phosphate buffered 
saline (PBS) and incubated in PBS for the remainder of the experiment. NRVM were 
collected in TRI Reagent® 0, 2,4,8, and 24 hours after PBS incubation. RNA was isolated 
and quantified as described in “2.2.6.1. Total RNA Isolation and Quantification”. 
Quantitative real time PCR was performed as described in “2.2.9. Quantitative Real Time 
PCR (qRT-PCR) Transcript Analysis”. Data are expressed as mean fold change ± SEM of 3 
independent experiments performed in triplicate. (B) Atrogin-1, MuRF1, pAMPK, and AMPK 
protein levels in response to nutrient deprivation. NRVM were incubate in PBS for 24 hours, 
collected in cell lysis buffer, and protein concentration was determined as described in 
“2.2.6.2. Protein Isolation and Quantification”. Protein and phosphorylation levels were 
determined as described in “2.2.10. SDS-PAGE, Western Blot Analysis and Quantification”. 
A representative western blot is shown on the left. Data are expressed as mean fold 
change ± SEM of 3 independent experiments performed in duplicate. *P<0.01 versus 
control, † P<0.01 versus respective controls. pAMPK, phosphorylated AMP-activated 
protein kinase; AMPK, AMP-activated protein kinase; GAPDH, Glyceraldehyde 3-
phosphate dehydrogenase. Reprinted with permission from KK Baskin and H Taegtmeyer, 
AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation Research, 
109, 10, 1153-1161 [358].    
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Figure 3.2. Regulation of ubiquitin ligases and AMPK by glucose deprivation in 
cardiomyocytes. 
 (A)  Atrogin-1 and MuRF1 expression in response to glucose deprivation. NRVM were 
isolated and incubated overnight in culture medium. NRVM were washed twice with 
phosphate buffered saline (PBS) and cultured in glucose-free culture medium for the 
remainder of the experiment. RNA was isolated from NRVM collected at the times indicated 
and qRT-PCR was performed. Data are expressed as mean fold change ± SEM of 3 
independent experiments performed in triplicate. (B) Atrogin-1, MuRF1, pAMPK, AMPK, 
pACC, and ACC protein levels in response to nutrient deprivation. A representative western 
blot from NRVM incubated in glucose-free medium for the times indicated is shown here. 
pACC, phosphorylated acetyl-CoA carboxylase; ACC, acetyl-CoA carboxylase. 
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and MuRF1 mRNA expression (Figure 3.2.A.); albeit to a lesser extent than with complete 
nutrient deprivation. Protein levels of both ligases were also significantly increased with 
glucose deprivation, most prominently, after 24 hours (Figure 3.2.B.). These data 
demonstrate a correlation between nutrient deprivation, AMPK activation, and Atrogin-1 and 
MuRF1expression. However, the consequence of nutrient deprivation had not been 
investigated in cardiomyocytes before.    
Fasting also increases protein degradation in the heart in vivo, but the mechanisms 
by which this occurs have not yet been explored [309, 359]. As a first step I investigated the 
consequence of nutrient deprivation on protein degradation in NRVM using pulse-chase 
analysis (as described in Chapter 2 in section 2.2.11. “Protein Turnover Assays”). The 
results shown in Figure 3.3. are expressed as percent total protein degraded after 24 hours 
of nutrient deprivation. To determine the relative contribution of proteasome- and 
autophagy-mediated protein degradation, I used inhibitors for both pathways (Bortezomib 
and 3-methyladenine (3-MA), respectively). Protein degradation was significantly decreased 
with Bortezomib or with 3-MA treatment under complete nutrient conditions (Figure 3.3.). 
However, protein degradation was enhanced with nutrient deprivation but could be reduced 
by treatment with either Bortezomib or 3-MA. Inhibition of both the proteasome and 
autophagy under complete nutrients or nutrient deprivation was not possible due to 
considerable cell death. Collectively, these data suggest that nutrient deprivation activates 
AMPK, which leads to enhanced expression of ubiquitin ligases and increased protein 
degradation.  
3.2. AMPK Regulates the Expression of Ubiquitin Ligases In Vitro and In Vivo 
To test the hypothesis that AMPK is responsible for the increased expression of 
Atrogin-1 and MuRF1 under nutrient deprivation conditions, NRVM were treated with 
AICAR, an activator of AMPK. AICAR is an adenosine analog which is rapidly 
phosphorylated upon entry into the cell (to ZMP) [360]. Accumulation of ZMP leads to 
activation of AMPK in the absence of metabolic stress (such as nutrient deprivation) [361]. 
Previous studies in NRVM used between 0.5mM and 2.0mM AICAR to activate AMPK. 
Initial time course studies were performed using AICAR (1.0mM) to define conditions for 
additional experiments. AICAR treatment increased phosphorylation of AMPK and acetyl-
CoA carboxylase (ACC), a direct target of AMPK. Phosphorylation occurred quickly with 
AICAR (1.0mM) (in less than 30 minutes, not shown) and both AMPK and ACC remained 
phosphorylated for at least 24 hours in the presence of AICAR. After 36 hours  
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Figure 3.3. Regulation of protein degradation by nutrient deprivation 
in cardiomyocytes.  
Protein degradation in response to nutrient deprivation. NRVM were 
isolated and several hours later incubated in pulse medium containing 
radiolabeled Phe (1µCi/mL [14C]), as described in “2.2.11. Protein Turnover 
Assays”. After 48 hours NRVM were washed twice with complete medium 
and incubated in chase medium with or without nutrients containing 
vehicle, Bortezomib (1µmol/L), or 3-methyladenine (3-MA, 10µmol/L). 
Chase medium was collected over 24 hours and rates of protein 
degradation were calculated as described in “2.2.11. Protein Turnover 
Assays”. Results are expressed as mean percent protein degradation ± 
SEM of 3 independent experiments performed in triplicate. *P<0.01 versus 
untreated, † P<0.01 versus complete nutrients. Reprinted with permission 
from KK Baskin and H Taegtmeyer, AMP-activated protein kinase 
regulates E3 ligases in rodent heart, Circulation Research, 109, 10, 1153-
1161 [358].   
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Figure 3.4. Time-dependent regulation of AMPK, Atrogin-1, and 
MuRF1 by AICAR in cardiomyocytes.  
(A) Activation of AMPK in response to AICAR. NRVM were isolated and 
incubated overnight in culture medium, washed twice with phosphate 
buffered saline (PBS), and incubated with AICAR (1.0mM) in culture 
medium for the designated times. A representative western blot from 
AICAR-treated NRVM is shown. (B) Atrogin-1 and MuRF1 expression in 
response to AICAR treatment. Data are expressed as mean fold change 
± SEM of 3 independent experiments performed in triplicate. *P<0.01 
versus 0 hours.  
  
88 
 
phosphorylation of AMPK and ACC declined (Figure 3.4.A.). Consequently, Atrogin-1 and 
MuRF1 expression increased in response to AICAR (1.0mM) treatment, but at a slow rate 
(Figure 3.4.B.). Atrogin-1 and MuRF1 expression significantly increased 3 and 2 fold, 
respectively, 24 hours after AICAR treatment. Therefore all subsequent experiments were 
performed at 24 hours.  
To further characterize the regulation of Atrogin-1 and MuRF1 by AMPK through 
AICAR, I performed dose-response experiments. Atrogin-1 and MuRF1 expression was 
increased by up to three fold in a dose-dependent manner after 24 hours of AICAR 
treatment (Figure 3.5.A.). Additionally, AMPK and ACC phosphorylation were increased at 
a relatively low concentration of AICAR (0.25mM) and continued to increase in a dose-
dependent manner as well (Figure 3.5.B.). Atrogin-1 and MuRF1 protein levels also 
increased in response to AICAR treatment, but required a higher dose. The protein levels of 
Atrogin-1 and MuRF1 were significantly increased with AICAR (1.0mM) and subsequent 
experiments were therefore performed using this concentration.    
To determine whether the increase of Atrogin-1 and MuRF1 was due to AMPK 
activation through AICAR, and not through another AICAR-mediated pathway, AMPK was 
inhibited using Compound C [287]. Compound C decreased AMPK phosphorylation to the 
same extent with or without AICAR. ACC was equally responsive to AICAR and Compound 
C, but phosphorylation of ACC was much lower with Compound C alone compared to the 
combined AICAR and Compound C treatment (Figure 3.6.A.). Atrogin-1 and MuRF1 
expression was also significantly decreased with Compound C treatment, in a dose-
dependent manner. AICAR treatment increased Atrogin-1 and MuRF1 expression nearly 
three fold, and addition of Compound C abrogated these changes (Figure 3.6.B.). 
The consequence of AMPK activation by AICAR was also determined in vivo. 
AICAR was delivered by intraperitoneal (IP) injection, and the effects of AICAR on AMPK, 
ACC, Atrogin-1, and MuRF1 in the heart were examined (Figure 3.7.A.). Acute treatment, 
one injection of AICAR, significantly increased Atrogin-1 and MuRF1 mRNA in a time-
dependent manner. Six hours after AICAR delivery, Atrogin-1 expression significantly 
increased (two fold) and further increased (to three fold) at 24 hours after AICAR injection. 
MuRF1 expression was increased, although not significantly, six hours post injection and 
was significantly increased to the same extent as Atrogin-1 24 hours post injection. Chronic 
AICAR treatment, by daily injections for 7 days, significantly increased both Atogin-1 and 
MuRF1 expression (each by more than 5 fold) (Figure 3.7.A.). AMPK regulates the 
transcription of GLUT4 [293] and UCP3 [290], which were quantified in the heart as positive 
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Figure 3.5. Dose-dependent regulation of AMPK, Atrogin-1, and MuRF1 by AICAR in 
cardiomyocytes.  
(A) Atrogin-1 and MuRF1 expression in response to AICAR treatment. NRVM were isolated 
and incubated overnight in normal culture medium, washed twice with phosphate buffered 
saline (PBS), and incubated with AICAR (0.25mM, 0.5mM, or 1.0mM) in culture medium for 
24 hours. Data are expressed as mean fold change ± SEM of 3 independent experiments 
performed in triplicate. (B) AMPK activation and Atrogin-1 and MuRF1 protein levels in 
response to AICAR treatment. A representative western blot is shown on the left. Data are 
expressed as mean fold change ± SEM of 3 independent experiments performed in 
duplicate. *P<0.01 versus untreated. Reprinted with permission from KK Baskin and H 
Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation 
Research, 109, 10, 1153-1161 [358].   
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Figure 3.6. Regulation of Atrogin-1 and MuRF1 by AICAR and Compound C in 
cardiomyocytes. 
(A) AMPK activation and inhibition and Atrogin-1 and MuRF1 protein levels in response to 
AICAR and/or Compound C treatment. NRVM were isolated and incubated overnight in 
culture medium, washed twice with phosphate buffered saline (PBS), and incubated with 
AICAR (1.0mM) and/or Compound C (10µM) in culture medium for 24 hours. A 
representative western blot is shown. (B) Atrogin-1 and MuRF1 expression in response to 
AICAR and Compound C treatment. Data are expressed as mean fold change ± SEM of 3 
independent experiments performed in triplicate. *P<0.01 versus untreated, † P<0.01 
versus AICAR. Reprinted with permission from KK Baskin and H Taegtmeyer, AMP-
activated protein kinase regulates E3 ligases in rodent heart, Circulation Research, 109, 10, 
1153-1161 [358].   
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Figure 3.7. Regulation of AMPK, Atrogin-1, and MuRF1 by AICAR in the mouse heart. 
(A) Atrogin-1, MuRF1, GLUT4, and UCP3 expression in the heart in response to AICAR 
injection(s). Mice were injected with AICAR (0.5mg/kg bw) (see text for details). Hearts 
were extracted, rinsed in ice-cold PBS, and snap frozen in liquid nitrogen. RNA was 
isolated from heart tissue and quantified as described in “2.2.6.1. Total RNA Isolation and 
Quantification”. Data are expressed as mean fold change ± SEM, n=6-8 per group, qRT-
PCR was performed in triplicate for each heart. *P<0.01 versus saline controls. (B) AMPK 
activation, Atrogin-1 and MuRF1 protein levels in the heart in response to AICAR 
injection(s). A representative western blot is shown on samples from the 7d saline control 
and AICAR group. GLUT4, glucose transporter 4; UCP3, uncoupling protein 3. Reprinted 
with permission from KK Baskin and H Taegtmeyer, AMP-activated protein kinase regulates 
E3 ligases in rodent heart, Circulation Research, 109, 10, 1153-1161 [358].    
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controls. GLUT4 and UCP3 expression in the heart also increased in a time-dependent 
manner in response to AICAR treatment (Figure 3.7.A.). As expected, chronic AICAR 
treatment also increased AMPK and ACC phosphorylation. Moreover, Atrogin-1 and 
MuRF1 protein levels were significantly increased in the heart with chronic AICAR 
treatment (Figure 3.7.B.). Taken together (Figures 3.1. – 3.7.), these results demonstrate 
that Atrogin-1 and MuRF1 are regulated in cardiomyocytes and in the heart by AMPK. 
 To exclude the possibility that the results described above were caused by off-target 
effects of pharmacological treatment, I used genetically modified AMPK adenoviruses in 
cardiomyocytes. NRVM are difficult to manipulate genetically, as most primary cells are. 
Therefore adenoviruses expressing active or dominant negative forms of AMPK were used 
in the following experiments. For a detailed description of the adenoviruses see Chapter 2 
(2.2.8., “Amplification and Quantification of Adenoviruses”). NRVM were infected with 
increasing amounts of virus (multiplicity of infection, MOI) and the expression of Atrogin-1 
and MuRF1 was determined. Atrogin-1 mRNA was significantly increased with the 
overexpression of active AMPK (aAMPK) in NRVM. Low expression of AMPK (MOI 1) led 
to a nearly two fold increase, while overexpression of dominant negative AMPK (dnAMPK) 
had no effect on baseline levels of Atrogin-1 (Figure 3.8.A.). MuRF1 mRNA was also 
significantly increased in response to aAMPK nearly two fold, and like Atrogin-1, MuRF1 
expression was also not affected by dnAMPK (Figure 3.8.B.).  
 Active AMPK is expressed as a truncated form of AMPKα2 that lacks the 
autoinhibitory domain and β-subunit binding domain (see Chapter 2 for details). Thus, the 
AMPK antibody used to determine protein levels in NRVM recognizes a lower molecular 
weight species of AMPK (Figure 3.8.C.). Unfortunately, the phospho-AMPK antibody did 
not detect phosphorylation of this species. Therefore, ACC phosphorylation was used as an 
indicator of active AMPK. ACC phosphorylation was enhanced with increasing expression 
of aAMPK (Figure 3.8.C.). Furthermore, the protein levels of Atrogin-1 and MuRF1 were 
increased by expression of aAMPK. It is not clear whether the AMPK antibody detects 
dnAMPK because with increasing amounts of dnAMPK adenovirus, neither total nor 
phosphorylated AMPK levels were altered (Figure 3.8.D.). However, ACC was responsive 
to dnAMPK as its phosphorylation status decreased in response to increasing amounts of 
dnAMPK expression (Figure 3.8.D.). Dominant negative AMPK also decreased the protein 
levels of Atrogin-1 and MuRF1 (Figure 3.8.D). It is interesting that Atrogin-1 and MuRF1 
mRNA levels were unaffected by dnAMPK expression while their protein levels were 
decreased. Although further investigation is still necessary, it is possible that the steady  
93 
 
 
 
                                          
 
Figure 3.8. Regulation of Atrogin-1 and MuRF1 by AMPK in cardiomyocytes. 
(A) Atrogin-1 expression and (B) MuRF1 expression in response to active AMPK (aAMPK) 
or dominant negative AMPK (dnAMPK) adenovirus expression. NRVM were isolated and 
cultured overnight in culture medium and infected with adenovirus (1, 10, 25, 50 MOI). Six 
hours post infection NRVM were washed twice with PBS and cultured an additional 18 
hours in culture medium. Data are expressed as mean fold change ± SEM of 3 independent 
experiments performed in triplicate. *P<0.01 versus empty virus control. (C and D) AMPK, 
ACC, Atrogin-1, and MuRF1 protein levels in response to dnAMPK and aAMPK. 
Representative western blots are shown. See text for details. Reprinted with permission 
from KK Baskin and H Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in 
rodent heart, Circulation Research, 109, 10, 1153-1161 [358].   
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state levels of Atrogin-1 and MuRF1 are altered by dnAMPK at the protein level but not at 
the mRNA level.   
Although, as shown above, aAMPK appears to be expressed in an active state, its 
phosphorylation status could not be verified directly using commercially available 
antibodies. Therefore I wondered whether aAMPK could be further stimulated by AICAR, 
thus enhancing the expression of Atrogin-1 and MuRF1. I infected NRVM with aAMPK or 
dnAMPK, and treated them with AICAR and/or Compound C. As previously shown, AICAR 
and aAMPK (to a lesser extent) increased expression of Atrogin-1, while Compound C 
alone decreased Atrogin-1 expression. dnAMPK, as shown in Figure 3.8.A., had no 
significant effect on Atrogin-1 expression (Figure 3.9.). AICAR and aAMPK had an additive 
effect on Atrogin-1 expression, while Compound C treatment decreased Atrogin-1 
expression in the presence of aAMPK. These data suggest that aAMPK is also 
pharmacologically regulated by AICAR and Compound C. Although the active sight within 
dnAMPK is mutated, NRVM expressing dnAMPK treated with AICAR and/or Compound C 
were still responsive to the treatment (as evidenced by changes in Atrogin-1 expression). It 
is possible that these effects are due to endogenous AMPK; however, this has yet to be 
demonstrated. 
The additive effects of pharmacological treatment and genetic expression on 
MuRF1 mRNA levels were also determined. The expression of MuRF1 in response to 
AICAR, Compound C, aAMPK, and dnAMPK, in this set of experiments was the same as 
previously discussed and shown in Figure 3.8.B. Like Atrogin-1, MuRF1 expression was 
increased with AICAR treatment and further increased with AICAR and expression of 
aAMPK. Unlike Atrogin-1, MuRF1 expression was not altered by AICAIR when dnAMPK 
was expressed; however, was decreased with Compound C when dnAMPK was expressed 
(Figure 3.10.). Taken together, these studies validate the usage of aAMPK and dnAMPK in 
NRVM, and demonstrate that genetic modification of AMPK does not completely activate or 
abolish total AMPK pools within the cardiomyocyte. These data provide evidence that 
AMPK, pharmacologically and/or genetically, regulates the expression of Atrogin-1 and 
MuRF1.         
To determine the consequence of genetic activation and inhibition of AMPK on 
protein degradation, I performed more pulse chase experiments in NRVM (using aAMPK 
and dnAMPK, MOI 10). Active AMPK, like nutrient deprivation, increased protein 
degradation in cardiomyocytes, while dnAMPK decreased protein degradation. Bortezomib, 
a proteasome inhibitor that decreases protein degradation, was used as a control (Figure  
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Figure 3.9. Synergistic regulation of Atrogin-1 by pharmacologic and genetic 
activation of AMPK  
Atrogin-1 expression in response to AMPK activation and inhibition. NRVM were isolated 
and cultured as described in Figure 3.8. except that 24 hours after virus infection with 
aAMPK or dnAMPK (MOI 10), AICAR and/or Compound C were added to the culture 
medium and NRVM were incubated 24 hours longer. Control NRVM were infected with 
empty virus (MOI 10) and is shown in the green bars on the left, NRVM infected with 
aAMPK are shown in the middle in grey, NVRM infected with dnAMPK are shown on the 
right in the pattern-filled bars. Data are expressed as mean expression ± SEM of 3 
independent experiments performed in triplicate. *P<0.01 versus untreated empty virus 
control, †P<0.01 versus AICAR, #P<0.01 versus virus, ‡P<0.01 versus virus + AICAR. 
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Figure 3.10. Synergistic regulation of MuRF1 by pharmacologic and genetic 
activation of AMPK  
MuRF1 expression in response to AMPK activation and inhibition. NRVM were isolated and 
cultured as described in Figure 3.8. except that 24 hours after virus infection with aAMPK 
or dnAMPK (MOI 10), AICAR and/or Compound C were added to the culture medium and 
NRVM were incubated 24 hours longer. Control NRVM were infected with empty virus (MOI 
10) and is shown in the black bars on the left, NRVM infected with aAMPK are shown in the 
middle in grey, NVRM infected with dnAMPK are shown on the right in the pattern-filled 
bars. Data are expressed as mean expression ± SEM of 3 independent experiments 
performed in triplicate. *P<0.01 versus untreated empty virus control, †P<0.01 versus 
AICAR, #P<0.01 versus virus, ‡P<0.01 versus virus + AICAR. 
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Figure 3.11. Regulation of protein degradation by AMPK in cardiomyocytes. 
Protein degradation in response to aAMPK and dnAMPK. NRVM were isolated 
and cultured as described in Figure 3.3. NRVM were infected with aAMPK (MOI 
10) and dnAMPK (MOI 10) 24 hours prior to changing the medium from pulse to 
chase medium. At the onset of the “chase”, NRVM were incubated in culture 
medium (control, aAMPK, dnAMPK), PBS (nutrient deprived), or culture medium 
with Bortezomib (1µmol/L). Data are expressed as mean percent protein 
degradation ± SEM of 3 independent experiments performed in triplicate. 
*P<0.01 versus control. † P<0.01 versus aAMPK. Reprinted with permission 
from KK Baskin and H Taegtmeyer, AMP-activated protein kinase regulates E3 
ligases in rodent heart, Circulation Research, 109, 10, 1153-1161 [358].   
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3.11.). Collectively, these results demonstrate that AMPK regulates the ubiquitin ligases 
Atrogin-1 and MuRF1 in cardiomyocytes (and in the heart) by enhancing their expression at 
the mRNA and protein level. In other words, AMPK increases protein degradation in 
cardiomyocytes.  
The hypothesis that AMPK could be involved in UPS-mediated protein degradation 
had not been considered until I began working on my thesis project, or so we thought. Much 
to my despair, and rather unfortunate for the lab, some of the work described thus far in my 
dissertation was published by several groups (although all experiments were performed in 
skeletal muscle). These studies are discussed in detail below. This situation offered itself as 
a learning experience, and I followed the advice of my mentor, “Dr. T.”, and “stuck with it.” 
This experience, and a cartoon illustrating the advancements and setbacks in AMPK 
research [362], inspired my T-shirt design for the 2011 annual Cell and Regulatory Biology 
(CRB) spring retreat (Figure 3.12.). 
Similar to our results presented thus far, experiments reported by Krawiec et.al. 
demonstrated that Atrogin-1 and MuRF1 mRNA was increased with AICAR treatment in a 
dose-dependent manner in C2C12 cells, a skeletal muscle cell line [363]. Their data support 
our findings that the expression of MuRF1 in response to AICAR increases in a time-
dependent manner, but at a slower rate compared to the increase in Atrogin-1 expression. 
They also found that Metformin, another activator of AMPK, increased Atrogin-1 and 
MuRF1 expression. Despite this finding in C2C12 cells, Metformin failed to increase the 
expression of either ligase in NRVM in our hands (data not shown). This could be due to 
differential metabolic demand and regulation in the heart compared to skeletal muscle, as 
Metformin does not activate AMPK directly [287]. Furthermore, the investigators used other 
methods to activate AMPK rather than nutrient deprivation, namely 2-deoxyglucose (2DG). 
2DG is a glucose analogue that enters the cell and is phosphorylated by hexokinase, but 
cannot be metabolized. Cells are essentially “glucose deprived”, however phosphorylated 
2DG may have other negative effects on intracellular signaling (S. Sen, H. Taegtmeyer, 
unpublished results). Although the data of Krawiec et. al. support our initial findings, they 
did not investigate the consequence of AMPK activation on protein degradation.    
 Another study published shortly thereafter also found, in C2C12 cells, that AICAR 
increases the expression of Atrogin-1 and to a lesser extent, MuRF1 [364]. Additionally, 
AICAR treatment increases protein degradation in muscle cells. Nakashima et. al. attributed 
these findings to increased FOXO activity, although only reported FOXO1 and FOXO3A 
mRNA expression and not protein or phosphorylation levels. I also wondered whether  
99 
 
 
Figure 3.12. Life as a CRB student. 
This cartoon depicts a simplified overview of life as graduate student. Many life lessons can 
be learned in this stage of a scientific career. The two most important: take the good with 
the bad, and embrace sarcasm. Special thanks to ‘Piled Higher & Deeper a grad student 
comic strip’ for finding humor in daily lab scenarios. 
(http://www.phdcomics.com/comics.php)  
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AMPK could be affecting FOXO3A activity in cardiomyocytes thus leading to increased 
expression of Atrogin-1 and MuRF1. At the time I performed the following set of 
experiments, it was already known that FOXO3A regulates Atrogin-1 expression in the 
heart [144]; however it was not known whether AMPK could regulate FOXO. Therefore, I 
determined the phosphorylation status of FOXO3a in NRVM expressing aAMPK or 
dnAMPK. Neither aAMPK nor dnAMPK expression affected the phosphorylation status of 
FOXO3a, at least on Ser253 (Figure 3.13.). Therefore, I proceeded to search for an 
alternative novel mechanism whereby AMPK regulates Atrogin-1 and MuRF1 expression. 
Shortly after I performed the experiments described in (Figure 3.13.), Greer et.al.  
identified phosphorylation sites on FOXO3 (including Ser588) which were regulated by 
AMPK. The consequence of FOXO phosphorylation on this site, however, was not 
described [365]. Although presumably important, no additional studies reported the 
regulation of FOXO3A by AMPK until recently. AMPK was shown to interact with and 
phosphorylate FOXO3A on Ser588. Although the expression of Atrogin-1 and MuRF1 was 
not investigated, autophagy gene expression was increased through FOXO3A-mediated 
transcription, as was the number of autophagosomes in muscle cells [366]. This study 
identifies another pathway by which AMPK regulates autophagy, however little is still known 
about AMPK-mediated protein degradation through the UPS in the heart.      
Data in support of our hypothesis that AMPK regulates the UPS by mediating 
Atrogin-1 and MuRF1 expression was also published by Tong et.al. [367]. This group 
demonstrated that AMPK activation was sufficient to increase Atrogin-1 and MuRF1 
expression, even in the presence of IGF-1, activation of AKT, and inhibition of FOXO3A 
[367]. The authors suggest that AMPK antagonizes the inhibition of FOXO3A-mediated 
transcription by AKT through phosphorylation of FOXO3A on other/multiple regulatory sites. 
This study does not exclude the possibility that AMPK regulates Atrogin-1 and MuRF1 
expression independent of FOXO3A, which we have found to be the case, and is the topic 
of discussion below. 
3.3. AMPK Activation Regulates the Expression of MuRF1 In Vitro Through the 
Transcription Factor Myocyte Enhancer Factor 2 
As already mentioned, previous studies in liver [285] and in skeletal muscle [289] 
have demonstrated that AMPK regulates transcription of several genes. AMPK regulates 
the transcription of GLUT4 in skeletal muscle through the transcription factor myocyte 
enhancer factor 2 (MEF2) [293]. Because MEF2 is a transcription factor involved in 
metabolic and structural remodeling in cardiomyocytes [368], and Atrogin-1 and MuRF1 are  
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Figure 3.13. Regulation of FOXO3a by AMPK in 
cardiomyocytes.    
FOXO3A protein and phosphorylation levels in 
response to dnAMPK and aAMPK expression. 
Representative western blots are shown. See text for 
details. 
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as well, it seemed very likely to me that a connection between AMPK, MEF2, and Atrogin-1 
and MuRF1 exists.  
 To explore potential transcriptional mechanisms by which AMPK regulates ubiquitin 
ligases, in silico experiments were performed to identify transcription factor binding sites 
within the Atrogin-1 and MuRF1 promoters. A well-established MEF2 binding site 
(CTAaAAATAG) was identified within the MuRF1 promoter (Figure 3.14.A.). Because 
AMPK-regulation of MEF2 has never been described in cardiomyocytes, I determined 
MEF2 transcriptional activity in response to AMPK activation. An ELISA-like assay 
containing a stationary MEF2 recognition sequence binds to MEF2 in its active state. MEF2 
binding is then detected using antibodies conjugated to HRP (horseradish peroxidase). 
Activation of AMPK with AICAR and aAMPK increased MEF2-DNA binding while 
Compound C (CC) and dnAMPK decreased MEF2-DNA binding (Figure 3.14.B.). These 
results strongly suggest that MEF2-regulated transcription may be mediated by AMPK.     
To determine whether MEF2 binds the MuRF1 promoter and regulates its 
transcription in cardiomyocytes, gene reporter and chromatin immunoprecipitation assays 
(ChIP) were performed. Gene reporter assays were generated using 1kb of the 
endogenous MuRF1 promoter upstream of luciferase. The “MuRF1 promoter” construct 
contains the MuRF1 promoter with the potential MEF2 binding site intact. The “mutated 
MuRF1 promoter” construct contains the MuRF1 promoter with the potential MEF2 binding 
site mutated (Figure 3.15.A.). The MuRF1 promoter or the mutated MuRF1 promoter 
construct were contransfected with a construct encoding β-galactosidase (β-gal) into H9c2 
cardiomyoblasts. After transfection and treatment cells were collected and assayed for 
luciferase and β-galactosidase activity. AMPK activation with AICAR or aAMPK increased 
luciferase activity of the endogenous promoter, while AMPK inhibition with CC or dnAMPK 
decreased luciferase activity (Figure 3.15.B.). These results indicate that AMPK directly 
regulates MuRF1 transcription. The mutated MuRF1 promoter, however, was not 
responsive to AMPK activation or inhibition, but was still transcribed in the absence of 
nutrients (Figure 3.15.B.). These data demonstrate that MEF2 is required for AMPK-
mediated MuRF1 transcription, but that MEF2 is not required for MuRF1 transcription 
during nutrient deprivation (Figure 3.15.B.). 
To determine whether MEF2 binds directly to the MuRF1 promoter, ChIP assays 
were performed. Myocytes were infected with adenovirus (MOI 10) and MEF2 was 
immunoprecipitated from nuclear extracts. DNA isolated from the extracts was amplified  
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Figure 3.14. Regulation of MEF2 transcription by AMPK in 
cardiomyocytes. 
(A) MEF2 consensus binding site and the potential MEF2 binding 
site identified in silico. (B) MEF2 binding activity in response to 
AMPK activation and inhibition. NRVM were treated for 24 hours 
with AICAR (1.0mM), CC (10µM) + AICAR (1.0mM), aAMPK (MOI 
10), or dnAMPK (MOI 10). Nuclear fractions were isolated as 
described in “2.2.6.3. Nuclear Fractionation of Cells” and used to 
determine MEF2 –DNA binding as described in “2.2.7.3. MEF2 
Activity Assay”. See text for details. Data are expressed as mean 
fold change ± SEM of 3 independent experiments performed in 
triplicate. *P<0.01 versus control. † P<0.01 versus AICAR or 
aAMPK. Reprinted with permission from KK Baskin and H 
Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in 
rodent heart, Circulation Research, 109, 10, 1153-1161 [358].    
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Figure 3.15. Regulation of MuRF1 transcription by an AMPK-MEF2 axis in myocytes. 
(A) Gene reporter assay constructs containing the endogenous MuRF1 promoter sequence 
with the potential MEF2 binding site intact or mutated (alanine to cytosine, AAA CCC) 
upstream of luciferase. (B) MuRF1 transcription in response to AMPK activation or inhibition 
in myocytes. H9c2 myoblasts were cotransfected with luciferase reporter constructs (1 µg) 
and a vector encoding β-galactosidase (1µg) using PolyJet™ transfection reagent as 
described in “2.2.7.1. Luciferase Reporter Constructs and Activity Assays”. Myocytes were 
incubated in culture medium containing AICAR (1.0mM) or CC (10µM) + AICAR (1.0mM), 
or in PBS (nutrient deprivation) for 24 hours. For adenovirus conditions, myocytes were 
infected 24 hours prior to transfection of luciferase reporter constructs. Myocytes were 
collected in reporter lysis buffer and enzyme activities were assayed as described in 
“2.2.7.1. Luciferase Reporter Constructs and Activity Assays” and “2.2.7.2. β-galactosidase 
Activity Assays and Staining”. Data are expressed as mean relative luminescent units 
(RLU) normalized to β-galactosidase absorbance ± SEM of 3 independent experiments 
performed in triplicate. *P<0.01 versus control. † P<0.01 versus AICAR or aAMPK. (C) 
MEF2 binding to the MuRF1 promoter. Myocytes were infected with empty, aAMPK, or 
dnAMK adenovirus (MOI 10). 24 hours post infection DNA was cross-linked to proteins and 
myocytes were collected. Chromatin immunoprecipitation (ChIP) was performed as 
described in “2.2.7.5. Chromatin Immunoprecipitation Assay (ChIP)”. See text for more 
details. Reprinted with permission from KK Baskin and H Taegtmeyer, AMP-activated 
protein kinase regulates E3 ligases in rodent heart, Circulation Research, 109, 10, 1153-
1161 [358].   
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using primers specific for the potential MEF2 binding region on the MuRF1 promoter. A 
distal sequence on the MuRF1 promoter was used as a negative control. Myocytes 
expressing aAMPK resulted in MEF2 binding to the endogenous MuRF1 promoter, while 
myocytes expressing dnAMPK or an empty virus did not (Figure 3.15.C.). Furthermore, 
MEF2 binding was specific for the identified site because MEF2 immunoprecipitation did not 
result in amplification of the distal region of the MuRF1 promoter (Figure 3.15.C.). 
Collectively, these experiments provide evidence that MEF2 binds the MuRF1 promoter 
and regulates the transcription of MuRF1 in an AMPK-dependent manner.  
3.4. MEF2 Transcriptional Activity and MuRF1Transcription Are Regulated by AMPK 
in the Heart  
To confirm the role of AMPK-mediated MEF2 transcription in the heart, we obtained 
MEF2-lacZ reporter mice from Dr. Eric Olson’s lab (UTSWMC, Dallas). These mice express 
β-galactosidase upon stimulation of MEF2 transcription (see section “2.1.1. Animals” for a 
detailed description of this mouse strain). MEF2-lacZ mice were treated with AICAIR daily 
for seven days to chronically activate AMPK in the heart. As a positive control, mice were 
treated with isoproterenol, which has previously been shown to regulate MEF2 
transcriptional activity [337]. Isoproterenol (ISO) and AICAR induced β-galactosidase 
expression, as evidenced by patches of blue staining within the treated hearts (Figure 
3.16.A.). Additionally, β-galactosidase activity, quantified using an enzyme activity assay, 
was also enhanced by AICAR, to the same extent as with ISO treatment (Figure 3.16.B.). 
Furthermore, AICAR treatment also increased MuRF1 expression in hearts from MEF2-lacZ 
mice (Figure 3.16.C.). These experiments provide evidence in support of the hypothesis 
that MEF2-mediated MuRF1 transcription is regulated by AMPK in the heart.  
 Studies in skeletal muscle have shown that AMPK phosphorylates histone 
deacetylase 5 (HDAC5), a repressor of MEF2-mediated transcription [294]. To determine 
whether AMPK mediates MEF2 transcriptional activity by inhibition of HDAC5 in 
cardiomyocytes, I first analyzed the phosphorylation status of HDAC5 in response to AMPK 
activation. As suggested in skeletal muscle, AICAR treatment increased, and Compound C 
decreased, HDAC5 phosphorylation in NRVM (Figure 3.17.A). Phosphorylation of HDAC5 
facilitates its export from the nucleus by 14-3-3 scaffolding proteins [369]. Despite 
enhanced HDAC5 phosphorylation, HDAC5 localization, determined by subcellular 
fractionation of NRVM, was not significantly affected by AMPK activation (Figure 3.17.B.). 
However, HDAC5 does not appear to inhibit MuRF1 transcription when AMPK is activated, 
as it was not detected on the MuRF1 promoter by chromatin immunoprecipitation (ChIP)  
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Figure 3.16. Regulation of MEF2 and MuRF1 by AMPK in the heart. 
(A) MEF2 activity (β-galactosidase expression) in response to AMPK activation. MEF2-lacZ 
transgenic mice were treated with AICAR (1 mg/g bw) or isoproterenol (15 mg/kg bw) once 
a day for seven days. Hearts were extracted and stained for β-galactosidase as described 
in “2.2.7.2. β-galactosidase Activity Assays and Staining”. (B)  β-galactosidase activity in 
response to AMPK activation. Heart lysate from treated mice was assayed for β-
galactosidase activity. (C) MuRF1 expression in response to AMPK activation in MEF2-lacZ 
mice. Data are expressed as mean fold change ± SEM, n=6-8 per group, qRT-PCR was 
quantified in triplicate for each heart. *P<0.01 versus saline controls. Reprinted with 
permission from KK Baskin and H Taegtmeyer, AMP-activated protein kinase regulates E3 
ligases in rodent heart, Circulation Research, 109, 10, 1153-1161 [358].   
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Figure 3.17. Regulation of HDAC5 by AMPK in the heart.  
(A) HDAC5 protein and phosphorylation levels in response to AMPK activation. NRVM were 
isolated and cultured as previously described. A representative western blot is shown. (B) 
Nuclear localization of HDAC5 in response to AMPK activation. NRVM were cultured as 
previously described. Myocytes were collected as described in 2.2.6.3. “Nuclear 
Fractionation of Cells”. A representative western blot is shown: C, cytosolic fraction; N, 
nuclear fraction. (C) HDAC5 binding to the MuRF1 promoter. ChIP was performed as 
described in Figure 3.15, except cross-linked DNA was immunoprecipitated using an 
HDAC5 antibody.   
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(Figure 3.17.C.). These data suggest that AMPK regulates MEF2 transcription of MuRF1, 
independent of HDAC5. 
To investigate the necessity of MuRF1 in AMPK-mediated protein degradation, adult 
cardiomyocytes isolated from WT or MuRF1-/- mouse hearts were used. Protein 
degradation in adult cardiomyocytes was determined in pulse-chase experiments as 
described above. WT and MuRF1-/- myocytes were responsive to bortezomib indicating that 
proteasome-mediated degradation was not altered in the absence of MuRF1 (Figure 3.18.). 
Nutrient deprivation increased protein degradation in WT cardiomyoytes by nearly 3 fold. 
Although nutrient deprivation also increased protein degradation in MuRF1-/- myocytes 
compared to control MuRF1-/- myocytes, the response was much less than what was 
observed in WT myocytes. These results indicate that MuRF1 is required for protein 
degradation in response to nutrient deprivation, at least in part. Furthermore, activation of 
AMPK (aAMPK) increased (by 2 fold), and inhibition of AMPK (dnAMPK) decreased (by 
half), protein degradation in WT cardiomyocytes. Interestingly, protein degradation in 
MuRF1-/- myocytes was not significantly altered with either activation or inhibition of AMPK 
(Figure 3.18.). Thus, this set of experiments defines the requirement for MuRF1 in AMPK-
mediated protein degradation in cardiomyocytes. 
3.5. MuRF1 is detrimental to the Heart during Fasting 
The results summarized above and illustrated in Figure 3.18. were initially very 
surprising because they suggest that during nutrient deprivation, MuRF1 is the major 
regulator of protein degradation in cardiomyocytes. Experiments performed up until this 
point provided evidence for the involvement of AMPK and MuRF1 in protein degradation in 
the heart, but the extent of this regulation was not clear. It was unexpected that MuRF1 
would be required for orchestrating protein degradation in response to AMPK activation. 
However, in support of these findings, in vivo experiments have demonstrated that MuRF1 
is necessary for the plasticity of the heart in the recovery from hypertrophic stress. MuRF1 
is required for improved cardiovascular function and normalization of cardiac size upon 
removal of aortic constriction [215]. We therefore wondered whether MuRF1 was required 
for cardiac remodeling under conditions other than changes in hemodynamic load, such as 
during fasting.      
 Fasting causes skeletal muscle atrophy in part through enhanced protein 
degradation through the UPS [370]. During fasting expression of Atrogin-1 and MuRF1 are 
significantly increased in skeletal muscle [141, 371]. To determine whether MuRF1 in the  
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Figure 3.18. Regulation of protein degradation in cardiomyocytes by AMPK requires 
MuRF1.  
Protein degradation in response to aAMPK and dnAMPK. Adult cardiomyocytes (AMCM) 
from WT and MuRF1-/- mice were isolated and cultured as described in “2.2.5. Isolation of 
Adult Mouse Cardiomyocytes”. Immediately after plating, AMCM were incubated in pulse 
medium containing radiolabeled Phe (1µCi/mL [14C]), as described in “2.2.11. Protein 
Turnover Assays”. AMCM were infected with aAMPK (MOI 10) and dnAMPK (MOI 10) 24 
hours prior to changing the medium from pulse to chase medium. At the onset of the 
“chase” AMCM were incubated in culture medium (control, aAMPK, dnAMPK), PBS 
(nutrient deprived), or culture medium with Bortezomib (1 µmol/L). Data are expressed as 
mean fold change in protein degradation ± SEM of 3 independent experiments performed 
in triplicate. *P<0.01 versus respective controls. † P<0.01 versus WT nutrient deprivation, 
# P<0.01 versus WT aAMPK. Reprinted with permission from KK Baskin and H 
Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation 
Research, 109, 10, 1153-1161 [358].   
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Figure 3.19. Regulation of MuRF1 and cardiac mass during fasting. 
(A) MuRF1 expression in the heart in response to fasting. (B) Body weight (g) in response 
to fasting. (C) Heart weight (wet weight, g) in response to fasting. (D) Cardiac function in 
response to fasting. Echocardiography was performed on fed and fasted mice as described 
in “2.2.3.1. Echocardiography”. M-mode parasternal short-axis images were used to 
calculate cardiac functional parameters, such as ejection fraction. See text for details. Data 
are expressed as mean or mean percent ± SEM, n=6-8 per group. qRT-PCR was 
quantified in triplicate for each heart. *P<0.01 versus saline controls, # P<0.01 versus 
MuRF1-/- fed, † P<0.01 versus WT fasted. Adapted with permission from KK Baskin and H 
Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation 
Research, 109, 10, 1153-1161 [358].   
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heart, like in skeletal muscle, is regulated by fasting, MuRF1 expression was quantified 
after chronic food deprivation. MuRF1 expression was significantly increased in the heart in 
response to fasting (Figure 3.19.A.). Fasting caused significant loss of body weight in WT 
and MuRF1-/- mice alike (Figure 3.19.B.). These results are in accordance with a report on 
the role of MuRF1 in skeletal muscle during amino acid (AA) deprivation [208]. This study 
found that WT and MuRF1-/- mice lost weight with AA deprivation, and also had decreased 
muscle size. These data suggest that MuRF1 is not required for fasting-induced muscle or 
cardiac atrophy.   
 To date, numerous studies have demonstrated that the mechanisms regulating 
protein degradation in muscle and in heart are very similar. Therefore we expected that the 
heart would respond analogous to the muscle during fasting. Despite a similar decrease in 
body weight between WT and MuRF1-/- mice, further investigation of the heart in MuRF1-/- 
mice revealed an unanticipated result. Unexpectedly, the absence of MuRF1 preserved 
heart weight during fasting (Figure 3.19.C.). Moreover, ejection fraction, although 
depressed with fasting, was preserved in MuRF1-/- mice (Figure 3.19.D.). Although other 
functional parameters were not significantly altered, fractional shortening was also 
preserved with fasting in MuRF1-/- mice (Table 3.1.).  
 MuRF1 ubiquitinates and leads to the degradation of sarcomeric proteins. It is 
possible that under fasting conditions, enhanced MuRF1-mediated protein degradation 
leads to loss of sarcomeric proteins in the heart, which contributes to the decline in cardiac 
function. To determine the effect of fasting on the molecular level, several protein targets of 
MuRF1 were investigated. As previously reported, and as shown above in cardiomyocytes, 
fasting (nutrient deprivation) leads to the activation of AMPK. Consequently, ACC is 
phosphorylated. AMPK was activated (pAMPK and pACC) to the same extent in hearts 
from WT and MuRF1-/- mice in response to fasting. Cardiac myosin-binding protein C 
(MyBP-C) protein levels were decreased in hearts of WT mice suggesting that an increase 
in MuRF1 leads to enhanced degradation of MyBP-C. However, MyBP-C levels were also 
decreased in the heart after fasting in the absence of MuRF1 (Figure 3.20.). This could be 
due to the fact that Atrogin-1 also targets MyBP-C for degradation, albeit through a different 
molecular mechanism [218].  
Another sarcomeric protein that is degraded by MuRF1 is cardiac troponin I (TnI). 
The degradation of TnI by MuRF1 has been shown to decrease contractility in isolated 
cardiomyocytes [166] and hence may lead to the cardiac dysfunction seen with fasting.  
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LV functional parameters in Fed and Fasted Wild Type and MuRF1
 -/-
 mice 
 Wild Type Fed 
Wild Type Nutrient 
Deprived MuRF1
-/-
 Fed 
MuRF1
-/-
 Nutrient 
Deprived 
IVSd, mm 0.681 ± 0.078 0.608 ± 0.050 0.596 ± 0.087 0.760 ± 0.105 
LVPW, mm 0.837 ± 0.092 0.752 ± 0.069 0.874 ± 0.122 0.956 ± 0.150 
LVIDd, mm 3.518 ± 0.203 3.677 ± 0.322 3.314 ± 0.276 3.650 ± 0.278 
LVIDs, mm 2.544 ± 0.293 2.862 ± .0404 2.498 ± 0.214 2.778 ± 0.374 
FS, % 34.28 ± 2.68 20.93 ± 2.47* 28.59 ± 2.51 25.72 ± 3.21 
 
 
Table 3.1. Left ventricular functional parameters in fed and fasted mice. 
Echocardiography was performed on mice as described in “2.2.3.1. Echocardiography”. M-
mode parasternal short-axis images were used to calculate cardiac functional parameters. 
Data are expressed as mean or mean percent ± SEM, n=6-8 per group. *P<0.01 versus WT 
fed. IVSd, interventricular septum in diastole; LVPW, left ventricular posterior wall; LVIDd, 
left ventricular inner diameter in diastole; LVIDs, left ventricular inner diameter in systole; 
FS, fractional shortening. Reprinted with permission from KK Baskin and H Taegtmeyer, 
AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation Research, 
109, 10, 1153-1161 [358].   
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Figure 3.20. Regulation of AMPK, MyBPC, and TnI during fasting. 
(A) AMPK activation and MuRF1-target protein levels in response to fasting. Mice were 
subjected to fasting for 3 days. Hearts were extracted as previously described. A 
representative western blot is shown. (B). Densitometric quantification of western blots. 
Data are expressed as mean ± SEM, n=6-8 per group. *P<0.01 versus fed WT controls, # 
P<0.01 versus fed MuRF1-/-. Reprinted with permission from KK Baskin and H Taegtmeyer, 
AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation Research, 
109, 10, 1153-1161 [358].   
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Indeed, TnI levels were decreased with fasting in hearts from WT mice. Interestingly, TnI 
levels were not altered by fasting in MuRF1-/- mice (Figure 3.20.). These data suggest that 
the absence of MuRF1 is protective during fasting in part by preservation of sarcomeric 
proteins. 
Many other sarcomeric proteins may be targeted for degradation by MuRF1, 
including telethonin (Tcap), myotilin, nebulin, nebulin-related protein, troponin T1 and T3, 
and myosin light chain 2 (MLC-2) [206]. The levels of these proteins were not investigated 
as many of these targets originally identified in yeast-two hybrid screens have not been 
validated in vitro or in vivo.        
MuRF1 may also play a role in metabolic adaptation and metabolic remodeling of 
the heart during fasting, in addition to its involvement in sarcomeric protein degradation. A 
recent study demonstrated that fasting decreases cardiac function [372] and in support of 
our findings, mice deficient for MuRF1 were spared from muscle and cardiac atrophy during 
fasting [208]. However, mechanistic experiments were not performed in either study. 
MuRF1 has been shown to target enzymes involved in ATP production for degradation, 
such as pyruvate dehydrogenase (PDH), which is downregulated in MuRF1 Tg mice [209]. 
PDH converts pyruvate to acetyl-CoA for entry into the Krebs cycle to produce reducing 
equivalents and, ultimately ATP. Consequently, decreased PDH potentially decreases ATP 
production in the cell, which could contribute to cardiac dysfunction, as we observe with 
long term fasting. Furthermore, activation of AMPK in response to decreased ATP levels, 
could feed forward to induce higher expression of MuRF1, leading to persistently lower 
intracellular ATP concentrations. Although we have not directly investigated the role of PDH 
in our model, the protective effects of fasting-induced metabolic derangements in the 
absence of MuRF1 in the heart, due to preservation of PDH-regulated ATP production, is 
an attractive hypothesis. 
Other metabolic changes occur in the heart during fasting such as enhanced 
glycogen storage and elevated citrate levels [373]. Citrate inhibits phosphofructokinase, a 
regulatory enzyme in the glycolytic pathway which phosphorylates fructose-6-phosphate to 
fructose-1,6-bisphosphate. During atrophy, MuRF1 is upregulated and phosphofructokinase 
is downregulated [99]. Since MuRF1 and phosphofructokinase localize to the M-line of 
sarcomeres [135, 374], it is tempting to speculate that MuRF1 ubiquitinates 
phosphofructokinase thereby leading to its degradation. As suggested above, upregulation 
of MuRF1 during starvation could lead to the downregulation of metabolic enzymes, 
decreased ATP production from glycolysis and/or inhibition of the conversion of pyruvate to 
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acetyl-CoA, and ultimately decreased cardiac function. In support of this hypothesis, we 
have preliminary data (not shown) suggesting that glucose oxidation rates in hearts from 
MuRF1-/- mice are at least three-fold higher than in the hearts from WT mice.     
In summary, I have shown that nutrient deprivation and pharmacologic and genetic 
activation of AMPK increases Atrogin-1 and MuRF1 expression in cardiomyocytes and in 
the heart. Activation of AMPK leads to increase proteasome-mediated protein degradation. 
AMPK transcriptionally regulates MuRF1 through the transcription factor MEF2, although 
the exact mechanism by which this occurs in the heart is still not known. AMPK-mediated 
protein degradation requires MuRF1 in the heart, suggesting a more general role for 
MuRF1 in protein degradation, potentially in autophagy-mediated degradation. AMPK-
mediated MuRF1 expression in the heart in response to fasting is detrimental to cardiac 
function. Not only does MuRF1 degrade sarcomeric proteins required for contractility, but 
MuRF1 also potentially negatively regulates cardiac metabolism, which has yet to be 
investigated. These findings are summarized in our working model described in Figure 
13.21.  
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Figure 3.21. Consequence of metabolic stress on protein degradation in the heart. 
Metabolic stresses such as nutrient deprivation or fasting lead to a decrease in the ratio of 
[ATP]/[AMP], thus activating AMPK. AMPK regulates the expression of a key ubiquitin 
ligase, MuRF1, through the transcription factor MEF2. Consequently, protein degradation in 
the heart is increased. This leads to cardiomyocyte remodeling, both structurally and 
metabolically. Continual metabolic derangements, such as what occurs during chronic 
fasting, leads to maladaptive cardiac remodeling, ultimately contributing to cardiac 
dysfunction. See text for details. Reprinted with permission from KK Baskin and H 
Taegtmeyer, AMP-activated protein kinase regulates E3 ligases in rodent heart, Circulation 
Research, 109, 10, 1153-1161 [358].   
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Chapter 4 
 
 
A ROLE FOR 5’-AMP-ACTIVATED PROTEIN KINASE IN 
CARDIAC HYPERTROPHY 
 
 
 
 
 
 
 
 
“Science, in the very act of solving problems, creates more of them [375].” 
  ~Abraham Flexner, Educational reformer and author   
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4.1. An Overview of AMPK in Cardiac Hypertrophy  
AMP-activated protein kinase (AMPK), as discussed in Chapter 1, is a key 
metabolic enzyme involved in many aspects of cellular signaling. In the preceding chapter I 
have shown that AMPK regulates ubiquitin ligases and proteasome-mediated protein 
degradation in the nutrient deprived heart [358]. The role of AMPK in cardiac hypertrophy, 
however, is presently not completely understood. Initial studies demonstrated that AMPKα1 
expression and activity is increased in the rat heart after 17-19 weeks of ascending aortic 
constriction in rats [268]. AMPK is also increased in the rat heart 8 weeks after abdominal 
aortic constriction to induce pressure overload [269]. These results suggest that AMPK may 
be activated during hypertrophy but the details are not known.  
The heart adapts to hemodynamic stress by remodeling structurally and 
metabolically (Figure 1.1.). Consequently, intracellular reorganization occurs in 
cardiomyocytes during the development of hypertrophy. Hypertrophy is initially an 
adaptation to stress. However, chronic hemodynamic stress leads to maladaptation of the 
heart, and eventually heart failure. In the studies mentioned above, cardiac function was not 
assessed during, or at the termination, of the experiments. Therefore, whether activation of 
AMPK was a cause or consequence of hypertrophy and/or heart failure is not known.  
AMPK has been shown to inhibit protein synthesis in muscle, in part by decreasing 
mTOR signaling [376]. AMPK also inhibits phenylephrine- and AKT-mediated hypertrophy 
by inhibiting protein synthesis in cardiomyocytes [270]. Therefore, according to Chan and 
Dyck, AMPK could be a target to reduce hypertrophy through inhibition of protein synthesis 
[377]. In support of this hypothesis my findings also suggest that AMPK can increase 
proteasome-mediated protein degradation [358], in addition to autophagy [277].  
While long term pressure overload leads to AMPK activation, short term pressure 
overload does not. In fact, AMPK activation is decreased within 30 minutes of aortic 
constriction in mice [378]. Cardiomyocytes treated with the hypertrophic stimulus 
Angiotensin II also exhibit decreased AMPK phosphorylation levels, and protein synthesis is 
decreased under these conditions. Treatment with AICAR, however, abrogates these 
effects [378]. Taken together, these studies suggest that activation of AMPK does not 
cause hypertrophy, but rather AMPK is activated during the maladaptation of the heart to 
chronic pressure overload. My results demonstrating that activation of AMPK also increases 
protein degradation in NRVM through regulation of ubiquitin ligases (see Chapter 3) 
suggest that AMPK could be a target to slow the progression of hypertrophy, by inhibiting 
protein synthesis and activating protein degradation. 
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4.2. Regulation of Cardiac Function by AICAR 
To test the hypothesis that activation of AMPK reduces cardiac hypertrophy, we 
investigated the role of ACIAR-mediated AMPK activation in a model of pressure overload. 
Mice (male, age 8 weeks), were subjected to 4 weeks of transverse aortic constriction 
(TAC) as described in Chapter 2 (section 2.2.2. “Transverse Aortic Constriction in Mice”); 
sham surgeries were performed on the control group. A subset of animals were treated with 
AICAR (0.5mg/ g bw) daily for several days prior to, and daily for four weeks after, surgery. 
Cardiac function was monitored throughout the experiment by magnetic resonance (MR) 
scanning at 7, 14, 21, and 28 days after TAC, as described in Chapter 2 (see section 
2.2.3.2. “Magnetic Resonance Imaging”). Cardiac parameters were calculated as described 
in 2.2.3. “Assessment of Cardiac Function”. This study was performed at MD Anderson 
Cancer Center in collaboration with the laboratory of Dr. Aarif Khakoo. Dr. Khakoo provided 
the surgery and MRI facilities, and Dr. Vishnu Chintalgattu performed TAC surgeries, 
Doppler measurements for the verification of TAC, trained me to use the MRI machine, and 
assisted in data analysis. Both are currently at Amgen in San Francisco, CA.  
 MRI images taken throughout the study were used to determine left ventricular end-
diastolic (LVED) volume, left ventricular end-systolic (LVES) volume, and stroke volume. 
Interventricular septal and posterior wall thickness and ventricular area were also 
determined. Cardiac output and ejection fraction were then calculated as described in 
Chapter 2. As expected, left ventricular end diastolic (LVED) volume did not change in the 
saline-treated sham controls throughout the 4 weeks. Chronic AMPK activation with AICAR 
treatment also had no significant effect on LVED volume (Figure 4.1A.). However, as 
previously reported, LVED volume increased over time in response to pressure overload 
(by TAC). Surprisingly, LVED volume in TAC animals increased with ACIAR treatment 
(Figure 4.1A.). Neither saline nor AICAR affected left ventricular end systolic (LVES) 
volume (Figure 4.1A.). But, like LVED, LVES volume was increased in response to TAC 
and further increased with AICAR treatment (Figure 4.1B.). Consequently, stroke volume 
was unchanged in saline and AICAR treated sham animals while stroke volume decreased 
over time with TAC and even more so with AICAR (Figure 4.1.C.).  
 Cardiac output, a measure of cardiac function, was determined throughout the 
experiment at the same time points. There was no change in cardiac output in either the 
sham saline treated or sham AICAR treated mice. However, with TAC cardiac output 
declined significantly 7 days after surgery and slowly continued to decline (Figure 4.2.A.). 
AICAR treatment further decreased cardiac output with TAC at seven days after surgery, 
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Figure 4.1. Synergistic effects of TAC and AICAR on cardiac parameters. 
(A) Left ventricular end diastolic volume (LVED), (B) Left ventricular end systolic volume 
(LVES), and (C) Stroke volume in response to AICAR treatment and/or transverse aortic 
constriction (TAC) at 7, 14, 21, and 28 days after surgery. Male mice (C57/BL6, 8 weeks 
old, n=6-8 per group) were subjected to TAC as described in 2.2.2. “Transverse Aortic 
Constriction in Mice”. AICAR treatment (0.5mg/g bw/ day) was given intraperitoneally daily 
for 4 weeks, beginning several days before surgery. The day after surgery, Doppler 
measurements were taken as described in 2.2.2. “Transverse Aortic Constriction in Mice” to 
verify successful placement of the sutures. MRI scans were performed, measurements 
were taken, and calculations made as described in 2.2.3.2. “Magnetic Resonance Imaging”. 
*P<0.01 versus same group at 7 days, † P<0.01 versus sham with same treatment at 
matched time point, # P<1.01 versus TAC Saline at matched time point. 
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and throughout the duration of the experiment (Figure 4.2.A.). Like cardiac output, ejection 
fraction was not affected by AICAR treatment (Figure 4.2.B.).  TAC decreased ejection 
fraction seven days after surgery and continued to decrease ejection fraction for 28 days. 
AICAR further decreased ejection fraction with TAC (Figure 4.2.B.). These data 
demonstrate that chronic AMPK activation does not affect basal cardiac function. However, 
contrary to what we expected, AMPK activation worsened cardiac function with pressure 
overload.               
The dimensions of the heart, interventricular septal and posterior wall thickness, can 
be used to determine the degree of cardiac hypertrophy that develops with pressure 
overload. It is well established that posterior wall thickness increases with TAC, and then 
declines with continuous pressure, an indication of cardiac dilation and heart failure. In our 
study, AICAR treatment did not affect septal (Figure 4.3.A.) or posterior wall thickness in 
the sham-operated animals (Figure 4.3.B.). TAC increased both septal and posterior wall 
thickness throughout the 4 week experiment. Initially, AICAR further increased septal and 
posterior wall thickness after TAC. However, after 3 and 4 weeks, posterior wall 
thicknesses declined. These data suggests that AICAR accelerates dilation and possibly 
heart failure symptoms during pressure overload-induced hypertrophy (Figure 4.3.A and 
B.).  
The functional data described above are easily visualized in MRI images shown in 
Figure 4.4. Enlargement of the left ventricle is seen with TAC. Although AICAR appears to 
increase cardiac dimensions, the averaged parameters were not significant throughout the 
study. However, hearts from AICAR treated TAC animals are larger than saline treated TAC 
animals, and is due to enlargement of both ventricles. Consistent with these findings, heart 
weight (normalized with either body weight or tibia length) was increased with TAC, but not 
with AICAR treatment. AICAR treated TAC animals had an even greater increase in heart 
weight compared to saline treated TAC animals (Figure 4.5.A and B.). Because AICAR 
treated TAC animals showed signs of left ventricular dilation and decreased wall thickness, 
lung weight was determined at the end of the experiment. Indeed, lung weight was 
significantly increased in AICAR treated TAC animals compared to saline treated TAC 
animals (Figure 4.5.C.). These characteristics are indicative of pulmonary edema and heart 
failure.    
Because AICAR treated TAC animals had depressed cardiac function, as compared 
to saline treated TAC animals, we wondered whether they had increased fibrosis. However, 
no sign of enhanced fibrosis was seen in cross sections of these hearts (Figure 4.6.A.). 
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Figure 4.2. Synergistic effects of TAC and AICAR on 
cardiac function. 
(A) Cardiac output and (B) Ejection fraction in response to 
AICAR and/ or TAC. Calculations were made based on 
measurements take from MRI images at the designated time. 
*P<0.01 versus same group at 7 days, † P<0.01 versus sham 
with same treatment at matched time point, # P<1.01 versus 
TAC Saline at matched time point. 
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Figure 4.3. Synergistic effects of TAC and AICAR on 
cardiac dimensions. 
(A) Septal and (B) Posterior wall thickness in response to 
AICAR and/ or TAC. Calculations were made based on 
measurements take from MRI images at the designated time. 
*P<0.01 versus same group at 7 days, † P<0.01 versus 
sham with same treatment at matched time point, # P<1.01 
versus TAC Saline at matched time point. 
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Figure 4.4. MRI images depicting synergistic effects of TAC and 
AICAR on the heart. 
Representative MRI image of the heart in diastole in response to 
AICAR and/ or TAC. LV, left ventricle; RV, right ventricle.  
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Figure 4.5. Synergistic effects of TAC and AICAR on heart and lung weight. 
(A) Heart weight to body weight ratios, (B) heart weight to tibia length, and (C) lung weight 
in response to AICAR and/ or TAC. Twenty-four hours after the last MRI scans, hearts, 
tibia, and lungs were collected as described in 2.2.6. “Cell and Tissue Collection and 
Preservation”. * P<0.01 versus respective Sham group, † P<0.01versus Sham saline. 
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Differences in cardiomyocyte diameter were observed and quantified in Figure 4.6.B. 
Myocyte diameter was significantly increased with TAC, and further increased with AICAR. 
Although, not significant, AICAR treatment alone showed a tendency to decrease myocyte 
diameter, consistent with studies performed in isolated cardiomyocytes.  
Angiogenesis occurs in the heart during hypertrophy and can be determined by the 
ratio of coronary microvessels per myocyte [319]. In muscle, AMPK regulates vascular 
endothelial growth factor (VEGF) thereby enhancing angiogenic repair during ischemia 
[379]. It is unclear whether AMPK plays a role in angiogenesis in the heart during 
hypertrophy. Therefore we evaluated the microvasculature by staining for CD31, a marker 
for endothelial cells within blood vessels. The number of capillaries per myocyte was 
increased with AICAR treatment and with TAC, and there was a slight, but insignificant, 
additive effect of AICAR treatment on TAC animals (Figure 4.7.). The collective results 
were somewhat puzzling to us at first. What could be causing the “protective” effect of 
AICAR to be detrimental to the heart in the setting of cardiac hypertrophy (in vivo)?       
4.3. Molecular Consequences of Chronic AMPK activation in the Heart 
 We were initially surprised by the additive effects AICAR had with aortic constriction 
on cardiac phenotype and function. We had reasoned that activation of AMPK in 
hypertrophy would be cardioprotective during hemodynamic stress due to AMPK’s role in 
regulating protein synthesis and degradation, in addition to its role in energy substrate 
provision. To gain an understanding of what could be responsible for the exaggerated 
changes seen in AICAR-treated TAC animals we first investigated established hypertrophic 
markers and pathways in the heart.   
The fetal gene program is considered a “classic” marker of trophic response in the 
heart with alteration in load [380-385]. Therefore we determined whether these genes were 
altered by AICAR treatment. Because ejection fraction and cardiac output were further 
decreased with AICAR in animals with TAC, we wondered whether expression of contractile 
proteins was altered with AMPK activation. The heart switches expression of contractile 
genes during hypertrophy: αMHC decreases and βMHC increases in the mouse. We found 
this to be the case with TAC, regardless of treatment. While AICAR treatment increased 
αMHC, its expression was decreased to the same degree with hypertrophy as was the 
saline treated group (Figure 4.8.A.). βMHC expression was increased with TAC but further 
increased with AICAR treatment suggesting a greater shift to slow twitch myosin expression 
(in the rodent) which may contribute to decreased cardiac function (Figure 4.8.B.). 
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Figure 4.6. Synergistic effects of TAC and AICAR on cardiac phenotype. 
(A) Representative images from cross sections of mouse hearts in response to AICAR and/ 
or TAC. Hearts were collected, prepared, and stained using hematoxylin and eosin (H&E) 
stain as described in section 2.2.6.4. “Histology and Immunohistochemistry. Scale bars = 
25µm. (B) Cardiomyocyte diameters were measured as described in section 2.2.6.4. 
“Histology and Immunohistochemistry. * P<0.01 versus respective Sham group, † 
P<0.01versus Sham saline.  
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Figure 4.7. Regulation of microvasculature in response to hypertrophy.  
(A) Representative images from cross sections of mouse hearts in response to AICAR and/ 
or TAC. Hearts were collected, prepared, and stained with an antibody to CD31 as 
described in section 2.2.6.4. “Histology and Immunohistochemistry. Scale bars = 25µm. (B) 
The number of capillaries and cardiomyocytes were counted per field and plotted as a ratio. 
* P<0.01 versus respective Sham group, † P<0.01versus Sham saline. 
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Atrial natriuretic factor (ANF), an early response gene was also further increased with 
AICAR in animals with TAC (Figure 4.8.C.).  
In addition to structural changes, the heart metabolically adapts to pressure 
overload by switching its substrate utilization from reliance on fatty acids to reliance on 
glucose for ATP production. This is another hallmark of the fetal cardiac phenotype. 
Glucose uptake is regulated by GLUT1 and GLUT4, the main glucose transporters in the 
heart. GLUT1 is expressed in the adult heart and is not affected by hypertrophy. While 
translocation of glucose transporters to the membrane is regulated by AMPK, GLUT1 
expression has recently been shown to be regulated by AMPK as well [386]. GLUT1 
expression was increased with AICAR treatment, which was preserved with TAC, as shown 
in Figure 4.8.C. During hypertrophy GLUT4 expression is decreased; however, GLUT4 is 
also regulated by AMPK. AICAR treatment increased GLUT4 expression, as shown in 
Chapter 3. Furthermore, AICAR increased GLUT4 expression even in the hearts of TAC 
animals (Figure 4.8.D.). These data demonstrate that AICAR has a synergistic effect on 
fetal gene expression with TAC. 
AMPK is known to regulate transcription of several groups of genes, one of which is 
involved in protein degradation. Indeed, AMPK activation in sham animals increased 
Atrogin-1 and MuRF1 expression, as previously discussed in Chapter 3. The expression of 
both ubiquitin ligases has also been shown to be increased in hypertrophy [199]. As with 
the expression of genes investigated thus far, both Atrogin-1 and MuRF1 expression were 
further increased with TAC upon stimulation with AICAR (Figure 4.9.A. and B.). Although 
pulse-chase analysis in vivo was not performed, I measured proteasome activity as a 
determinant of proteasome-mediated protein degradation. In the previous chapter I 
demonstrated that protein degradation in cardiomyocytes was increased with AICAR and 
decreased with Bortezomib, a proteasome inhibitor (Figure 3.11.). Consistent with these 
results, proteasome activity was significantly increased hearts with chronic AICAR 
treatment (Figure 4.8.C.). It has already been reported that proteasome activity is 
increased in the hypertrophied heart [125], which I also observed; however, AICAR 
treatment did not enhance proteasome activity in hearts from TAC animals (Figure 4.8.C.).     
AMPK also regulates the expression of genes involved in autophagy. We found this 
to be the case in our experiments as well. AICAR increased the expression of Beclin, Atg5, 
and LC3 (Figure 4.10.A-C). Beclin, Atg 5, and Atg 12 expression was increased after TAC 
and further increased with AICAR treatment (Figure 4.10.A, B, and D). These results imply 
that AMPK activation regulates protein degradation in the heart, even during hypertrophy.  
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Figure 4.8. Reactivation of the fetal gene program during hypertrophy. 
(A) α-Myosin Heavy Chain (αMHC), (B) β- Myosin Heavy Chain (βMHC), (C) Atrial 
nateuretic factor (ANF), (D) Glucose transporter 1 (GLUT1), and (E) GLUT4 gene 
expression in response to AICAR and/or TAC.  * P<0.01 versus respective Sham group, † 
P<0.01versus Sham saline. 
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Figure 4.9. Regulation of the ubiquitin proteasome system in response to 
hypertrophy. 
(A) Atrogin-1 and (B) MuRF1 gene expression in response to AICAR and/or TAC. (B) 
Proteasome activity (20S) in response to AICAR and/or TAC. The proteasome activity 
assay was performed as described in 2.2.7.4. “Proteasome Activity Assay”. * P<0.01 versus 
respective Sham group, † P<0.01 versus respective treatment group. 
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Figure 4.10. Regulation of autophagy genes in response to hypertrophy. 
(A) Beclin, (B) Autophagy gene 5 (Atg5), (C) Light Chain 3 (LC3), (D) Autophagy gene 12 
(Atg12) gene expression in response to AICAR and/or TAC. * P<0.01 versus respective 
Sham groups, † P<0.01 versus respective treatment group. 
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Although we initially thought that enhanced protein degradation would be a protective 
mechanism in hypertrophy, our data suggest otherwise.  
To investigate further the mechanism by which AICAR mediates cardiac dysfunction we 
examined signaling pathways known to regulate hypertrophy. mTOR is phosphorylated in 
response to TAC, thus activating protein synthesis. AMPK is a known inhibitor of the mTOR 
signaling pathway. Activation of AMPK abolishes signaling through mTOR during 
hypertrophy (Figure 4.11.). The AKT signaling pathway is also a prominent hypertrophic 
pathway. Although AKT and AMPK seem to regulate each other, their interaction is still 
unclear Our data presented here is not clean-cut either. AMPK, in the sham operated 
group, appears to slightly activate AKT; however, AMPK activation with TAC may decrease 
AKT phosphorylation. In any case, AKT is activated during hypertrophy (Figure 4.11.). 
AMPK, as previously shown, is increased in response to TAC and AICAR; however, there is 
not an additive effect of AICAR and TAC on AMPK. Acetyl-CoA carboxylase (ACC) is also 
phosphorylated in response to AMPK activation, whether the stimulus was AICAR or TAC 
(Figure 4.11.).   
 Collectively, our data show that chronic AICAR treatment, and thus activation of 
AMPK is detrimental to the heart on several different levels. First, cardiac function is 
impaired following TAC with AICAR treatment. Although AICAR alone doesn’t impair 
cardiac function, it causes a significant increase in lung weight, suggesting that AICAR may 
have systemic side effects, possibly unrelated to AMPK activation. It is also interesting to 
note that despite the role that AMPK plays in regulating protein degradation through 
autophagy and proteasome-mediated protein degradation, TAC animals responded to 
AICAR through an enhanced hypertrophic response. Cardiomyocyte size and the fetal gene 
program were increased in response to TAC but more so with AICAR treatment in addition 
to TAC.     
 Although analysis of these experiments is ongoing, and I now focus on the 
metabolic aspects of the AICAR with TAC, I was not able to determine metabolic 
derangements in the hearts of these animals, as these studies require metabolic flux 
measurements. It would be ideal to repeat this study, but before terminating the experiment, 
measure substrate oxidation by perfusing the heart in working mode. The hypertrophied 
heart uses preferentially glucose as substrate whereas activation of AMPK not only 
increases glucose uptake, but also increases fatty acid oxidation. It would be interesting to 
investigate the combined cardiometabolic effects in the heart in response to TAC and  
  
134 
 
             
 
 
 
 
 
 
 
 
                   
 
Figure 4.11. Regulation of signaling pathways during 
hypertrophy in response to AICAR. 
Representative western blot of heart tissue in response to AICAR 
and/or TAC. 
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AICAR, as GLUT4 expression in AICAR treated TAC animals is significantly increased 
(Figure 4.8.B.).  
This study is also limited by the fact that the experiment only allowed for terminal 
molecular changes to be investigated. Cardiac functional parameters taken throughout the 
course of the experiment allowed us to determine that AICAR may actually contribute to 
heart failure, although whether this is mediated directly through AMPK, and not a 
pharmacological side effect of AICAR treatment remains to be determined. 
At the onset of our study, a similar report was published with results in striking 
contrast to what we observed [271]. In a rat model, 7 weeks of AICAR treatment (the same 
dose that we used) attenuated hypertrophy, as determined by echocardiographic analysis 
(fractional shortening and left ventricular end diastolic dimensions) and heart weight to body  
weight ratios. Serial echos were not taken and therefore cardiac function throughout AICAR 
treatment in this study is not known. A possible explanation in the drastically differing 
outcomes in mice compared to rats is a difference in the hypertrophy model. In the rat 
model, hypertrophy might develop slower than in mice, and after 7 weeks of TAC, vehicle 
treated rats are just beginning to show signs of severe hypertrophy. It is also interesting that 
after 7 weeks of TAC they found AICAR was able to normalize expression of the fetal 
genes ANP and BNP, and as we have shown here, decrease mTOR phosphorylation.       
Along the same lines, a recent study provided evidence that ablation of α2AMPK in 
the mouse heart deems them more susceptible to pressure-overload-induced hypertrophy 
[387]. Ejection fraction was significantly decreased in the knockout mice subjected to TAC. 
Moreover, these mice had increased myocardial fibrosis and cardiomyocyte size. Another 
study using the same mouse model induced short term hypertrophy by 7 days of 
isoproterenol (ISO) injections [306]. Consequently, AMPKα2-/- mice were more sensitive to 
ISO treatment and hypertrophied to a greater extent than WT mice. In this same study, the 
absence of α2AMPK in the heart stimulated basal activity of p70S6 kinase, thus further 
highlighting the importance of AMPK in regulating protein synthesis.        
It is also important to consider another activator of AMPK, the antidiabetic drug 
metformin. Metformin has been shown to activate AMPK indirectly by several mechanisms, 
although recently was shown to mediated energy charge in the liver independent of AMPK 
[388]. Ischemia-induced heart failure in mice can be minimized with metformin treatment, 
which does not occur in AMPK dominant negative Tg mice [389]. This study suggests that 
AMPKα2 is critical for metformin-mediated cardioprotection in heart failure. In support of 
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this hypothesis, diabetic patients with heart failure treated with metformin have a better rate 
of survival and fewer hospital admissions [390-393].   
In conclusion, my results imply that the metabolic effects of long-term AMPK 
activation override AMPK’s role in other cellular processes such as the regulation of protein 
turnover. Activation of AMPK increases insulin and non-insulin mediated glucose uptake 
suggesting that during hypertrophy, AICAR treated mice may suffer from excessive fuel 
overload, in addition to structural changes triggered by pressure overload. In a broad 
sense, these results give rise to the hypothesis that metabolic dysregulation may play a role 
in this process, although this is the topic of current investigation. 
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Chapter 5 
 
 
CONCLUDING REMARKS AND OUTLOOK 
 
 
 
 
 
 
“The game of science is, in principle, without end. He who decides one day that scientific 
statements do not call for any further test, and that they can be regarded as finally verified, 
retires from the game [394].” 
~Sir Karl Popper, CH FRS FBA (1935) 
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  The heart is a dynamic organ that adapts metabolically and structurally to various 
types of stress. This remodeling process is critical for survival because cardiomyocytes are 
terminally differentiated cells. Although there is evidence for the existence of sub-
populations of cardiac progenitor cells [395], they have been suggested to generate and 
replace cardiomyocytes at a very low rate compared to other cell types [396]. Thus, 
intracellular homeostasis in the broad sense is vital for cardiomyocyte preservation and, 
ultimately, cardiac function.   
In the preceding chapters I have provided evidence in support of the hypothesis that 
AMPK regulates proteasome-mediated protein degradation in the heart by regulating 
ubiquitin ligases. I have demonstrated that this occurs during nutrient deprivation (fasting) 
and also in the hypertrophied heart. Interestingly, and contrary to what I expected, fasting-
induced AMPK activation and the activation of AMPK with AICAR during hypertrophy are 
detrimental to the heart.   
The multifaceted role that AMPK plays in the cardiomyocyte makes it both an 
intriguing and challenging kinase to investigate. AMPK has been shown to be a 
transcriptional regulator and a regulator of protein synthesis, as well as protein degradation, 
as presented in my thesis. The metabolic function of AMPK in regulating substrate uptake 
and oxidation, particularly under stress, is undoubtedly the most important process that 
AMPK controls in the heart. This is evident by the results shown in Chapter 4. The 
activation of AMPK increases protein degradation during hypertrophy, while at the same 
time further enhancing glucose uptake (increased GLUT4 expression). Although currently 
under investigation, it is possible that, with chronic AMPK stimulation, and the added stress 
of pressure overload, glucose uptake is increased to the point of glucotoxicity, which 
contributes to cardiac dysfunction. 
We have proposed that metabolic remodeling precedes, triggers, and sustains 
structural and functional remodeling of the heart [8, 272, 397] and metabolites themselves 
might be regulating cardiac remodeling directly. One possible mechanism is protein 
modification by direct metabolite interaction, such as AMP binding to AMPK, leading to 
AMPK activation. Another example is fatty acid regulated protein function, such as the 
transcriptional activation of peroxisome proliferator-activated receptor α, PPARα [398]. Yet 
another example of metabolite-mediated protein modification is O-linked glycosylation. This 
has been shown to occur during excessive glucose uptake in the heart, resulting in 
enhanced transcription through modification of transcription factors [397]. Thus, in the 
hearts of AICAR treated TAC animals, the level of glucose metabolites could be increased, 
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leading to activation of detrimental processes including ER stress, in spite of the protective 
effects of enhanced protein degradation.   
A recent study focusing on the “exercise mimetic” properties of AICAR received 
publicity from mainstream media due to the possibility of “exercise in a pill” [399, 400]. In 
this study, mice given AICAR daily for four weeks (the same dose I used in all my in vivo 
experiments) exhibited enhanced exercise endurance without exercise training. In muscle, 
AICAR treatment resulted in expression of an “endurance gene signature” comprised of 
metabolic genes. While the heart was not investigated in this study, it raises an interesting 
question. If AICAR-mediated AMPK activation significantly increases glucose uptake in the 
hypertrophied heart, and consequently increases glycolytic intermediates that can be 
detrimental on the heart, can these intermediates be reduced by exercise, thus preventing 
cardiac dysfunction?   
 Metabolic changes that occur in the heart during fasting, like in cardiac hypertrophy, 
precede any structural changes. Metabolic changes that result from fasting are complex 
and occur at the whole body level, organ level, and at the intracellular level as reviewed in 
[401]. Initially during fasting, liver glycogen stores are broken down and used for ATP 
generation. Once glycogen stores are depleted in the liver, proteins in the muscle are 
broken down and are used in the liver for gluconeogenesis. Lipolysis occurs during the later 
stages of fasting; fat is mobilized from adipose tissue to provide fatty acids as substrates for 
β-oxidation. Although numerous metabolic changes occur during fasting, I focused only on 
the cardiovascular changes in my in vivo fasting experiments (see Chapter 3).  
While the heart has a limited capacity to store substrates, glycogen accumulates in 
the heart during fasting [402]. This is most likely a protective mechanism of the heart: it 
stores enough endogenous substrate for temporarily use during extreme conditions in order 
to maintain contractile function. I did not thoroughly investigate the metabolic changes in 
the heart during fasting. It would be interesting to determine if substrate uptake and 
utilization is differentially regulated during fasting in the absence of MuRF1. I have 
preliminary data suggesting that under fed conditions hearts from MuRF1-/- mice show 
increased rates of glucose oxidation, but whether this is maintained during fasting, and 
whether it is detrimental to the heart during fasting is not known.      
It would have also been of interest to determine how MuRF1 Tg mice respond to 
fasting. Because the absence of MuRF1 seems to protect the heart during fasting, I 
propose that increased amounts of MuRF1, higher than what occurs in WT mice in 
response to fasting, would be detrimental to the heart. Mitochondrial content in the heart is 
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increased in MuRF1 Tg mice, although there is no significant change in steady-state ATP 
levels [217]. Increased mitochondrial content could be caused by alterations in 
mitochondrial dynamics (decreased fusion or increased fission). Although I did not 
investigate mitochondrial changes in response to fasting, it has recently been shown that 
fasting decreases mitochondrial function in skeletal muscle [403]. MuRF1 might be 
responsible for these observations. Additionally, MuRF1-mediated degradation of the 
pyruvate dehydrogenase complex also suggests that MuRF1 is involved in mitochondrial 
regulation [209].  
MuRF1 also ubiquitinates β-hydroxyisobutyrate dehydrogenase [208], an enzyme 
that is critical in the catabolism of valine.  β-hydroxyisobutyrate dehydrogenase oxidizes 3- 
hydroxyisobutyric acid to methylmalonic acid semialdehyde, ultimately producing succinyl-
CoA which enters the Krebs cycle [404]. Branched chain amino acids (BCAA) in the plasma 
decrease during conditions that lead to muscle wasting, for example during metabolic 
acidosis [405] and fasting. The absence of MuRF1 decreases the BCAA levels in the 
plasma even further [208]. These data suggest that protein degradation in the absence of 
MuRF1 is decreased, thus decreasing the release of BCAA into the blood stream. 
Furthermore, increased levels of β-hydroxyisobutyrate dehydrogenase in MuRF1-/- mice 
suggests an increase in BCAA, and specifically valine, catabolism [208].  
Another interesting observation is that hearts from MuRF1 Tg mice exhibit 
decreased AMPK phosphorylation at baseline [217]. The ramifications of this observation, 
and whether this is important during fasting, have yet to be considered. It is also not clear 
as to what degree fasting-induced cardiac dysfunction is mediated specifically through the 
AMPK-MuRF1 axis. In order to determine the contribution of AMPK-MuRF1 in fasting, 
MuRF1-/- and MuRF1 Tg mice could be crossed with AMPKα2-/- or AMPKα2DN mice and 
subjected to fasting. However, it is possible that AMPKα2-/- or AMPKα2DN mice themselves 
may be sensitive to fasting due to the central role of AMPK in metabolic regulation in the 
heart during stress. 
 AMPK phosphorylation was decreased in the hearts of MuRF1 Tg mice, as 
mentioned above. This is intriguing because it raises the possibility that AMPK itself might 
be regulated by MuRF1. This concept is not entirely novel, because Atrogin-1, shown to be 
transcriptionally regulated by FOXO3A, can feed back on FOXO3A  [156]. Atrogin-1 
ubiquitinates FOXO3A. Consequently, ubiquitination decreases the ability of FOXO3A to be 
phosphorylated and thus excluded from the nucleus, and enhances its transcriptional 
activity [156]. It is possible that AMPK is a substrate for MuRF1 ubiquitination. Although 
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AMPK regulation and/or degradation by ubiquitin modification has not been thoroughly 
investigated, Qi et. al. demonstrated that the β-subunit of AMPK can be ubiquitinated by the 
ligase Cidea, thereby decreasing AMPK activity [406].      
 The role of Atrogin-1 in the heart during fasting was also not investigated here. 
Given that Atrogin-1 and MuRF1 seem to contribute equally to fasting-induced protein 
degradation in muscle, it seems reasonable to hypothesize that Atrogin-1 is also important 
in the heart during fasting. Atrogin-1 targets a different set of proteins for degradation and 
therefore cardiac function may not be preserved in the absence of Atrogin-1, as seen in the 
absence of MuRF1.  
 It is well established that Atrogin-1 and MuRF1 play a critical role in proteasome-
mediated protein degradation in skeletal muscle and in the heart. While the UPS is an 
essential system regulating protein degradation, there are other systems at work as well. 
The calpain system and autophagy contribute to general protein degradation (see Chapter 
1), whereas the degradation of misfolded proteins during protein processing through the 
endoplasmic reticulum (ER), known as ER-associated degradation (ERAD), is also 
important. These systems act together to coordinate protein quality control (PQC) in the 
heart to maintain cardiac protein homeostasis [119]. PQC is especially important in 
eliminating damaged proteins during times of cardiac stress, and can be a protective 
mechanism to preserve cardiac function.           
 While there are still many more questions than answers, it is evident that the role of 
protein degradation in the heart, while complex, is critical for cardiac function. I have 
provided strong evidence to support the hypothesis that protein turnover is metabolically 
regulated. Under conditions of extreme metabolic stress, AMPK is still able to regulate 
protein degradation. The results presented here extend the long-established concept of the 
“dynamic state of body constituents” set forth by Rudolph Schoenheimer in 1942 [407]. 
There is, I am certain, much more to come.    
 
 
 
“What we learn from experience depends on the kind of philosophy we bring to experience [408].” 
~C.S. Lewis, Author, Christian Scholar 
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